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ABSTRACT 
 
The translocation t(8;21) is the most prevalent chromosomal rearrangement in acute 
myeloid leukaemia (AML) and results in the expression of the oncogenic fusion 
protein RUNX1/ETO. The fusion protein is required for maintaining the leukaemic 
phenotype. Previous in vivo work identified genes related to glycolysis, namely 
SLC2A3 and PFKP as potential transcriptional targets for RUNX1/ETO.  
This project aimed to functionally investigate the role of SLC2A3 and PFKP in 
RUNX1/ETO-driven leukaemia both in vivo and in vitro. 
SLC2A3 significantly maintained the fitness of leukaemic cells under limited glucose 
and hypoxic conditions in the RUNX1/ETO-expressing Kasumi-1 cell line. Notably, 
SLC2A3 knockdown impaired the competitive fitness of patient-derived xenograft 
(PDX) cells in high glucose and oxygen condition. Furthermore, PFKP knockdown 
results in loss of populations both in vitro and in vivo. Besides, double knockdown of 
SLC2A3 and PFKP caused G1 cell cycle arrest and had a greater effect in impairing 
leukaemic cell propagation and fitness when compared to the single knockdowns.  
Moreover, RUNX1/ETO-expressing cells showed to have a high sensitivity towards 2-
deoxyglucose (2DG). 2DG is an analogue of glucose molecule that blocks glycolysis 
upstream of PFKP. RUNX1/ETO cells treated with this inhibitor undergo apoptosis 
associated with the overall decrease in cell number. The combination of 2DG and cell 
cycle inhibitor, palbociclib led to an additive effect and severely impaired expressions 
of genes in the glycolysis pathway. 
Collectively, the oncogenic fusion protein, RUNX1/ETO shows dependency on 
glycolysis through SLC2A3 and PFKP. Targeting these two genes may instruct new 
treatment strategies with reduced toxicity in t(8;21) leukaemia. 
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 Haematopoiesis 
Haematopoiesis is the process of blood cell formation from the haematopoietic stem 
cells (HSCs), to provide 1012 new blood cells each day in an average human adult. 
The process begins in the yolk sac and progresses temporarily to the liver, before 
finally residing in the bone marrow and thymus (Huyhn et al., 1995). During 
embryonic development, there are two waves of haematopoiesis that take place. The 
first wave is called primitive haematopoiesis, which involves the development of 
erythroid progenitors to erythrocytes and macrophages in the yolk sac. The early rise 
of erythrocytes is to provide tissue oxygenation during the rapid growth of an embryo. 
The second wave is known as definitive haematopoiesis, which involves the 
generation of mature blood cell types from HSCs. The early experiments with human 
embryos confirm HSCs originate from haemangioblast precursor cells in the Aorta-
Gonad-Mesonephros, that move toward the ventral aorta and give rise to the 
haematopoietic progenitor cells and endothelial cells (Tavian M., 2010, Huyhn et al., 
1995, Ivanovs et al., 2011).  
HSCs constitute only 0.05% to 0.1% of total bone marrow cells (Yang et al., 2005) 
and are maintained by long-term HSCs (LT-HSCs) that have the ability to self-renew 
and maintain pluripotency. This sub-population of HSCs remains quiescent and 
dormant throughout the lifetime of an organism (Ito and Suda, 2014).  
The second sub-population of HSCs is short-term HSCs (ST-HSCs) that have 
restricted self-renewal capacity. ST-HSCs give rise to multipotent progenitors (MPPs) 
cells for 4-12 weeks before senescence (Colvin et al., 2009).  
MPPs are described as highly proliferative, exhibit more robust differentiation activity 
(Morrison et al., 1997) and lack of self-renewal capacity. MPPs differentiate into two 
types of multipotent cells; common myeloid progenitors (CMPs) and common 
lymphoid progenitors (CLPs). CLPs give rise to restricted lymphoid lineages, while 
CMPs differentiate into a more morphologically, functionally and phenotypically 
distinct subset of cell types that include granulocytes, monocytes, macrophages, 
erythrocytes, megakaryocytes and mast cells.  
In contrast to the classical model of haematopoiesis, recent studies revealed that 
HSCs are heterogeneous: they have continuous lineage segregation characteristics. 
HSC heterogeneity is described as a single cell of HSCs exhibits diverse molecular 
signatures, cellular fate and functional outcome to preferentially produce specific 
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lineage (Copley et al., 2012, Crisan and Dzierzak, 2016, Zhang et al., 2018b). This 
new concept proposes the origin of leukaemia to be from HSCs as well as disease 
resistance and relapse.  
  
Figure 1-1: Hierarchical organisation of the haematopoietic system.  Long-term 
haematopoietic stem cell (LT-HSC) resides at the peak of the system and undergoes 
self-renewal or sequential multilineage differentiation to produce lineage-specific 
blood cells in the body. Adapted from Zhang et al. (2018b). 
  
 Acute Myeloid Leukaemia (AML) 
Acute myeloid leukaemia (AML), also called acute myelogenous leukaemia and 
acute myeloblastic leukaemia, is an aggressive malignancy of myeloid progenitor 
cells. It is highly heterogeneous with respect to the chromosomal abnormalities, gene 
mutations and changes in expression of genes and microRNAs. AML starts with the 
clonal transformation of defective myeloid precursor cells in the bone marrow. These 
cells lose their ability to differentiate but manifest the proliferative and survival ability. 
The abnormal differentiation of myeloid cells results in an immature population of 
marrow elements in the bone marrow and peripheral blood, thus increasing the risk 
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of fatal infection, severe bleeding and other symptoms such as anaemia. The 
development of AML is fast and fatal within a short period if no treatment is provided. 
 
 Epidemiology 
In 2013 to 2015, approximately 3000 new cases of AML and 2600 deaths were 
reported every year in the UK with higher incidence observed in male (Figure 1-2) 
(Cancer Research UK). The incidence of AML increases with age and ranges from 
0.7% to 3.9% cases per 100,000 between 0-60 years old. Whereas, for people aged 
60 years and above, the incidence increases to between 6.7 and 19.2 cases in 100 
000 people (Schoch et al., 2001).  
Childhood AML constitutes 15 to 20% of paediatric leukaemia cases (Reedijk et al., 
2018). The five-year overall survival (OS) for childhood AML has improved greatly 
from 40% in the early 1990s to more than 70% in 2010-2015 (Kaspers et al., 2013). 
However, a significant 30 to 40 percent of patients relapse and within this patient 
subgroup, the five-year OS is 16-34% (Kaspers et al., 2013, Abrahamsson et al., 
2007).  
 
Figure 1-2: Incidence of AML in the UK per year. The average number of new 
cases detected per year and age-related incidence rate in 100 000 population. 
Adapted from Cancer Research UK. 
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 AML and cytogenetics abnormalities 
Cytogenetic abnormalities can be detected in 50-60% of newly diagnosed AML 
patients (Kumar, 2011). This feature remains the most important prognostic indicator 
for remission rate, relapse and OS. The most recurrent cytogenetic abnormality in 
AML is the t(8;21), which is found in 15-20% of AML patients and is considered to 
have a favourable prognosis. Other karyotypic abnormalities that are in the 
favourable prognostic group are t(15;17), inv(16) and t(16;16) (Grimwade et al., 
2010, Mrózek and Bloomfield, 2012). 
Based on the Medical Research Council (MRC) classification, complex karyotype 
abnormalities that contain more than four unrelated abnormalities are considered as 
poor prognosis group (Grimwade et al., 2010). Among the poor prognostic groups 
are monosomies of chromosome 5, 7 and 17. Abnormalities related to chromosome 
3, which are inv(q21;q26.2) and t(q21;q26.1) are also associated with the adverse 
risk (Yi et al.). However, a balanced rearrangement of t(3;5)(q21~25;q31~35) and the 
normal karyotype are classified into intermediate risk group (Grimwade et al., 2010).  
 
 The mutational landscape of AML 
Approximately 40% to 50% of AML patients present with a normal karyotype (Kumar, 
2011). This subgroup of AML is classified into the intermediate-risk group, but not all 
patients have the same response to treatment. This is likely due to the large 
variabilities in gene mutations and expression in this subset of patients. Recent 
advanced genetic screens have allowed the detection of mutations that could be the 
driver of AML. These alterations were classified into two categories, Class I and II.  
 Class I  
Class I is comprised of mutations that modulate signal transduction pathways and 
result in increased proliferation and survival of leukaemia. Class I mutations include 
KIT, FLT3 and RAS.  
KIT mutation. The KIT gene, located on chromosome 4q11-12, encodes a 145 kD 
type III receptor tyrosine kinase. The KIT protein has five extracellular-kinase 
domains, a juxtamembrane domain and an intracellular kinase domain. Activation of 
its ligand by stem cell factors sends proliferative signals and is important in 
haematopoiesis (Wakita et al., 2011) (Rönnstrand, 2004). In the t(8;21) patients, KIT 
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activating mutation contributed to significantly lower 5-year OS than patients without 
KIT mutation (P-value < 0.001, 5-year, 26.5%-with KIT vs 60.9%-non KIT) (Park et 
al., 2011). The same observations were also seen in favourable prognosis group 
inv(16). KIT activating mutation caused higher incidence of relapse (P = 0.05; 5 year, 
56%-KIT v 29%-non KIT) and significantly lower survival (P=0.009; 5 year, 36%-KIT 
vs 62%-non KIT) (Paschka et al., 2006).  
FLT3 mutation. Fms-like tyrosine kinase 3 (FLT3) is a receptor tyrosine kinase that 
functions in cell survival, proliferation and differentiation of haematopoietic cells. 
There are two major activating mutations which are internal tandem duplication (ITD) 
mutations of the juxtamembrane region and point mutations in the tyrosine kinase 
domain (TKD). Both mutations cause constitutive tyrosine kinase activity in the 
absence of ligand. FLT3 mutations occur in approximately 30% of AML and the 
incidence increases with age. FLT3 mutations confer poor prognosis in AML patients 
(Kumar, 2011). 
RAS mutation. Mutations in NRAS present in 8-13% of AML cases, while KRAS can 
be found in 2% of adult AML and 9% in children with AML (Al-Issa and Nazha, 2016). 
Both NRAS and KRAS mutations did not show any impact on OS of AML patients 
(Al-Issa and Nazha, 2016, Bowen et al., 2005). 
 Class II 
The Class II comprises mutations that affect the transcription factors or components 
of the cell cycle machinery which include RUNX1, CEBP-α mutations and MLL 
rearrangement.  
RUNX1 mutation. RUNX1 is a transcription factor that plays critical roles in 
haematopoiesis. RUNX1 mutations are found in 6% to 30% of AML cases (Schnittger 
et al., 2011, Zhang and Rowley, 2013). Mutations in the RUNX1 gene bestows an 
unfavourable prognosis (Takahashi, 2011).  
CEBP-α mutation. CEBP-α is a transcription factor that is crucial for the differentiation 
of granulocytes. Mutations in the CEBP-α gene are found in 5% to 14% of AML 
cases (Lin et al., 2005). CEBP-α mutations are considered to impart a good 
prognosis even when associated with FLT3-ITD positive patients (Marcucci et al., 
2008, Takahashi, 2011). When compared with wild-type CEBP-α, mutations in 
CEBP-α seem to have an improved rate of complete remission (p = 0.06, 5-year, 
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93% vs. 77%) and OS (p = 0.002, 5-year, 58% vs. 27%). However, hitherto it is still 
unclear the reason why CEBP-α mutation confers a good prognosis.  
Recently, new mutations were discovered that did not fit in either Class I or II, thus 
making the classification of AML mutations and genomic abnormalities even more 
complex (Figure 1-3). For example, mutations in Tp53 are strongly correlated with 
complex karyotypes (Ferrari et al., 2014) and drug resistance (Kadia et al., 2016). 
p53 is related to stress-inducing signals to different anti-proliferative cellular 
responses such as DNA damage (Zilfou and Lowe, 2009). Another example, a 
DNMT activating mutation that results in substitution of the amino acid arginine with 
histidine (R882H) is found in 60% of AML cases (Kim et al., 2013). The mutation 
leads to a lower OS in AML patients with mutant DNMT compared to patients without 
the mutation (median: 7.0 months vs 19.5 months, P = 0.004)(Yan et al., 2011). 
 
 
Figure 1-3: Distribution of cytogenetically and molecular subsets of AML.  For 
each cytogenetically defined subset of AML denoted in the pie chart, frequent 
associated cooperating mutations are shown in the respective boxes. Mutational 
frequencies are derived from the integration of data from previous studies. Adapted 
from (Grimwade et al., 2016). 
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 AML with t(8;21) 
The translocation in t(8;21)(q22;q22) was first discovered by (Rowley) in 1973, and is 
the most common karyotypic abnormality, presenting in 15-20% of all AML cases 
(Figure 1-4) (Lam and Zhang, 2012, Miyoshi et al., 1993). It is usually reported as 
core-binding factor (CBF) AML and is closely associated with the AML-M2 subtype 
(French-American-British Classification). This subtype of AML is generally associated 
with a better clinical outcome; but, the prognosis worsens with age (Reikvam et al., 
2011, Vardiman et al., 2002). Ten-year survival rates for this subtype of leukaemia 
are more than 70% when using standard chemotherapy treatments (Thomas and 
Majeti, 2017).   
In this chromosomal rearrangement RUNX1 (also known as AML1), which is 
originally located on chromosome 21, fuses to the ETO gene (also known as 
RUNX1T1 or MTG8) on chromosome 8 and vice versa (Figure 1-4). However, only 
RUNX1/ETO expression is detectable in t(8;21) patients (Peterson et al., 2007a). The 
breakpoints occur in intron 5 of the RUNX1 gene locus and either intron 1a or 1b of 
the ETO gene (Miyoshi et al., 1991, Lam and Zhang, 2012). This chimeric gene 
generates a fusion protein, RUNX1/ETO, containing 752 amino acids: 128 amino 
acids found on the N-terminal of Runt domain of RUNX1 and almost the entire ETO 
protein.  
 
Figure 1-4: Chromosomal rearrangement involving chromosome 8 and 21 
discovered by Rowley (1973).  The q22 arm of chromosome 21 translocates to q22 
arm of chromosome 8. 
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 RUNX1 
RUNX1 is a transcription factor that belongs to the Runt-related transcription factor 
family. From twelve currently identified RUNX1 isoforms resulting from alternative 
splicing, there are three that are well-described; RUNX1A consists of 250 amino 
acids, RUNX1B consists of 453 amino acids and RUNX1C consists of 480 amino 
acids (Figure 1-5-A). Both RUNX1A and RUNX1B have the same proximal start but 
differ in the carboxyl terminal. RUNX1C has the same carboxyl terminus with 
RUNX1B but has 32 amino acids encoded by an alternative exon at the distal N-
terminus. Each isoform functions in different tissues and haematopoietic stages. For 
instance, RUNX1A is primarily found in CD34+ progenitor populations in human cord 
blood and are able to potentiate engraftment in mice (Tsuzuki et al., 2007). While 
RUNX1B drives neutrophil proliferation and differentiation, RUNX1C functions in 
lymphocytes definitive differentiations (Telfer and Rothenberg, 2001).  
These three isoforms share the same N-terminal region that contains 128 amino 
acids: Runt Homology Domain (RHD) (Figure 1-5-B) (Sood et al., 2017). The RHD is 
required to facilitate binding of RUNX1 to DNA and interacts with its 
heterodimerisation partner, core-binding factor beta (CBFβ) (Lam and Zhang, 2012). 
The heterodimerisation complex of RUNX1-CBFβ increases the DNA-binding affinity 
of RUNX1 (Lam and Zhang, 2012). Besides the complex formation with CBFβ, 
RUNX1 also co-operates with other transcription factors and transcriptional co-
regulators.  
RUNX1B and RUNX1C share another domain, namely TAD, which contains 
activating and inhibitory domains that interact with several activator and repressor 
proteins (Sood et al., 2017). Moreover, RUNX1 mediates transcriptional activation 
through a 31 amino acid region namely nuclear matrix targeting signal (NMTS) 
located at the C-terminal region (Lam and Zhang, 2012, Sood et al., 2017). 
Furthermore, VWRPY motifs are conserved in Runt family members at the last 5 
amino acids of the C-terminus (Sood et al., 2017).  
RUNX1 is essential in determining the fate of HSCs in haematopoiesis. In mouse 
development, Runx1 was detected in both primitive and definitive haematopoiesis 
(North et al., 1999). Further studies also showed that Runx1-deficiency shortened the 
lives of mice and caused severe haemorrhaging along the central nervous system 
when compared to healthy heterozygous mice (Wang et al., 1996, Okuda et al., 
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1996). The extreme haemorrhaging may be caused by a lack of angiopoietin-1 
expression, as the ANGPT1 gene is one of the genes regulated by RUNX1 
(Takakura et al., 2000).  
In adults, RUNX1 plays a role in both haematopoiesis and HSC-niche interaction. 
Runx1-knockout mice display an accumulation of a putative HSC population, myeloid 
progenitors but a lack of thrombocytes and lymphocytes (Ichikawa et al., 2004, 
Growney et al., 2005, Ichikawa et al., 2008). Furthermore, Runx1 is required to 
maintain Cxcr4, a gene involved in stem cell homing and niche interactions in HSCs 
(Jacob et al., 2010). Notably, there are two RUNX1 binding sites in the CXCR4 
promoter region (Jacob et al., 2010). RUNX1 interacts with target genes in various 
blood types. In the myeloid lineage, RUNX1 directly interacts with the promoters of 
genes related to myeloid growth factor signalling; IL-3, GM-CSF, M-CSF and c-MPL 
(Lam and Zhang, 2012, Satoh et al., 2008, Cameron et al., 1994, Takahashi et al., 
1995) as well as to the enzyme involved with myeloid functions such as 
myeloperoxidase, neutrophil elastase and mast cell protease 6 (Ogihara et al., 1999, 
Nuchprayoon et al., 1994, Lam and Zhang, 2012). In the T-cell lineage, RUNX1 
directly binds to the promoters and enhancers of T-cell receptors (Ryuji Uchino)(Sun 
et al., 1995). In the B-cell lineage, RUNX1 interacts with B-cell specific src family 
tyrosine kinase promoters known as blk and Iga and the immunoglobulin antigen 
receptor enhancers (Lam and Zhang, 2012, Erman et al., 1998, Zhang and Derynck, 
2000). 
 
Figure 1-5: RUNX1 isoforms.   A) The three major isoforms of RUNX1 (1A, 1B and 
IC). B) The domains of RUNX1C. The three isoforms share an RHD domain at the N-
terminal, but only RUNX1B and RUNX1C have the TAD and VWPRY motif at C-
terminal. Adapted from Sood et al., (2017). 
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 ETO 
ETO (Eight-twenty-one), also known as MTG8 or CBFA2T1, was first identified in 
translocation breakpoints in t(8;21) acute myeloid leukaemia (Miyoshi et al., 1993, 
Miyoshi et al., 1991). ETO expression is relatively low in haematopoietic tissues as 
ETO-RUNX1 transcripts are not detectable in t(8;21) patient samples (Peterson et al., 
2007b). Mice with Eto knockout showed normal haematopoiesis and no expression 
was detected in hematopoietic cells (Calabi et al., 2001). Instead, Eto is found highly 
expressed in the gut, as well as in the brain, suggesting important roles for ETO 
within these two organs (Sacchi et al., 1998, Calabi et al., 2001). ETO expression is 
also detected in the heart, pancreas and skin (Nathan Davis, 2003). 
ETO shares 50-70% of Nervy homology region (NHR) similarities with Drosophila 
numbered 1 through 4 (Figure 1-6) (Davis et al., 2003). Briefly, NHR1 has sequence 
similarities with TATA-binding protein-associated factors, including human TAF105 
and TAF130 and Drosophila TAF110 (Lam and Zhang, 2012). Similarities of these 
NHR1 domains gave rise to an early idea that ETO functions as a transcription factor. 
NHR2 is often referred to as a hydrophobic heptad repeat (HHR) due to an 
amphipathic amino acid sequence (Liu et al., 2006). It can mediate both alpha-helical 
tetramer formation and homo- and hetero-oligomerisation of ETO and its other family 
members, including ETO2 (MTG16) and MTGR1 (Liu et al., 2006). The alpha-helices 
align in a head to tail manner to form an anti-parallel dimer, through hydrophobic and 
ionic interactions and positioned on top of each other like a sandwich. This structure 
produces an extremely stable ETO tetramer and is thought to contribute to 
RUNX1/ETO stability (Liu et al., 2006). NHR2 was also shown to contain histone 
deacetylases (HDAC) contact site (Amann et al., 2001, Hildebrand et al., 2001, 
Lutterbach et al., 1998). NHR3 contains a coiled-coil motif, which has structural 
homology with PKA anchoring proteins and binds to a regulatory subunit of type II 
cyclic AMP-dependent protein kinase (PKA RIIalpha). NHR3 may  interact with 
subsequent adjacent NHR domains (Lam and Zhang, 2012). NHR4, also known as 
the myeloid-Nervy-DEAF1 (MYND) domain, has zinc chelating motif (Lam and 
Zhang, 2012).  
These NHR domains have in common the ability to interact with other proteins and 
thus define the function of ETO. For example, NHR1 facilitates binding with E 
proteins and inhibits the ability for E proteins to recruit co-activator molecules like 
p300/CBP (Lam and Zhang, 2012). Furthermore, both NHR2 and NHR4 interact with 
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co-repressors NCOR/SMRT (Zhang et al., 2004a). NHR2 also binds with other co-
repressors such as mSin3a and HDACs (Kitabayashi et al., 1998). 
ETO also contains a nuclear localisation signal (NLS) within amino acids 241-280, 
located between NHR1 and 2 domains. A NLS is required for nuclear localisation; 
however, no functional roles have been defined thus far (Davis et al., 2003). 
 
Figure 1-6: Schematic depiction of ETO and its protein interaction domains.  
A map of ETO is shown with NHR1–4 indicated as shaded regions. Some of the 
interacting corepressors are listed with the corresponding ETO-interaction domains 
underlined. Adapted from Davis, 2003 #614. 
 
 RUNX1/ETO 
As a result of the translocation, almost the entire ETO protein replaces the C-terminal 
RUNX1 domains, creating a large 752 amino acid sequence. The RUNX1/ETO 
fusion protein keeps the N-terminal DNA-binding RHD domain of RUNX1 and loses 
the C-terminal of RUNX1, which is then replaced by C-terminal functional domains of 
the ETO protein. As in normal function of RUNX1, the resulting RUNX1/ETO fusion 
protein also binds to DNA through RHD, but interferes with transcriptional activation 
through ETO’s interaction with co-repressors.  
There are several isoforms of RUNX1/ETO transcripts detected in t(8;21) patient 
samples, but most studies focus on the full-length RUNX1/ETO. RUNX1/ETO on its 
own cannot induce leukaemia, as shown in several models. RUNX1/ETO expression 
in human CD34+ cells did not cause leukaemia in mice (Mulloy et al., 2002, Mulloy et 
al., 2003). This was also demonstrated in patients’ samples who had RUNX1/ETO 
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transcripts in their neonatal blood, but did not develop leukaemia until after several 
years (Wiemels et al., 2002, Burjanivova et al., 2006, Mulloy et al., 2003). Instead, 
RUNX1/ETO positive cells require additional genetic alterations to develop into 
leukaemia. Association of RUNX1/ETO with KIT, FLT3-ITD, NRAS or KRAS 
mutations in mouse haematopoietic progenitors was able to produce in vivo 
leukaemia. In one mouse study, induction of RUNX1/ETO and mutated KIT on the 
exon 7 resulted in lethal haematopoietic neoplasms, and the mice died within 2 to 4 
months after transplantation:  mice without additional mutations but expressing 
RUNX1/ETO rarely progressed to lethal disease within a year (Nick et al., 2012a). 
KIT mutations on the loop of the kinase domain results in D816V or N822K amino 
acid alterations and are found in approximately 11% to 44% cases of t(8;21) positive 
AML (Jiao et al., 2009, Nick et al., 2012a). These activating mutations are associated 
with a high incidence of relapse and poor survival in t(8;21) patients (Jiao et al., 
2009, Wichmann et al., 2015).  
Two isoforms of truncated RUNX1/ETO that lack the NHR3 and NHR4 domains have 
been reported (Yan et al., 2004, Wolford and Prochazka, 1998). Mice transplanted 
with RUNX1/ETO-transduced-bone marrow cells were reported to have developed 
aggressive leukaemia. The leukaemic cells of these mice contained a mutated 
RUNX1/ETO cDNA, which resulted in a 552 amino acid fusion protein (Yan et al., 
2004). Another isoform harbours an extra ETO exon which is widely detected in 
t(8;21) patients. This transcript produces a shorter C-terminal region of the 
RUNX1/ETO protein, known as RUNX1/ETO9a (Wolford and Prochazka, 1998). 
RUNX1/ETO9a has 572 amino acids, which is almost identical to the truncated 
isoform and both of these isoforms rapidly induces leukaemia in mice models.  
Mice with heterozygous RUNX1/ETO allele died at an early embryonic stage and 
displayed haematopoietic defects similar to mice with homozygous RUNX1 deletion 
(Yergeau et al., 1997, Okuda et al., 1998). Interestingly, RUNX1/ETO requires the 
normal function of RUNX1 for leukaemic survival. Depletion of RUNX1 inhibits the 
growth and survival of RUNX1/ETO leukaemia cells in CD34+ cord blood cells and 
t(8;21)-positive cell line (Ben-Ami et al., 2013, Goyama et al., 2013). 
Co-repressor recruitment through the ETO moiety defines a dominant inhibition role 
of RUNX1/ETO-induced leukaemia. Given that RUNX1/ETO shares 60% of binding 
sites with RUNX1 (Ptasinska et al., 2014), RUNX1/ETO blocks RUNX1 binding to 
DNA and interferes with normal haematopoietic maturation, inducing a pre-leukaemic 
 14 
 
condition. In myeloid differentiation, RUNX1/ETO binds to haematopoietic 
transcription factors such as CEBPA, PU.1 and GATA1 (Vangala et al., 2003, Pabst 
et al., 2001b, Choi et al., 2006, Ptasinska et al., 2014, Ptasinska et al., 2012). 
RUNX1/ETO abolishes CEBPA self-activation on CEBPA by direct interaction with 
the promoter site; thus inhibiting granulocytic differentiation (Pabst et al., 2001a). 
RUNX1/ETO also represses the expression of UBP43, which functions in cytokine-
induced monocytic differentiation (Liu et al., 1999). Moreover, GATA-1 requires p300 
for transcriptional activity and programming of erythroid differentiation. However, 
RUNX1/ETO indirectly interferes with GATA-1 by forming an inhibitory complex with 
p300 and inhibits erythroid lineage commitment. 
Despite well-established repressor roles in transcriptional activities, RUNX1/ETO was 
also shown to increase the expression of RUNX1 target genes in order to promote 
leukaemogenesis (Martinez-Soria et al., 2018). Recent findings have shown that 
RUNX1/ETO directly regulates high expression of CCND2 through co-operation with 
AP-1 (Martinez-Soria et al., 2018), a transcription factor that is involved in  cell 
proliferation and differentiation (Bakiri et al., 2002). Knockdown of RUNX1/ETO 
reduces AP-1 binding to the CCND2 promoter region and lowers CCND2 expression. 
Furthermore, to enhance leukaemic clonogenicity, RUNX1/ETO binds directly to the 
promoter of telomerase (TERT), leading to constitutive expression of TERT (Martinez 
et al., 2004, Ptasinska et al., 2014). In addition, RUNX1/ETO forms a pre-initiation 
complex with p300 to drive the expression of downstream target genes such as Id1, 
p21 and Egr1 that function in self-renewal activity (Wang et al., 2011a). Moreover, 
RUNX1/ETO was shown to inhibit senescence and increase stem cell marker, CD34, 
indicating that RUNX1/ETO is indeed essential for leukaemic maintenance (Martinez 
et al., 2004).  
 
Figure 1-7: Scheme of RUNX1/ETO fusion protein.   The full length of 
RUNX1/ETO fusion protein. RUNX1/ETO comprises the RHD domain from RUNX1 
and 4 Nervy homology regions from ETO. Adapted from (Lam and Zhang, 2012). 
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 Animal models of t(8;21) AML 
Generation of t(8;21) AML animal models has been challenging over the years. Early 
work involved knock-in of RUNX1/ETO into the RUNX1 locus to produce 
heterozygous RUNX1/ETO mice (Yergeau et al., 1997, Okuda et al., 1998). The  
experiment resulted in embryonic fatalities which occurred around embryonic stage 
12.5 to 13.5 days (Okuda et al., 1998). These embryos failed to establish normal 
mature blood cells and presented with a severe haemorrhage phenotype which was 
also seen in homozygous deletion of RUNX1 (Okuda et al., 1996) or CBFβ mice 
(Wang et al., 1996). However, in contrast to RUNX1- or CBFβ- deficient embryos, 
cells from RUNX1/ETO knock-in mice were able to generate a mix of abnormal 
myeloid lineage cells including erythroid precursors, monocytes, megakaryocytes 
and hypergranular cells that have a higher self-renewal capacity (Okuda et al., 1998).  
An attempt was made to evade the RUNX1/ETO in vivo lethal effects by introducing 
a controlled expression of RUNX1/ETO using a tetracycline-inducible transgenic 
model (Rhoades et al., 2000). Interestingly, while RUNX1/ETO expression was 
detected in the bone marrow cells and macrophages, the mice did not show any 
onset of leukaemia. Furthermore, a primary colony formation assay from bone 
marrow cells showed no differences between control and RUNX1/ETO-expressing 
cells. Conversely, a serial replating of RUNX1/ETO-expressing cells resulted in block 
of myeloid differentiation, causing the cells to pause at an immature stage (Rhoades 
et al., 2000). Rhoades’ study has made an important observation of RUNX1/ETO’s 
capacity to induce self-renewal ex vivo; however, the inducible animal models did not 
exhibit haematopoietic abnormalities or tendency to develop leukaemia. These 
observations were also seen in knock-in of RUNX1/ETO cDNA that expressed the 
protein in the marrow of adult mice. The progenitors from these mice were able to be 
serially transplanted in vivo, but the mice did not develop leukaemia (Higuchi, 2000). 
Instead, treatment with a mutagen in these mice actuated leukaemia and 
granulocytic sarcoma which is similar to the clinical observation seen in patients with 
t(8;21) translocation. This notion was also supported in a transgenic mouse study, in 
which expression of RUNX1/ETO was under the control of human myeloid MRP8 
promoter (Yuan et al., 2001). The mice were healthy during their life-span, but 
treatment with DNA-alkylating mutagen (N-ethyl-N-nitrosourea) caused the mice to 
develop leukaemia. These studies suggest that RUNX1/ETO alone is insufficient to 
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develop leukaemia and secondary mutation(s) is required to induce disease 
progression.  
Severe immunocompromised (Scid)-based mouse strains have been used to study 
HSCs and AML in vivo (Bhatia et al., 1997, Pearce et al., 2006); however, hitherto, 
there is no suitable animal model for the RUNX1/ETO human leukaemia background. 
Established cell lines as well as patient-derived t(8;21) leukaemic blasts do not or 
rarely engraft in vivo (Pearce et al., 2006, Soria et al., 2008). A study on 
RUNX1/ETO-transduced HSCs described the stemness property, marked by CD34 
expression, as a prerequisite for successful RUNX1/ETO-leukaemia in vivo 
engraftment (Mulloy et al., 2003). However, one study showed that CD34 expression 
did not correlate with engraftment capability in t(8;21) leukaemia blasts (Pearce et al., 
2006). Additionally, we have reported a successful RUNX1/ETO-positive cell line 
xenotransplantation model in Rag2−/−γc−/− mouse strain that lacks B, T and natural 
killer cells (Soria et al., 2008). This model was shown to promote CD34+ cord 
blood cell development towards adaptive immune system in newborn mice 
(Traggiai et al., 2004).  
 
 Therapeutic strategies for RUNX1/ETO-leukaemia 
 The t(8;21) AML rearrangement is grouped with inversion 16 (inv(16)) AML in the 
CBF leukaemia subset, which has favourable prognosis. Standard treatment for this 
group involves the induction chemotherapy with cytarabine for seven days in 
combination with three daily doses of anthracycline. The mode of action of cytarabine 
involves phosphorylation into its triphosphate form: mimicking native deoxycytidine 
triphosphate. This drug competitively incorporates into DNA and blocks synthesis of 
DNA by inhibiting DNA and RNA polymerase (Hatlen et al., 2012, Veuger et al., 
2002). Whereas, anthracycline forms a complex with DNA and the topoisomerase 2α 
enzyme, which is highly expressed in proliferating and tumour cells, thereby causing 
double-stranded DNA breaks. The complex inhibits DNA replication, disrupts the cell 
cycle and finally induces apoptosis (McGowan et al., 2017, Stojak et al., 2014). 
Furthermore, if complete remission is achieved, a consolidation high-dose cytarabine 
is incorporated into the regimen for t(8;21) AML patients.   
Consolidation of 3 to 4 cycles of high-dose cytarabine has been shown to improve 
cure rates of t(8;21) patients to 80% when compared to 40% of patients with one 
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cycle of high-dose cytarabine (Kantarjian, 2016, Byrd et al., 1999, Byrd et al., 2004). 
Recent studies demonstrated the use of fludarabine in combination with high-dose 
cytarabine and gemtuzumab ozogamicin or idarubicin have remarkably improved 
cure rates to 80 to 90% of patients in the CBF group (Borthakur et al., 2008, Burnett 
et al., 2010). The addition of gemtuzumab ozogamicin to the therapy regimen was 
reported to be the factor for improved survival (Burnett et al., 2010). Gemtuzumab 
ozogamicin is a drug-linked monoclonal antibody that targets CD33; however, it is 
reported to cause severe veno-occlusive disease and higher fatality rates in when in 
the combination group versus the group receiving chemotherapy alone 
(16/283=5.7% vs 4/281=1.4%; P = .01) (Nelson, 2010). Although it was once 
withdrawn from the market in 2010, gemtuzumab ozogamicin was approved again for 
adults with newly diagnosed AML, as well as patients 2 years of age and older with 
relapsed/refractory disease (https://clinicaltrials.gov). The new approval includes 
changes in the administered schedule and  a lower dose than was initially approved 
(Rowe and Löwenberg, 2013). 
 
 Cancer and Metabolism 
Cancer cells are characterised by accelerated proliferation, increased self-renewal 
capacity and an altered metabolism. These features require pathway reprogramming 
of nutrient acquisition and metabolism in order to support the accelerated 
bioenergetic demands. The reprogramming activity is now recognised as a hallmark 
of cancer, as recent works have uncovered plasticity of the pathways regulated by 
tumour cells to support these key functions.  
The first metabolic reprogramming pathway was established by Otto Warburg, who 
observed abnormal glucose uptake and lactate production in the presence of oxygen, 
which is in contrast to the normal physiological function (Warburg, 1956b). The 
increased rate of glycolysis in cancer cells renders metabolic intermediates 
supplication to fulfil metabolic demand. Recent findings showed that dysregulation of 
oncogene/tumour suppressors and up-regulation of several key pathways are the 
reasons for the metabolic reprogramming. 
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 Glycolysis  
Glycolysis is a metabolic process of converting 1 mole of glucose into 2 moles of 
pyruvate, producing in a net gain of two moles of ATP and two moles of NADH. 
Glucose is transported into the cells through glucose transporters. There are five 
glucose transporters that are expressed in the mammalian system; SLC2A1 and 
SLC2A3, which are expressed in most tissues; SLC2A2, SLC2A4 and SLC2A5 
conversely show tissue-specific expressions. Upon entry into the cells, glucose is 
phosphorylated by hexokinase (HK), trapped within the cells and then undergoes a 
series of transformations to produce pyruvate (Figure 1-8). Depending on the 
environmental condition, pyruvate has two fates; either to enter the mitochondria for 
the tricarboxylic cycle (TCA) to allow efficient ATP production or to divert to a less 
energy efficient process by converting to lactate. In normal oxygen conditions, 
pyruvate enters the mitochondria and is completely oxidised to CO2. This process 
yields 36 moles of ATP from one mole of glucose. Under oxygen limitation, pyruvate 
is converted to lactic acid by lactate dehydrogenase (LDH) and mediates the 
conversion of NADH to NAD+.  Furthermore, lactate generated during anaerobic 
exercise is converted back to pyruvate and glucose in the liver, in a process called 
the Cori Cycle.  
Pyruvate also provides the carbon backbone for the synthesis of amino acids (Figure 
1-9). Pyruvate enters mitochondria to provide a carbon precursor for the synthesis of 
asparagine. The glucose by-products in glycolysis donate the carbon backbone for 
the synthesis of cysteine and glycine. Pyruvate can also be converted to alanine 
which provides the carbon backbone for amino acid synthesis Figure 1-9.  
In cancer cells, increased glucose uptake is due to the upregulation of glucose 
transporters. For example, SLC2A3 has been reported to be upregulated in many 
cancer types and correlated to poor clinical outcome (Cosset et al., 2017, Starska et 
al., 2015, Flavahan et al., 2013). Upregulation of SLC2A3 is associated with 
accelerated glucose uptake and drives cancer proliferation (Hou et al., 2017) as well 
as inhibiting apoptosis in breast cancer cell lines (Wahdan-Alaswad et al., 2013).  
Moreover, one of the key enzymes in glycolysis is phosphofructokinase-1 (PFK1) 
which catalyses the irreversible conversion of fructose-6-phosphate (F-6-P) to 
fructose-1,6-biphosphate (F-1,6-BP). There are three isoforms of PFK1 which are 
PFKP, PFKL and PFKM. PFKP is highly expressed in cancer cells in comparison to 
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the other two isoforms (Thakkar et al., 2010). PFKP activity is tightly regulated 
through several allosteric mechanisms. For example, high levels of ATP inhibits 
PFKP activity and blocks the production of F-1,6-BP. The intermediates upstream of 
PFKP can be used for other biosynthesis pathways such as the pentose phosphate 
pathway (PPP). Another allosteric regulator for PFK1 activity is fructose-2,6-
biphosphate (F-2,6-BP) which is the product of 6-phosphofructo-2-kinase/fructose-
2,6-biphospahatases (PFK2/FBPases2) activity. F-2,6-BP is a potent activator for 
glycolysis and degradation of this molecule by TP53-inducible glycolysis and 
apoptosis (TIGAR) inhibits PFKP activity (Bensaad et al., 2006). A recent study 
showed reduced PFK1 activity by O-linked β-N-acetylglucosamine (O-GlcNAc) 
transferase is detected in many cancer cell lines (Yi et al., 2012). This resulted in 
decreased glycolytic flux and redirected the intermediates to the PPP, allowing a 
growth advantage to cancer cells. 
Furthermore, cancer cells preferentially transport lactate out to the extracellular 
environment, making it more acidic. This acidic environment mediates tumour 
invasion, angiogenesis and immune evasion (Nagarajan et al., 2016). For example, 
activation of the sodium-proton exchanger (NHE1) by the E7 oncogene is shown to 
cause gradual acidification of the extracellular microenvironment, which is associated 
with malignant transformation in human papilloma virus-transformed fibroblasts cells 
(Reshkin et al., 2000, Nagarajan et al., 2016).  
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Figure 1-8: Metabolic pathways involving glycolysis and glutaminolysis.  
Glucose uptake results in the production of pyruvate which could either enter TCA 
cycle or converted into lactate. Upon entry into the cells, glutaminase converts 
glutamine to glutamate and then is converted into α-ketoglutarate in mitochondria. 
Both glucose and glutamine are required for the synthesis of amino acids, 
nucleotides and lipids. Metabolic changes in cancer cells are driven dysregulation of 
oncogenes (Myc and Ras) and tumour suppressor (p53). Glycolysis is indicated in 
red arrow. Glutaminolysis is indicated in orange. Biosynthetic pathway is shown in 
green (Adapted from Joshi, 2015 #601).  
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 Glutaminolysis  
Glutaminolysis is a metabolic process to convert glutamine into α-ketoglutarate (αKG) 
via glutamate. It is an important molecule required as a carbon and nitrogen 
backbone donor in the synthesis of micromolecules such as nucleotides and 
nonessential amino acids (NEAA). Glutamine enters the cell via its specific 
transporter and is converted to glutamate by glutaminase (GLS) in the cytoplasm. 
GLS1, which is the kidney-type of glutaminase is overexpressed in many types of 
cancer and reported to be associated with poor prognosis (Li et al., 2018). Glutamate 
is then converted to αKG and provides its nitrogen compound (amine group) to 
glucose- or glutamine-derived carbon compound to produce NEAA (glucose-derived; 
alanine, serine and aspartate; glutamine-derived; ornithine). Glutamine also donates 
its carbon skeleton and nitrogen to the synthesis of proline (Wise and Thompson, 
2010, Young and Ajami, 2001). Moreover, glutamine can also replenish metabolites 
of the TCA cycle, a process called anaplerosis. Glutamine can also generate lactate 
via oxidative carboxylation of malate to pyruvate, thereby increasing NADPH 
production. 
Studies have shown that glutamine is the essential amino acid required for tumour 
growth and some cancer cells exhibited higher glutamine uptake (R Wise et al., 
2008). Cancer cells such as non-small cell lung cancer (NSCLC), breast cancer and 
brain tumours, exhibit a high dependency on glutamine for their growth and survival 
(Choi and Park, 2018, Márquez et al., 2017). 
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Figure 1-9: Glutamine and glucose as a nitrogen and carbon donor for the 
synthesis of non-essential amino acid.   Glutamine, as well as glucose, provides 
carbon and nitrogen for the synthesis of nonessential amino acids (NEAA). 
Compounds containing carbon are shown in red, whereas compounds containing 
both carbon and nitrogen are shown in blue. Glycolysis and glutaminolysis provide 
carbon precursors for amino acid biosynthesis. (Glycolysis; 3-phosphoglycerate, 2-
phosphoglycerate and pyruvate; Glutaminolysis; oxaloacetate, glutamic acid γ-
semialdehyde). Glutamic acid derived from glutamine (glu) donates its amine group 
to these carbon substrates to produce NEAA (serine, alanine, aspartate, ornithine) 
and α-ketoglutarate (αKG). Alanine (ala) serves as the amine donor to produce 
serine and pyruvate in mitochondria for the production of glycine. Glutamine provides 
both carbon and nitrogen sources for the synthesis of proline, ornithine and arginine 
as well as a direct nitrogen donor in the synthesis of asparaginase from aspartic acid. 
Adapted from Wise et al. (2010).  
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 Hypoxia  
Low levels of oxygen is one of the common features for many tumours (Muz et al., 
2015). In highly proliferative tumour tissue, oxygen demand exceeds oxygen supply 
and the distance between the cells from existing vascular tissues increases, thus 
restricting oxygen diffusion and creating an even more hypoxic microenvironment. 
The average oxygen level in the hypoxic tumour environment including in the bone 
marrow was reported to be between 1%-2% (Muz et al., 2015) (Spencer et al., 2014).  
Hypoxia activates several complex intracellular signalling pathways such as hypoxia-
inducible factor-1 (HIF-1). HIF is a family of transcriptional regulators that are 
regulated by oxygen sensors, including prolyl-4-hydroxylase domain (PHD) and 
factor inhibiting HIF1 (FIH-1). In normoxia, HIF1-α subunits are hydroxylated by PHD 
which requires oxygen as well as iron. The complex mediates binding of von Hippel-
Lindau (VHL) tumour suppressor protein and results in proteasomal degradation. 
When the oxygen level reduces, the PHD enzymes lose the activity, leading to 
stabilisation of HIF1-α and translocation to the nucleus. In the nucleus, HIF1-α 
dimerises with constitutively expressed HIF1-β subunits, binds to DNA and initiates 
transcription.   
Hypoxia is known to increase the expression of glucose transporters SLC2A1 and 
SLC2A3, as well as glycolytic enzymes such as ALDA and PGK1 (Iyer et al., 1998). 
Furthermore, studies have shown that decreasing oxygen tension would also 
accelerate glycolysis, as this is associated with a higher expression of SLC2A3 (Yu 
et al., 2012, Christensen et al., 2015). Moreover, hypoxia is associated with 
resistance to chemotherapy and poor patient survival. Chemotherapy-resistant AML 
cells preferentially localised to the hypoxic endosteal niche in the bone marrow 
(Ishikawa et al., 2007). Several reports have shown therapeutic advantage of 
targeting HIF-1 in leukaemia (Wang et al., 2011b, Rouault-Pierre et al., 2013); 
however, several studies demonstrated contradictory evidence (Velasco-Hernandez 
et al., 2019, Vukovic et al., 2015). For instance, a study demonstrated deletion of Hif-
1a led to a more aggressive phenotype in a MLL-AF9 mouse model (Velasco-
Hernandez et al.,2018). One possibility of this is the enrichment of PTEN/PI3K/AKT 
pathway which induces Hif-a activation (Zundel et al., 2000) and at the same time 
promotes AML cell proliferation (Griessinger et al., 2014). Furthermore, HIF-1 
stabilisation promotes the release of proangiogenic cytokines such as vascular 
endothelial growth factor (VEGF) (Moeller et al., 2004). In addition to promoting new 
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blood vessel formation, VEGF secretion enhances the protection of tumour blood 
vessels from radiotherapy, hence tumour resistance (Gorski et al., 1999). 
  
 Regulation of metabolism by tumour suppressors or oncogenes 
 Tp53 
The tumour suppressor p53 regulates many of the proteins involved in metabolic 
pathways such as: cytochrome C oxidase (SCO2), TP53-induced glycolysis and 
apoptosis regulator (TIGAR), glucose transporters and phosphoglycerate mutase 
(PGM) (Harami-Papp et al., 2016, Bensaad et al., 2006). p53 induces the expression 
of an assembly factor SCO2 in the nucleus. SCO2 is an important regulator of the 
complex IV mitochondria, which is part of the respiratory chain for oxidative 
phosphorylation. p53 has also been shown to regulate glycolysis by suppressing it 
through induction of TIGAR, which shares similarity to Phosphofructokinase-
2/fructose biphosphatase-2 (PFK-2/FBPase-2) (Bensaad et al., 2006). However, only 
the catalytic unit of the biphosphatase domain is well-conserved in TIGAR, 
suggesting that TIGAR may function similarly to FBPase-2 (Bensaad et al., 2006). 
FBPase-2 degrades fructose-2-6-biphosphate, a potent activator of PFK-1 and 
inhibits glycolysis. This inhibition results in increased flux of glucose-6-phosphate to 
the PPP pathway and consequently increases the synthesis of ribose sugars for 
nucleotide biosynthesis and NADPH for cellular antioxidants. However, p53 can also 
function as a negative regulator for PPP through direct inhibition of glucose-6-
phosphate dehydrogenase (G6PD), the first rate-limiting enzyme in the PPP 
pathway. This results in decrease of NADPH generations and affects overall cellular 
reactive oxygen species (ROS) levels.  
Another direct target of p53 is glutaminase 2 (GLS2), which catalyses the conversion 
of glutamate from glutamine in the mitochondria. This enzyme promotes antioxidant 
glutathione (GSH), thereby blocking ROS productions and act as a defence 
mechanism. 
Tp53 mutation is the most common mutation found in cancers and more than 75% of 
the mutations result in the loss of p53 function (Kawauchi et al., 2008). Mutant p53 
has been implicated in loss of mitochondrial respiration and supports a glycolytic 
phenotype (Kawauchi et al., 2008). Mutation in the DNA-binding domain of p53 
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abolishes the p53 repressor effect on glucose transporters and PFKP, thereby 
increasing glucose metabolism and cell energy supply in osteosarcoma cell lines 
(Schwartzenberg-Bar-Yoseph et al., 2004, Harami-Papp et al., 2016). The 
mechanism on how mutant p53 increases the expression of glucose transporters is 
through activation of NFKB. Wild-type p53 inhibits the activity of IκB kinases (IKK) 
that are required for NFKB activation and therefore suppresses  glucose transporter 
expression (Kawauchi et al., 2008).  
 
 IDH 
Isocitrate dehydrogenase (Thakkar et al.) 1 and 2 catalyse the oxidation of isocitrate 
to α-ketoglutarate (αKG). These enzymes also function in epigenetic regulation, 
redox states and DNA repair and are among many dysregulated oncogenes that are 
detected in glioma and AML patients (Parsons et al., 2008, Mardis et al., 2009, 
DiNardo et al., 2015). In AML, mutations in IDH1 and IDH2 present in about 6-19% 
and 8-34% of patients respectively, and is commonly found in adult patients (Im et 
al., 2014, DiNardo et al., 2015, Mardis et al., 2009). IDH1 is localised primarily in the 
cytoplasm and IDH2 is localised in the mitochondria. The mutations lead to the 
absence of a β-carboxyl group which is present in wild type IDH. These result in the 
neomorphic enzyme activity of IDH and favours irreversible conversion of αKG to an 
oncometabolite, 2-hydroxyglutarate (2HG). 2HG has an identical chemical backbone 
as isocitrate but lacks the carboxyl group (Figure 1-10) (Molenaar et al., 2018). As a 
consequence, IDH mutated cells impair TCA cycle metabolism, thus shifting the 
dependency towards glutaminolysis, which provides anaplerosis to the TCA at the 
level of αKG. 2HG accumulation elevates the risk of in vivo malignant brain tumours 
as shown in a study (Dang et al., 2009).  
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Figure 1-10: Mutations in the active carboxyl site of IDH1 and IDH2 result in 
neomorphic enzymatic activity.   Wild-type IDH catalyse the reversible conversion 
of isocitrate to α-ketoglutarate (αKG) (left reaction) and at the same time reduce 
NADP+ to NADPH and produce CO2. Mutations in IDH result in neomorphic enzymes 
that catalyse irreversible αKG to 2-hydroxyglutarate (2HG) and oxidised NADPH to 
NADP+ (Ward et al., 2010, Reitman et al., 2010). 
 
 PI3K/AKT pathway 
PI3K/AKT signalling is one of the important pathways in the regulation of metabolic 
processes. This pathway is triggered in many cancers through abnormal activation of 
receptor tyrosine kinases, loss of PTEN or by activating mutations in PIK3CA, AKT or 
RAS. Activation of this pathway has been implicated in metabolic reprogramming in 
cancer cells. For instance, AKT has been suggested as a “Warburg kinase” as it 
promotes cancerous glycolysis (Robey and Hay, 2009). AKT upregulates the 
glycolytic enzyme PFK-2 and thus increases glycolytic flux through increased activity 
of PFK-1 (Deprez et al., 1997). Glucose transporters were also shown to be 
upregulated upon activation of AKT and are associated with radioresistance (Fang, 
2015). In a study, constitutive activation of AKT by myristoylation caused glucose 
transporter-1 localisation to the cell surface, thus increasing uptake and 
phosphorylation of glucose (Rathmell et al., 2003). Aberrant expression of AKT also 
promotes localisation of HK2 to the mitochondrial membrane for direct access of ATP 
from ATP synthase and this accelerates glycolysis (Mathupala et al., 2006). 
Interestingly, high AKT activity protects prostate cancer cell lines from TRAIL-induced 
apoptosis (Nesterov et al., 2001). This protective mechanism is consistent with the 
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loss of PTEN function that is frequently observed in many cancers (Nesterov et al., 
2001, Hollander et al., 2011).  
 
 Targeting altered cellular metabolism in cancer 
Altered metabolism in cancer cells could be used to establish new therapeutic 
strategies to improve the outcome of patients. As cells depend on the synthesis of 
macromolecules such as nucleotides, amino acids and fatty acids to promote rapidly 
proliferating transformed cells, one could, therefore, take advantage of this loophole. 
 Targeting glucose metabolism  
Tumour cells exhibit accelerated glucose uptake which can be imaged by 
fluorodeoxyglucose positron emission tomography (FDG-PET). 2-deoxyglucose 
(2DG), an inhibitor for glycolysis, was developed in the 1950s (Wick et al., 1957) and 
suppresses  glycolysis by its disability to convert to fructose-6-phosphate.  Initially, 
2DG showed promising effects both in vitro and in vivo, but 2DG alone is insufficient 
for therapeutic benefit (Maschek et al., 2004). Another inhibitor in glucose 
metabolism is lonidamine, which inhibits glycolysis at the level of hexokinase 2,but 
has limited anti-tumour activity as a monotherapy agent (Nancolas et al., 2016). 
Despite restricted therapeutic values as a single agent, 2DG and lonidamine showed 
a promising effect when in combination with other chemotherapy agents (Maschek et 
al., 2004, Nancolas et al., 2016).  
 Targeting amino acid metabolism  
Currently, the only anticancer agent that targets amino acid metabolism is L-
asparaginase. This drug is FDA-approved for paediatric and adult ALL. Normal cells 
can produce asparagine, a non-essential amino acid, from aspartate and glutamine 
via asparagine synthetase. However, some cancer cells such as leukaemic 
lymphoblasts, do not express asparagine synthetase and therefore rely on the blood 
serum for asparagine supply. Asparaginases degrade asparagine resulting in the 
quick depletion of this amino acid in serum. Asparaginases also catalyse 
deamidation of glutamine, thus suppressing glutamine-derived asparagine. Since the 
1950s, treatment of ALL patients with asparaginases and standard chemotherapy 
drugs has aided the  in 5-year OS rate, to be more than 90% in the present day (Pui 
et al., 2009). Asparaginases showed a mix of antineoplastic effects on AML cell lines 
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(Jun et al., 2011). Although, asparaginases inhibited growth and induced apoptosis in 
some of the cell lines, there was no strong correlation between asparaginase 
sensitivity to asparagine synthetase expression in asparaginase-resistant cell lines 
(Jun et al., 2011).  
 Targeting nucleotide metabolism 
Gemcitabine, cytarabine and 5-fluorouracil are three antimetabolite 
chemotherapeutics targeting nucleotide biosynthesis. Although these drugs do not 
display tumour specificity, they cause improved patient survival in many different 
types of cancers. These agents target all actively dividing cells, thus explaining the 
frequent observation of side effects such as hair loss and nausea. 
 Targeting lactate metabolism 
Increased flux of glycolysis and concomitant lactate production is one of the 
characteristics of cancer cells (Nagarajan et al., 2016). Blocking the lactate 
transporters using a small molecule inhibitor (AZD3965) (Curtis et al., 2017) is 
currently in a phase I clinical trial in the UK for diffuse large B cell lymphoma and 
Burkitt lymphoma (https://www.cancerresearchuk.org/). AZD3965 selectively inhibits 
monocarboxylate transporter-1 (MCT-1), resulting in intratumoral lactate 
accumulation, and significantly inhibits tumour growth in vivo (Noble et al., 2017). 
Another putative target in lactate metabolism is lactate dehydrogenase (LDH), an 
enzyme that converts pyruvate to lactate. However, hitherto the inhibitor 
development remains a challenge as LDH has a small size of its substrate site 
(Zhang et al., 2018a). 
 Mutated enzyme 
As described previously, mutations in IDH1 and IDH2 enzymes result in the failure of 
normal αKG functions and leads to accumulation of the oncometabolite 2HG. 2HG is 
secreted into the serum and urine and has become one of the predictive biomarkers 
for AML (Mondesir et al., 2016, Fathi et al., 2012). Both IDH1 and IDH2 inhibitors 
(Ivosidenib and enasidenib mesylate) are currently in clinical trial phases I and II in a 
biomarker-based treatment of AML in the United States (https://www.cancer.gov/). 
These drugs lower 2HG levels both in vitro and xenograft models (Hansen et al., 
2014, Yen et al., 2017). 
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 Identification of SLC2A3 and PFKP as partner genes in RUNX1/ETO-driven 
leukaemia 
 
The oncogenic transcription factor RUNX1/ETO drives a complex transcriptional 
network, hence its perturbation affects the expression of many genes that is being 
bound by the fusion protein (Ben-Ami et al., 2013, Ptasinska et al., 2012, Ptasinska 
et al., 2014). We predicted that such a transcriptional network would contain crucial 
elements relaying the oncogenic function of the fusion protein, which could be 
exploited for potential pharmacological inhibition. RNA sequencing, Chip-sequencing 
and microarray data were intersected to identify a set of 110 RUNX1/ETO-bound 
genes that are responsive to RUNX1/ETO depletion. These genes are down-
regulated upon RUNX1/ETO knockdown, and therefore potentially required for 
RUNX1/ETO maintenance. A total of 374 shRNA constructs were produced using a 
pTRIPZ doxycycline (dox)-inducible vector and transduced on two RUNX1/ETO 
positive cell lines, Kasumi-1 and SKNO-1 (Figure 1-11-A). The screen was divided 
into two arms; dox-induced and a no-dox arm for both in vitro and in vivo, with the 
differentially expressed shRNA constructs being identified by comparison between 
the two corresponding arms. For the in vitro screen, the changes in shRNA pool 
compositions were determined after prolonged suspension culture for up to 56 days 
or in colony forming assay after three platings. To screen for genes relevant to 
leukaemogenesis in vivo, the shRNA library was intrafemorally transplanted in 
NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice with a total of 5x105 and 1x105 cells for 
both SKNO-1 and Kasumi-1. The screen results revealed that shSLC2A3 and 
shPFKP were significantly depleted in vivo in both of the cell lines; however, these 
two genes did not score in vitro (Figure 1-11-B). 
Further analysis of the corresponding shRNAs present in the pool showed that two of 
three SLC2A3 shRNAs were at least two-fold significantly depleted in vivo in both of 
the cell lines; however, there was no change in vitro (Figure 1-11-C). This was also 
the case for PFKP shRNA, where two constructs were depleted in vivo; however, 
there was no variation in long-term suspension culture and replating assays (Table 
1-1). As described in section 1.9.1, these two genes function in glycolysis and their 
overexpression is often associated with cancer (Thakkar et al., 2010, Cosset et al., 
2017). The screen was carried out by Dr Natalia Martinez Soria and Dr Lynsey 
McKenzie, and the analysis was done by Dr Sirintra Nakjang.  
 30 
 
 
 
Figure 1-11: shRNA in vitro and in vivo screen identifies SLC2A3 and PFKP as 
potential partner genes for RUNX1/ETO.   A) Scheme of RNAi screen targeting 
374 shRNA constructs conducted with dox-induced and no-dox arms for both in vitro 
and in vivo arms. B) Heatmap showing top hits of potential partner genes of 
RUNX1/ETO displayed as fold changes calculated based on collapsed changes of 
shRNAs using the RRA approach of MAGeCK. SLC2A3 and PFKP were depleted 
only in vivo but not identified in vitro (highlighted in red box). CFA, colony formation 
assay; LTC, long-term suspension culture; K1, Kasumi-1; S1, SKNO-1. C) Fold 
change of shSLC2A3 and shPFKP constructs in vivo. Two constructs were depleted 
in both cell lines. Figures were modified from Martinez-Soria et al. (2018).  
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shRNA Cell lines Construct log2fold change P-value 
shSLC2A3 Kasumi-1 1 -3.41 1.08E-06 
2 -2.84 0.002031 
3 -0.50 0.368761 
SKNO-1 1 -4.05 0.002054 
2 -6.31 2.7E-08 
3 0.03 0.970968 
shPFKP Kasumi-1 1 -3.74 2.13E-07 
2 -2.62 0.010734 
3 0.41 0.492792 
SKNO-1 1 -4.88 5.78E-06 
2 -1.55 0.132151 
3 -0.02 0.974915 
Table 1-1: Log2 fold change and p-value for shSLC2A3 and shPFKP depletion 
in vitro. Fold change of all the constructs of SLC2A3 and PFKP in vitro in both 
Kasumi-1 and SKNO-1. 
 
 Hypothesis and aims  
Therefore, this thesis describes the functions of glycolysis to promote 
leukaemogenesis. I hypothesised the oncogenic transcription factor RUNX1/ETO 
dysregulates SLC2A3 and PFKP to reprogramme metabolic functions for leukaemic 
propagation. 
The aims of this thesis are: 
1) To validate SLC2A3 and PFKP as the direct targets of RUNX1/ETO and as a 
potential therapeutic target in both in vitro and in vivo assays. These will 
include siRNA- and shRNA-mediated knockdown on RUNX1/ETO-positive cell 
lines, primary and patient-derived xenograft (PDX) cells. 
2) To explore the mechanism of potential metabolic reprogramming through 
SLC2A3 and PFKP in RUNX1/ETO-driven leukaemia in limited nutrient and 
oxygen conditions. This will include assessing the proliferation and colony 
formation in limited nutrient and oxygen conditions. The metabolic 
reprogramming will also be evaluated by using Seahorse Metabolic Assay. 
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3) To evaluate the efficacy of small molecule inhibitors in eradicating leukaemic 
cells. Firstly, by using a glycolysis inhibitor alone and in potential combination 
with a novel cell cycle inhibitor, palbociclib. Furthermore, investigation of the 
potential mechanism by which palbociclib-treated cells shunt its metabolic 
pathway will also be conducted. 
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Chapter 2 : Materials and Method 
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 Materials 
 Laboratories Equipment and Software 
2.1.1.1 Laboratories Equipment 
Equipment Manufacturer 
Flow cytometry 
FACSCanto II 
FACSCalibur 
Fortessa X20 
Attune NxT 
FACSAria III 
 
BD Biosciences 
BD Biosciences 
BD Biosciences 
ThermoFisher Scientific 
BD Biosciences 
Thermal cycler 
ViiA 7 Real-Time PCR System 
GeneAmp PCR 2700 
 
ThermoFisher Scientific 
AB Applied Biosystem 
Centrifuge 
Centrifuge 5804R 
Centrifuge 5804 
Centrifuge 5415 R 
Centrifuge 5424 
Ultracentrifuge 
 
Eppendorf 
Eppendorf 
Eppendorf 
Eppendorf 
Eppendorf 
Incubator 
Hypoxia  
 
Baker Ruskinn 
Imaging 
ChemiDoc MP 
GBox 
 
Bio-Rad 
Syngene 
Seahorse Analyser 
Seahorse Analyser 
 
Agilent Technologies  
Nanodrop 
Nanodrop-ND100 
 
Nanodrop Technologies  
Table 2-1: Equipment used in the study. 
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2.1.1.2 Software 
Software Manufacturer 
FACS Diva BD Biosciences 
FlowJo v10.0.8 FlowJo, LLC 
Seahorse Wave Desktop Agilent Technologies 
SnapGene Viewer GSL Biotech LLC 
Primer Express 2.0 Applied Biosystem 
QuantStudio Real-Time PCR System Applied Biosystem 
SDS 2.3 Applied Biosystem 
Living Image 4.5.5 Perkin Elmer 
Table 2-2: Software used for analysis of data. 
 
 Chemicals and Reagents  
2.1.2.1 Kits and chemicals 
Name Manufacturer 
RNeasy Mini Kit Qiagen 
RevertAid™ H Minus cDNA Synthesis Kit Thermo Fisher Scientific 
QIAquick Gel Extraction Kit Qiagen 
DNeasy Blood & Tissue Kit Qiagen 
EndoFree Plasmid Maxi Kit Qiagen 
QIAprep Spin Miniprep Kit Qiagen 
QIAshredder  Qiagen 
BCA Protein Assay Kit Bio-Rad 
Immobilon Western Chemiluminescent HRP 
Substrate 
Milipore 
FITC Annexin V Apoptosis Detection Kit I BD Bioscience 
BV421 Annexin V BD Bioscience 
2-(N-(7-Nitrobenz-2-oxa-1,3-diazol-4-yl)Amino)-2-
Deoxyglucose (2-NBDG) 
Cayman Chemical 
4',6-Diamidino-2-Phenylindole, Dihydrochloride 
(DAPI) 
Sigma 
SOB Medium Sigma 
LB Miller  Sigma Aldrich 
Platinum® SYBR® Green qPCR SuperMix-UDG Invitrogen 
ATP Detection Assay Abcam 
CellROX Green Flow Cytometry Kit Life Technoligies 
Molecular weight ladder (N3232L)  New England Biolabs 
DNA gel loading dye (B7024S) New England Biolabs 
Table 2-3: Kits and chemicals. 
 
2.1.2.2 Tissue culture media and supplements 
Reagents Manufacturer 
RPMI 1640, R8758 Sigma 
RPMI 1640, R5886 Sigma  
DMEM, D5671 Sigma 
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RPMI 1640, no glucose Gibco 
L-Glutamine  Sigma 
GM-CSF Stemcell Tech. 
D-Glucose Sigma 
Sodium Pyruvate (S8636-100ml) Sigma 
Penicillin/Streptomycin Sigma 
StemSpan™ Myeloid Expansion Supplement (SFEM II)  Stemcell Tech. 
StemSpan™ Myeloid Expansion Supplement II (100X) Stemcell Tech. 
Seahorse XF Base Media Agilent 
Fetal Calf Serum (FCS) Gibco 
Table 2-4: Tissue culture media and supplements. 
 
 
 Media Composition and Buffers 
2.1.3.1 Cell culture media 
Cells (Condition) Media Supplements 
Kasumi-1 
(Standard Culture) 
RPMI 1640, R8758  10% (v/v) FCS  
Kasumi-1 (2.5 mM 
Glucose) 
RPMI 1640, no glucose  10% (v/v) FCS 
2.5 mM Glucose 
Kasumi-1 (1 mM 
Glutamine) 
RPMI 1640, R5886  10% (v/v) FCS 
1 mM Glutamine (Sigma) 
SKNO-1 (Standard 
Culture) 
RPMI 1640, R8758  20% (v/v) FCS  
7 ng/µl GM-CSF 
SKNO-1 (2.5 mM 
Glucose) 
RPMI 1640, no glucose  
 
20% (v/v) FCS  
7 ng/µl GM-CSF 
2.5 mM Glucose 
SKNO-1 (1 mM 
Glutamine) 
RPMI 1640, R5886 20% (v/v) FCS  
8 ng/µl GM-CSF 
1 mM Glutamine (Sigma) 
THP-1 RPMI 1640, R8758  10% (v/v) FCS 
MV4-11 RPMI 1640, R8758 20% (v/v) FCS 
HL-60 RPMI 1640, R8758 20% (v/v) FCS 
293T DMEM, D5671 
 
10% (v/v) FCS  
1% (v/v) Sodium Pyruvate 
1% (v/v) L-glutamine 
BM-iPSC-MSC  SFEM II  Unpublished 
Patients-derived 
xenograft (PDX) 
and primary cells 
SFEM II  StemSpan™ Myeloid Expansion 
Supplement II (100X) 
20% (v/v) FCS 
Table 2-5: Cell culture media and composition. 
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2.1.3.2 Bacterial culture 
Inoculation buffer 55 mM MnCl2 
 
15 mM CaCl2 
 
250 mM KCl 
 
10 mM PIPES (pH 6.7) 
 
Up to 1 l of H2O 
Lysogeny Broth (LB) 25 g LB Miller 
medium Up to 1 l of H2O 
LB agar 6 g Bacto agar 
 
12.5 g of LB Miller 
 
Up to 500 ml of H2O 
 
 
2.1.3.3 Transfection buffer  
CaCl2 solution 36.75 g CaCl2 
 
Up to 500 ml of H2O 
HeBS, 2X, pH 7.00 16.36 g NaCl 
 
11.9 g HEPES 
 
0.213 g Na2HPO4 
 
Up to 1l of dH2O 
Special water 125 µl of 1M HEPES (pH 7.3) 
 
50 ml of dH2O 
 
2.1.3.4 Flow cytometry  
Flow cytometry staining buffer 2% FCS 
 0.02% sodium azide 
 PBS 
Flow cytometry sort buffer 0.5% (w/v) bovine serum albumin 
 PBS 
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2.1.3.5 Clonogenic assay 
Methylcellulose medium 0.56 g methylcellulose 
 
5 ml PBS 
 
85 ml corresponding growth 
medium 
 
10 ml FCS 
      
2.1.3.6 DNA electrophoresis buffer 
5X DNA loading dye 
 
10X TAE buffer 48.4 g Tris 
 
11.4 ml glacial acetic acid (17.4 M) 
 
3.7 f ETA, disodium salt 
 
Up to 1 l of H2O 
2.1.3.7 Western blotting  
Urea buffer  9M Urea 
 
4% (w/v) CHAPS 
 
1% (w/v) EDTA 
 
1% (w/v) DTT 
10% SDS: 100 g SDS 
 
1 l H2O 
10% APS 1 g Ammonium persulfate 
 
10 ml H2O 
4x Separating Gel Buffer 1.5 M Tris 
 
0.4% (w/v) SDS 
 
pH 8.8 with HCl 
4x Stacking Gel Buffer 500 mM Tris 
 
0.4% (w/v) SDS 
 
pH 6.8 with HCl 
10x Tris-Glycine Buffer 250 mM Tris 
 
1.92 M Glycine 
Electrophoresis Buffer 1x Tris-Glycine Buffer 
 
0.1% (w/v) SDS 
Blotting Buffer 1x Tris-Glycine Buffer 
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10% (v/v) Methanol 
2x SPAG Loading Buffer 50% (v/v) 4x Stacking gel buffer 
 
20% (v/v) Glycerol 
 
4% (w/v) SDS 
 
5% (v/v) β-Mercaptoethanol 
 
0.1% (v/v) Bromophenol Blue 
10x TBS 100 mM Tris-Cl pH 8.0 
 
1.5 M NaCl 
 
1 l H2O  
1XTBS-T 10 mM Tris-Cl pH 8.0 
 
0.15 M NaCl 
 
0.1% (v/v) Tween 
10% Milk 5 g dry milk 
 
50 ml 1XTBS-T 
Ponceau-S red Solution  0.5% (v/w) Ponceau-S red  
 
1 % (v/v) Acetic acid  
 
50 ml H2O 
 
2.1.3.8 Cell cycle 
Staining buffer 1 µg/ml DAPI 
 0.25% (v/v) Triton-100 
 
2.1.3.9 Enzyme and buffer 
Name Manufacturer 
BsmBI Thermo Scientific 
T4 Polynucleotide Kinase Thermo Scientific  
T4 DNA Ligase Thermo Scientific 
Table 2-6: Enzyme and buffer for cloning methods. 
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 Cell Culture Methods 
 Cell Culture 
2.2.1.1 Cell lines 
Each cell lines were cultured in standard culture conditions in every experiment 
unless otherwise stated. Positive acute myeloid leukaemia cell lines (Kasumi-1 and 
SKNO-1) were used in this study and cultured at 37°C, 5% CO2. Cells were counted 
using the trypan blue exclusion method and split to 5.0 x 105 cell/ml with fresh, pre-
warmed media. Cells are generally passaged 3 times a week. 
2.2.1.2 Patients derived xenograft (PDX) materials 
Patients’ derived xenograft (PDX) materials were obtained from frozen stock in our 
lab. The PDX materials were prepared by Dr Helen Blair. The frozen vials were 
thawed in a warmed water bath, cleaned with 75% ethanol and quickly transferred 
into 10 ml pre-warmed media in 20 ml universal tube. The tube was spun down at 
300 g for 5 minutes and the supernatant was removed. A volume of 10 ml fresh 
warmed media was added into the tube and cells were counted by trypan blue 
exclusion method (Section 2.2.1.3). The cells were cultured in SFEM II media 
containing 1X myeloid expansion media and 20% FCS at a concentration of 1.0 x 106 
cells/ml.  
2.2.1.3 Cell Counting  
Haemocytometer (Hawksley) with a chamber depth of 1.0 mm was used for counting 
the cells. The haemocytometer was cleaned with 70% ethanol prior to counting and 
allowed to dry. A glass coverslip was then fixed in place. Cell suspension and trypan 
blue were mixed with the ratio 1:1 and 10 µl of the mixture was added to the 
chamber. Cells in four corner squares were counted (each square was 1 mm2 equal 
to 0.1 µl). Cells touching top and left line of each grid were counted and those 
touching bottom and right line of each grid were not counted. The average number of 
cells per square was calculated, multiplied by 2 (dilution factor) and 104 to obtain the 
number of cells per ml. 
2.2.1.4 Cell Thawing 
Frozen cells were thawed rapidly in 37oC water bath, quickly transferred to 20 ml 
universal tube and diluted with 10 ml warmed culture media. The cells were then 
spun down at 300 g for 5 minutes. Supernatant was removed and cells were 
resuspended in corresponding culture medium and concentration.  
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2.2.1.5 Cell Freezing 
Cells were counted and pelleted at 300 g for 5 minutes. A volume of corresponding 
freezing media was added to make the concentration 5 x 106 cell/ml and transferred 
a maximum of a ml to a pre-labelled cryovial tube. The tubes were placed in an 
insulated freezer box or immediately transferred to the -80oC freezer.  
2.2.1.6 Cell Lysis 
Lysis buffer was prepared by adding 10 µl of β-merchaptoethanol (β –ME) into 1 ml 
of RLT buffer (Qiagen) and it is stable for a month at room temperature.  
Cells were counted and pelleted in a universal tube at 300 g for 5 minutes. The 
supernatant was removed and 10 ml of PBS was added and spun down at 300 g for 
5 minutes. The supernatant was removed and 1 ml of PBS was added into the cells 
pellet, pipetted up and down and then transferred into a 1.5 ml Eppendorf tube. The 
tube was centrifuged at 300 g for 5 minutes and PBS was removed. Lysis buffer was 
added according to the cell number as described in table below. The lysed cells were 
extracted immediately or stored in -20oC.  
 
Number of cells (x106 cell) Volume lysis buffer (µl) 
5.0 – 10 600 
0.5 – 5.0 350 
Table 2-7: Volume of lysis buffer used to lyse cells according to the number of 
cells. 
 
 Electroporation 
Small interfering RNA (siRNA) was used as a tool to down-regulate target genes. 
siRNA is a double-stranded RNA consist of 19-22 nucleotides that can be introduced 
into the cells by applying electricity, called electroporation. This procedure was first 
performed to deliver DNA in fibroblasts and then generalised to other cell types 
including lymphocytes and embryonic stem cells (Wong and Neumann, 1982, Potter 
et al., 1984, Potter and Heller, 2003). The principle involves electric pulse delivered 
between two electrodes to increase permeability of cell membrane by forming pores 
and therefore siRNA may pass through the membrane.  
Inside the cytosol, siRNA binds to RNA induced silencing complex (RISC) which 
separates the more stable antisense dsRNA and remove sense strand. The 
antisense strand remains attached to the RISC complex and binds to the target 
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sequence of messenger RNA (mRNA). The target mRNA is then cleaved by RISC 
complex, degraded and therefore cannot be translated into protein, effectively 
silencing the gene.  
The siRNAs were resuspended in nuclease-free H2O to produce stock siRNA of 100 
µM which was then aliquoted and stored in -20oC. Prior to the electroporation, cells 
were counted and pelleted at 300 g for 5 minutes. The pellets were then 
resuspended in fresh media to make the concentration of 1.0 x 107 cell/ml and 
transferred into an electroporation cuvette. siRNA was added into the electroporation 
cuvette to the final concentration of 200 nM and gently mixed before placing it in 
electroporator. The voltage and duration for each cell lines are listed in Table 2-8. As 
to confirm electricity has been applied, foamy bubbles should be observed in the 
cells suspension media in cuvette. The cells were then allowed to recover for 15 
minutes at room temperature before transferred into culture flask to the final 
concentration of 0.5 x 106 cell/ml and kept at 37oC in CO2 incubator.  
Cell line Voltage (V) Time (ms) 
Kasumi-1 330 10 
SKNO-1 350 10 
PDX and primary cells 350 (twice) 10 
Table 2-8: Electroporation voltage and time used to do electroporation for each 
type of cells. 
 
siRNA Sequence 
Target site 
location 
siRE 5′-CCUCGAAAUCGUACUGAGAAG-3′ 2102-2122 
 
3′-UUGGAGCUUUAGCAUGACUCU-5′ 
 
siMM 5′-CCUCGAAUUCGUUCUGAGAAG-3′ 2102-2122 
 3′-UUGGAGCUUAAGCAAGACUCU-5′  
siSLC2A 5’-AAGTACGTTATTGTTGACTTA-3’ 3254-3274 
 3’-UUCGCCAACUGCUUCUCAGGCUGCC-5’  
siPFKP 5’-CAGGAUCAUCGAGGUCGUCGA-3’ 592-672 
 3’-UCGACGACCUCGAUGAUCCUG-5’  
Table 2-9: siRNA sequences and the target genes. 
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 Lentivirus production 
Lentivirus was produced in 293T cells using calcium phosphate precipitation method 
consisted of lentiviral envelope (pMD2.G), packaging (pCMVdR8.91) and expression 
plasmids.  
 293T sub-culture 
The 293T cells were cultured in a T175 cm2 tissue culture flask and split when it 
reached 70-80% confluency. The medium was aspirated from the flask and gently 
washed with pre-warmed PBS to remove excess medium and serum. A volume of 2 
ml of pre-warmed trypsin/EDTA was added to the cells monolayer and incubated 10-
15 minutes at 37oC in CO2 incubator. EDTA acts as a chelator for calcium and 
magnesium that are essential for cell to cell attachment, while trypsin breaks focal 
adhesion of cells to culture vessel and disaggregates adherent cells into single 
suspension. The cells were checked under the microscope to confirm all the cells 
were detached from culture flask.  
Once all the cells were confirmed to detach, an 8 ml of medium was added to inhibit 
trypsin activity and mixed by pipetting. The total cell count was determined by trypan 
blue exclusion method (2.2.1.3) and seeded in a new flask with the concentration of 
1-3 x 105 cell/ml in 20 ml medium. 
 Co-transfection 
A day before co-transfection, the 293T cells were seeded in 100 mm tissue culture 
dishes at the concentration of 2 x 105 cells/ml in 10 ml medium. On the next day, 
when the cells had reached 30-60% confluency, 5 µg of lentiviral envelope 
(pMD2.G), 15 µg of packaging (pCMVdR8.91) and 20 µg of expression plasmids 
were mixed in a sterile microfuge tube. The volume of the mixture was adjusted with 
HEPES buffer solution to a total volume of 250 µl, followed by addition of 250 µl of 
0.5 M calcium chloride solution and mixed well. The solution was then added slowly 
droplet by droplet into pre-prepared 500 µl of 2X HeBS solution (pH 7.00) in a 5 ml 
vial and mixed by vortexing. The mixture was left at room temperature for 30-40 
minutes to allow the formation of calcium phosphate precipitate. This suspension was 
then added dropwise onto the 293T cell monolayer and cultured at 37oC in a CO2 
incubator for 12-16 hours. Afterwards, the medium was removed, the cells were 
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washed with pre-warmed PBS, a 30 ml of fresh growth medium was added and 
cultured in standard culture condition for three days.   
 Lentiviral harvesting and concentrating 
Approximately 90 hours after the co-transfection, the lentivirus supernatant was 
collected in 50 ml collection tube. It was centrifuged at 600 g for 15 minutes at 4oC, 
and the supernatant was further filtered using 0.45 µm PVDF membrane filter to 
remove any residual debris. The lentivirus was concentrated using a Beckman 
Optima L-100 XP Ultracentrifuge at 120,000 g, 4oC for 2 hours in a swinging bucket 
rotor. Once completed, the supernatant was removed carefully by decanting, and the 
viruses were resuspended in 1 ml of corresponding target cells growth media, 
aliquoted into several tubes and stored in -80oC freezer. 
 Lentiviral Transduction 
Lentiviral transduction was performed using spinoculation method. The target cells 
were pelleted and adjusted to the concentration of 1.0 x 106 cell/ml with standard 
growth medium. Polybrene was added to the cells to a final concentration of 8 µg/ml 
to help neutralises charge repulsion between virions and sialic acid of the cells. A 
total of 500 µl cells were then plated in a 48-well plate and different volume of viruses 
was added. The plate was centrifuged at 900 g at 34oC for 50 minutes and incubated 
in a 37oC CO2 incubator for the next three days.  
 Colony Formation Assay 
Colony formation assay was carried out in semi-solid medium to check the ability of a 
single cell to grow into a colony. Cells were counted and 5000 cells were pipetted 
into a sterile 20 ml tissue culture tube. A total of 500 µl pre-filtered methylcellulose 
media was added into the tube and mixed slowly to reduce formation of bubbles. The 
mixture was then added into a 24-well plate an incubated at 37oC in a CO2 incubator. 
After approximately 7-10 days, a colony with at least 30 cells were counted.  
 
  
 45 
 
 Cell Viability Analysis 
2.3.6.1 Cell cycle 
Cell cycle was carried out using nuclear and chromosome counterstain, 4',6-
Diamidino-2-Phenylindole, Dihydrochloride (DAPI). DAPI emits blue fluorescence 
upon binding to AT regions of DNA and is useful for flow cytometry quantification. A 
total of 1.0 x 106 cells was pelleted and washed twice with PBS. The cells were fixed 
4% paraformaldehyde (PFA) for 15 minutes and washed twice with PBS. The fixed 
cells were either directly stained or resuspended in PBS and kept in 4oC for later 
analysis. A volume of 200 µl staining buffer that contained 0.25%-Triton 100 was 
added and incubated for 10 minutes in the dark before analyses with flow cytometer. 
Triton-100 permeabilises the cell membrane and allows DAPI to stain the 
chromosomes. Flow cytometry data was then analysed using FlowJo software. 
2.3.6.2 G0 separation 
A total of 1 x 106 cells was resuspended in a 1 ml culture media containing 10 µg/ml 
Hoechst33342 to make the final concentration of 1.0 x 106 cell/ml. The cells were 
incubated at 37oC for 45 minutes in the dark to allow binding of Hoechst33342 to 
DNA. Next, the cells were stained with pyronin Y at the concentration of 100 µg/ml, 
further incubated for 15 minutes at 37oC in CO2 incubator, transferred on ice and 
measured with flow cytometer. The flow cytometry data was then analysed with 
FlowJo software. 
2.3.6.3 Apoptosis Assay 
Apoptosis assay was carried out using either FITC Annexin V apoptosis Detection Kit 
I or BV421 Annexin V. The FITC Annexin V kit contained two dyes; Annexin V 
conjugated to FITC that stained early apoptotic cells and propidium iodide (PI) that 
stained late stages of cell death. Annexin V has higher affinity to the membrane 
phospholipid phosphatidylserine (PS) in the presence of Ca2+. Cells undergoing 
apoptosis have its PS exposed to the extracellular environment, bound to Annexin V 
and can be detected with flow cytometry.  
A total of 1.0 x 106 cells was washed twice with cold PBS in 5 ml flow cytometry tube 
and resuspended in 100 µl of 1X Binding Buffer. This buffer contained 100 mM Ca2+ 
that formed phospholipid-calcium complexes to mediate Annexin V binding to PS. A 
volume of 5 µl Annexin V was added for one colour analysis or together with 5 µl PI 
for two colour analyses. The cells were incubated for 15 minutes in the dark at room 
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temperature and measured immediately by flow cytometry. The flow cytometry data 
was then analysed with FlowJo software. 
2.3.6.4 Reactive Oxygen Species Assay 
A total of 5.0 x 105 cells was spun down and resuspended in 1 ml fresh media. A 
positive control was stained with tert-butyl hydrogen proxide (TBHP) at the final 
concentration of 200 µM and incubated at 37oC for 45 minutes. Following that, cells 
were then stained with CellROX green at the final concentration of 500 nM and 
incubated at 37oC for 45 minutes protected from light. CellROX green reagents are 
cell-permeable and do not fluorescent while in the reduced state. Upon entry into the 
cells, CellROX is oxidised by reactive oxygen species (ROS) and emits bright green 
fluorescent. Data was captured with Facs Canto II and analysed using FlowJo 
software. 
 Small molecule inhibitor assay 
Cells were seeded at 5 x 105 cell/ml and drugged on day 0. Subsequent analyses 
was carried out on day 3. Table 2-10 shows small molecule inhibitor used in this 
study. 
Name Supplier 
2-deoxyglucose Sigma 
palbociclib DC Chemicals 
Table 2-10: Small molecule inhibitors used in this study. 
 
Drug combinations study was performed based on Chao-Talalay method. This 
method used several concentrations for each compound and mixed at a constant 
ratio as the third drug. Effective concentration that caused 50% of inhibition (EC50) of 
single treatment was compared to the median effect achieved by the combination of 
the two drugs to derive a combination index (CI) value. CI was calculated based on 
the following equation: 
𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 𝐶𝐶𝐶𝐶𝑖𝑖𝑖𝑖𝑖𝑖 (𝐶𝐶𝐶𝐶) = 𝐶𝐶𝐶𝐶50𝑐𝑐𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 𝐶𝐶𝑜𝑜 𝐷𝐷1
𝐶𝐶𝐶𝐶50𝑠𝑠𝐶𝐶𝐶𝐶𝑠𝑠𝑠𝑠𝑖𝑖 𝐶𝐶𝑜𝑜 𝐷𝐷1 + 𝐶𝐶𝐶𝐶50𝑐𝑐𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 𝐶𝐶𝑜𝑜 𝐷𝐷2𝐶𝐶𝐶𝐶50𝑠𝑠𝐶𝐶𝐶𝐶𝑠𝑠𝑠𝑠𝑖𝑖 𝐶𝐶𝑜𝑜 𝐷𝐷2 
𝑊𝑊ℎ𝑖𝑖𝑒𝑒𝑖𝑖;𝐷𝐷1 = 𝐷𝐷𝑒𝑒𝑢𝑢𝑠𝑠 1 𝐶𝐶𝐶𝐶𝑖𝑖 𝐷𝐷2 = 𝐷𝐷𝑒𝑒𝑢𝑢𝑠𝑠 2 
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The description of CI values is listed below. 
Symbol Description 
<0.1 +++++ Very strong synergism 
0.1-0.3 ++++ Strong synergism 
0.3-0.7 +++ Synergism 
0.7-0.85 ++ Moderate synergism 
0.85-0.90 + Slight synergism 
0.90-1.10 ± Nearly additive 
1.10-1.20 – Slight antagonism 
1.20-1.45 – – Moderate antagonism 
1.45-3.3 – – – Antagonism 
3.3-10 – – – – Strong antagonism 
>10 – – – – – Very strong antagonism 
Table 2-11: The combination index values and its description. CI values indicate 
synergism, additive and antagonism effects as outlined in Chao-Talalay method 
(Cubitt et al., 2013). 
 
 
 Flow Cytometry and Sorting  
 Flow cytometry 
Flow cytometry analyses were carried out to measure endogenous fluorescent 
protein and immunophenotypes of cells. The analyses were carried out using Facs 
Calibur, Facs Canto II or Fortessa X20.  
2.4.1.1 Endogenous fluorescent protein/marker 
Some cells were transduced to express endogenous fluorescent proteins or 
incubated with a fluorescent marker and therefore cells can be detected by flow 
cytometry. For endogenous expression of fluorescent protein, a small number of cells 
were added into FACS tube, pelleted at 300 g for 5 minutes and resuspended with 
200 – 500 µl of PBS and analysed according to the appropriate channel. In some 
cases, the fluorescent colour of the cells in single tube overlapped onto each other, 
thus compensation setting was required. In this case, a single positive fluorescent 
colour was prepared, and compensation setting was done according to the machine 
protocol.  
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2.4.1.2 Immunophenotyping 
A total of 1.0 x 106 cells were pelleted in a FACS tube at 300 g for 5 minutes. The 
cells were washed 2 times with PBS and further blocked by flow cytometry staining 
buffer for 15 minutes at room temperature. Afterwards, the primary antibody (Table 
2-12) was added and incubated at room temperature for 30 minutes in the dark. The 
cells were washed twice with flow cytometry staining buffer to remove unbound 
antibody. Cells were resuspended in 200 µl of flow cytometry staining buffer and 
immediately captured with Flow Cytometry.  
Antibody-species 
raised in 
Supplier Catalogue 
number 
Human Glut3 R&D System FAB1415G 
Mouse IgG2B-Isotype 
Control 
R&D System IC0041G 
Mouse CD45 Biolegend 103109 
Human CD45 Biolegend 368521 
Human CD34 Biolegend 343613 
Human CD33 Biolegend 366605 
Human CD15 Biolegend 301903 
Human CD14 BD Pharmigen 506180 
Table 2-12: Antibody used in the flow cytometry analysis. 
 
2.4.1.3 Sorting 
Cells sorting technique was used to isolate cells population from a mixed population. 
The technique utilises the identification of endogenous fluorescent protein or pre-
stained specific immunophenotype to differentiate each population. Cells were sorted 
using FACs Aria III that is located in Herschel Building and sorting was carried out by 
Flow Cytometry Core Facility support staffs. Cells labelling with specific 
immunophenotype was assisted by Dr Helen Blair. Cells for sorting were counted 
and pelleted at 300 g for 5 minutes. It was then washed twice with PBS at the same 
speed and time. Cells were then resuspended in sort buffer and proceed with the 
sorting. The sorted cells were collected in the flow cytometry staining buffer, washed 
and continued with further application. 
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 Molecular Biology Methods  
 Cloning 
The cloning procedure involved insertion of shRNA sequences into digested vector. 
Briefly, synthesised oligonucleotides were phosphorylated to create overhang 
templates before being ligated into a linearised vector.  
2.5.1.1 Oligo phosphorylation 
The sense and antisense oligonucleotides were synthesised from Sigma-Aldrich 
(Table 2-13). In the reaction that contains ATP, the complementary oligonucleotides 
were hybridised and phosphorylated on the 5’ terminus to create oligo duplex, thus 
able to ligate into the desired vector.   
shRNA Primers 
shPFKP1 Fwd AGCGACGTGTTTGACTGCAGGAAGAATAGTGAAG
CCACAGATGTATTCTTCCTGCAGTCAAACACGC  
Rv GGCAGCGTGTTTGACTGCAGGAAGAATACATCTG
TGGCTTCACTATTCTTCCTGCAGTCAAACACGT 
shPFKP2 Fwd AGCGCGCATATGAGCAGAATTAATTATAGTGAAGC
CACAGATGTATAATTAATTCTGCTCATATGCA  
Rv GGCATGCATATGAGCAGAATTAATTATACATCTGT
GGCTTCACTATAATTAATTCTGCTCATATGCG 
shPFKP3 Fwd AGCGCTCCCGCTACTGTGTCCAACAATAGTGAAG
CCACAGATGTATTGTTGGACACAGTAGCGGGAA  
Rv GGCATTCCCGCTACTGTGTCCAACAATACATCTGT
GGCTTCACTATTGTTGGACACAGTAGCGGGAG 
shSLC2A3#1 Fwd AGCGCGCTCCTGGAGCCTTTGAATATAGTGAAGC
CACAGATGTATATTCAAAGGCTCCAGGAGCA  
Rv GGCATGCTCCTGGAGCCTTTGAATATACATCTGTG
GCTTCACTATATTCAAAGGCTCCAGGAGCG 
shSLC2A3#2 Fwd AGCGCGGGAGAAATGTTGTTCATTATAGTGAAGC
CACAGATGTATAATGAACAACATTTCTCCCA  
Rv GGCATGGGAGAAATGTTGTTCATTATACATCTGTG
GCTTCACTATAATGAACAACATTTCTCCCG 
shSLC2A3#3 Fwd AGCGCGACCAAAGAATGTTTATAGCAAATAGTGAA
GCCACAGATGTATTTGCTATAAACATTCTTTGGG  
Rv GGCACCCAAAGAATGTTTATAGCAAATACATCTGT
GGCTTCACTATTTGCTATAAACATTCTTTGGTCG 
shRUNX1/ETO Fwd AGCGAAACCTCGAAATCGTACTGAGATAGTGAAG
CCACAGATGTATCTCAGTACGATTTCGAGGTTC 
 Rv GGCAGAACCTCGAAATCGTACTGAGATACATCTGT
GGCTTCACTATCTCAGTACGATTTCGAGGTTT 
shNTC Fwd AGCGATCTCGCTTGGGCGAGAGTAAGTAGTGAAG
CCACAGATGTACTTACTCTCGCCCAAGCGAGAG 
 Rv GGCACTCTCGCTTGGGCGAGAGTAAGTACATCTG
TGGCTTCACTACTTACTCTCGCCCAAGCGAGAT 
Table 2-13: shRNA sequences used in this study.  
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Thermal cyclers were pre-heated to 37oC and 95oC. The components of the reactions 
(Table 2-14) were mixed in a clean 1.5 ml tube.  
Components Volume (µl) 
Sense oligo (100 µM) 1.0 
Antisense oligo (100 µM) 1.0 
T4 DNA ligase buffer (Fermentas) 1.0 
T4 Polynucleotide kinase (Fermentas) 0.5 
H2O 6.5 
Total volume 10.0 
Table 2-14: Hybridisation and phosphorylation reaction of oligonucleotides.  
 
The tube was incubated at 37oC for 30 minutes to allow the phosphorylation reaction. 
It was then transferred to 95oC thermal block and incubated for 4 minutes to denature 
the DNA and inactivate the kinase activity. Next, the hybridisation process was 
carried out by setting the thermal cycler to 70oC, and the temperature decreases at 
about 5oC per minute. Once the thermal block reached 70oC, the reaction was left for 
10 minutes and continued to cool down to 22oC using the same thermal block. The 
reaction was left at room temperature for 4 hours or overnight to achieve complete 
hybridisation. The annealed oligo duplex was diluted 1:200 with H2O for further 
application.     
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2.5.1.2 Vector digest 
Vector digest was performed to cleave plasmid DNA using specific restriction 
endonucleases (Thermo Fisher Scientific) and provide template for shRNA 
oligonucleotides. In 1.5 ml clean tube, an amount of 1 µg plasmid DNA was mixed 
with the component as listed in Table 2-15 below. 
Components Volume (µl) 
Restriction enzyme 0.5  
10X restriction buffer 1.0 
H2O Up to 20 
Table 2-15: Restriction digestion reaction. 
 
The reaction was incubated at the appropriate temperature of the enzymes (mostly 
37oC; referred to the datasheet of the enzyme) for one hour.  
2.5.1.3 Gel electrophoresis 
Electrophoresis was performed to separate the DNA by size for visualisation and 
purification of the digested plasmid. The electrophoresis gel was prepared by mixing 
0.5 g agarose in 50 ml 1X TAE buffer and heated in microwave until the agarose was 
completely dissolved. The mixture was let to cool down for 5 minutes and GelRed 
Nucleic Acid Stain was added in a ratio of 1:10000. The solution was poured into a 
gel tray with a comb in place and left to solidify at room temperature. Once it has 
solidified, the gel was loaded into electrophoresis unit and covered with 1X TAE 
buffer. Molecular weight ladder (New England Biolabs, N3232L) was loaded into the 
first well. DNA gel loading dye (New England Biolabs, B7024S) was mixed with 
plasmid DNA in a ratio of 1:10 and loaded into the next wells. The electrophoresis 
was set at 100 V until the dye line reached approximately 75% way down of the gel 
and visualised with BioRad Imaging.  
2.5.1.4 Gel purification 
Electrophoresed gel was visualised on UV box with proper safety equipment were in 
place. The digested vector was cut off from the gel by using a clean razor blade and 
placed in a clean 1.5 ml microfuge tube. The tube filled with the cut vector was 
weighed after zeroing the scale with an empty tube. The weight of the gel was used 
to determine how much of buffer required to liquefy the gel in the DNA isolation step. 
DNA purification was carried out using QIAquick Gel Extraction Kit (Qiagen, 28704). 
The excised gel was lysed in high-salt conditions buffer and precipitated by adding 
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isopropanol. This mixture allows nucleic acid to adsorb to the silica membrane. The 
DNA was washed with 750 µl PE that contained 70% ethanol to dissolve remaining 
salt in the silica membrane and finally eluted with an appropriate volume of elution 
buffer.        
2.5.1.5 Ligation 
Ligation reaction was carried out to ligate oligo duplex (2.5.1.1) into its appropriate 
digested vector. In this reaction, DNA ligase mediates ligation of the 3’-hydroxyl end 
(acceptor) to 5’-phosphoryl end (donor) with the presence of ATP to create new 
phosphodiester bond. The mixture of the reaction is described in the table below: 
 
Components Proportion 
Vector 30 ng 
Insert 1 µl 
10X T4 DNA ligase buffer 1 µl 
T4 DNA ligase 2.5 U 
H2O Up to 10 µl 
Table 2-16: Ligation reaction mix preparation. 
 
The reaction was carried out at room temperature for longer than 3 hours or 
overnight. The products were either stored at -20oC or directly transformed into 
bacteria. 
 Bacterial transformation 
Bacterial transformation is a technique to introduce exogenous DNA into a bacteria 
cell. In our lab, we used Stbl3 competent bacteria derived from HB101 Escherichia 
Coli (E. Coli) as a tool to store and amplify plasmids. It was first purchased from Life 
Technologies and thereafter were amplified in our lab.   
2.5.2.1 Production of competent bacteria Stbl3 
Stbl3 was prepared from competent E. Coli based on Inoue et al. (1990 #226). All of 
the containers, buffers and solutions were prepared sterile and aseptic technique 
was practised during this protocol. The cells were treated without antibiotics unless 
otherwise stated. 
Stbl3 was grown overnight on LB agar plate without antibiotics at 37oC. Colonies 
were picked and cultured in 25 ml LB broth in 250 ml flask for 6-8 hours at 37oC with 
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vigorous shaking (250-300 rpm). This culture was then used to inoculate three 
different 500 ml flasks containing 250 ml LB media. Each flask received 2 ml, 4 ml 
and 10 ml, respectively and incubated overnight at 18-22oC with moderate shaking 
(200 rpm).  
The next morning, OD600 was monitored using spectrophotometer at every 45 
minutes. Once the OD600 reading reached between 0.4 and 0.6, the culture vessel 
was transferred onto ice for 10 minutes. The cells were then harvested in 50 ml tubes 
by centrifugation at 2500 g for 10 minutes at 4oC. The medium supernatant was 
removed and the tubes were placed upside down on a tissue paper for 2 minutes to 
completely remove the media. The cells were resuspended in a 40 ml ice-cold Inoue 
transformation buffer by swirling gently on ice and harvested by centrifugation at 
2500 g for 10 minutes at 4oC. The supernatant was removed as described previously, 
and the cells were then resuspended in 10 ml ice-cold Inoue transformation buffer. 
DMSO was added to the final concentration of 7% and the bacterial suspension was 
mixed gently on ice by swirling and left on ice for 10 minutes. The bacterial mix was 
then quickly aliquoted into a sterile microfuge tubes and snapped-freeze by 
immersing in liquid nitrogen before storing in -80oC for long-term storage.  
The efficiency of the competent bacteria was tested by transforming either ligation 
products (section 2.5.2.2) and/or supercoiled plasmid (section 2.5.2.3) on LB agar 
plate containing different antibiotics.    
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2.5.2.2 Ligation product 
Plasmids from ligation (section 2.5.1.5) were transformed in a ratio of 1:3 
vector:insert ratio. Stbl3 competent bacteria were thawed on ice approximately about 
20-30 minutes before transformation starts. As much as 4 µl of plasmid from ligation 
was used to transform 50 µl Stbl3 competent bacteria in 1.5 ml microfuge tube. The 
tube was mixed by flicking and incubated on ice for 30 minutes. It was then incubated 
in thermal block at 42oC for 42 seconds to create pores on bacterial membrane in the 
presence of CaCl2 in the Inoue transformation buffer. The tube was incubated on ice 
for 2 minutes before 250 µl of SOC media was added, mixed and incubated in 37oC 
bacterial incubator with moderate shaking for 1 hour. At this stage, there were no 
antibiotics added to allow production of antibiotic resistance proteins encoded by the 
plasmid backbone. After an hour, 50 µl and 200 µl of transformed bacteria were 
plated on LB agar plate containing plasmid specific antibiotic and incubated in 37oC 
bacterial incubator for 12-16 hour. The bacterial colonies were either processed or 
kept in 4oC for up to a week and a half.   
2.5.2.3 Supercoiled plasmid 
A total of 1 - 2 µl supercoiled plasmid that contained 300 ng-1000 ng of DNA was 
transformed in 25 µl Stbl3 competent bacteria. The mixture was directly plated on LB 
agar plate containing plasmid specific antibiotic and incubated in 37oC bacterial 
incubator for 12-16 hour. The bacterial colonies were either processed or kept in 4oC 
for up to a week and a half. 
2.5.2.4 Mini prep plasmid isolation 
Mini prep plasmid isolation was carried out using Qiagen QIAprep Miniprep Kit to 
separate small amount of plasmid ranging from 5 – 25 µg. In general, the procedure 
consists of alkaline lysis of bacteria with the presence of RNAse A, neutralisation and 
binding of plasmid to the silica column, washing for removing endonucleases and 
salts and elution of DNA. All centrifugation steps in this procedure were carried out at 
17,900 g at room temperature. 
A single colony from transformation from section 2.5.2.2 was picked using pipette tip 
and transferred into a 5 ml LB medium containing appropriate antibiotics. The culture 
was incubated for 12-18 hours in a 37oC bacterial incubator with vigorous shaking 
(200-250 rpm). The bacteria cells were harvested by centrifugation at 6,800 g for 3 
minutes at room temperature. They were resuspended in 250 µl of buffer P1 
 55 
 
containing LyseBlue (0.1% v/v) and RNAse A (100 µg/ml). LyseBlue is used to 
indicate inefficient cell lysis and incomplete precipitation of SDS, cell debris and 
genomic DNA in the following steps. The cells were lysed in 250 µl alkaline lysis 
buffer, buffer P2 and the solution turned blue in the presence of LyseBlue. The cells 
suspension was mixed gently by inverting the tube 5-6 times until homogenously 
coloured solution was achieved. The lysis mixture was incubated at room 
temperature for 5 minutes and terminated by adding 350 µl neutralisation buffer 
(buffer N3). At this stage, the solution was immediately mixed until it became 
colourless. Buffer N3 contained high-salt conditions that precipitated denatured 
proteins, chromosomal DNA, cellular debris and SDS; however, it allowed the 
plasmid DNA to stay soluble. To separate the plasmid DNA and precipitates, the 
sample was centrifuged for 10 minutes in a tabletop microcentrifuge. The 
supernatant was applied to QIAprep 2.0 spin column and centrifuged for 1 minute to 
allow plasmid DNA binding to the column. The column was washed twice; firstly with 
500 µl buffer PB to remove endonuclease and, secondly, with 750 µl buffer PE that 
contained 70% ethanol to remove remaining salts. These washing steps were carried 
out by centrifugation for 1 minute.  Additional centrifugation was carried out for 1 
minute to remove residual wash buffer. Finally, plasmid DNA was eluted into a clean 
1.5 ml microfuge tube by adding 50 µl buffer EB, incubated for 1 minute and 
centrifuged for 1 minute. Plasmid DNA was stored at -20oC until further application 
been carried out.   
Sequence verification of whether there is successful integration of the shRNA 
sequences was performed by sending the plasmid DNA sample for sequencing. The 
primer used to confirm the sequence is listed in Table 2-17 below. 
Vector Sequence (5’ to 3’) 
pLKO.5d.miRNA30 GCCTGCTTCTCGCTTCTGTTC 
 Table 2-17: Primer sequence used for plasmid DNA sequencing. 
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2.5.2.5 Maxi prep 
To isolate larger plasmid quantity which is up to 500 µg, Qiagen EndoFree Plasmid 
Maxi kit was used. The procedures consist of alkaline lysis (NaOH/SDS), 
neutralisation, endotoxin removal, binding of the plasmid DNA to the QIAGEN resin, 
removing the impurities, plasmid elution with high-salt buffer, and concentrated and 
desalted of the plasmid. 
A single colony from transformation from section 2.5.2.2 was picked using pipette tip 
and transferred into a 5 ml LB medium containing appropriate antibiotics. The culture 
was grown as a starter culture by incubating at 37°C for approximately 8 h with 
vigorous shaking (225 – 300 rpm).  
After 8 hours incubation, a 500 µl of the culture was transferred into 250 ml LB media 
with the appropriate selection antibiotic and grown at 37°C for 12 – 16 h with 
vigorous shaking. The bacterial cells were pelleted by centrifugation at 4,000 g for 15 
min at 4°C and were resuspended in 10 ml Buffer P1. Buffer P1 was supplemented 
with 1% LyseBlue and 100 µg/ml RNAse A. The bacteria was then lysed by adding 
10 ml of Buffer P2 that contains alkaline lysis buffer. The tube was mixed by gentle 
inverting for six times or until the mixture turned homogeneously blue. The mixture 
was then incubated for 5 min at room temperature. The lysis reaction was terminated 
by adding 10 ml chilled Buffer P3. The tube was gently inverted six times or until the 
suspension became completely colourless. It was immediately transferred into 
QIAfilter Cartridge and incubated for 10 min at room temperature to float the 
precipitates. These precipitates contained proteins, plasmid DNA and detergent. The 
lysate was then filtered through the cartridge and 2.5 ml of endotoxin removal 
reagent (Buffer ER) was added. The solution was mixed by inverting the tubes for ten 
times and incubated on ice for 30 min. 
A 10 ml Buffer QBT was added into QIAGEN-tip 500 and left to drain completely by 
gravity flow. The lysate was then applied to the QIAGEN-tip and allowed to empty by 
gravity flow. The Qiagen-tip was washed twice with 30 ml Buffer QC to remove the 
contaminants. The plasmid was then eluted with 15 ml high-salt buffer (Buffer QN), 
followed by the addition of 10.5 ml room-temperature isopropanol to precipitate DNA 
during the centrifugation step. The centrifugation was performed at 16,000 g for 30 
min at 4°C. The supernatant was carefully discarded and the DNA pellet was washed 
with endotoxin-free 70% ethanol at 16,000 g for 10 min at 4°C to remove remaining 
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salt. The supernatant was discarded and the DNA pellet was dissolved in 400 – 500 
µl endotoxin-free Buffer TE. 
 
 RNA Extraction 
Extraction of RNA was done using Qiagen RNeasy kit which is based on silica 
membrane spin column nucleic acid purification. The negatively charged DNA 
backbone binds to the negatively charged silica membrane through the positively 
charged salts bridge. 
Lysed cells in RLT buffer were added into Qiashredder Mini Spin Column to 
homogenise high molecular weight genomic DNA and other high-molecular weight 
cellular components.  
A volume of 70% ethanol was then added to the homogenised lysate and mixed by 
pipetting. This mixture precipitates nucleic acids out of solution. The homogenised 
lysate was transferred into Qiagen Mini Spin column and centrifuge at 13,000 rpm for 
2 minutes. The flow-through was transferred into a fresh 2 ml centrifuge tube and 
isopropanol at 2 times volumes of the sample was added and kept in -20oC for 
protein precipitation (section 2.5.5).  
Spin column containing RNA was washed three times; once with salt-containing 
buffer RW1 and twice with ethanol-containing buffer RPE. A total of 700 µl buffer 
RW1 was added into the spin column tube and centrifuge at 8,000 g for 30 seconds 
to wash out the impurities.  
Then, 700 µl of buffer RPE that contained 80% ethanol was added to mini spin 
column and centrifuged at 8,000 g for 30 seconds to wash out impurities, followed by 
a second wash with 500 µl buffer RPE and centrifuged at 8,000 g for two minutes. 
The spin column was centrifuged again at 13,000 rpm for one minute to completely 
remove any carryover of buffer RPE. 
Finally, the spin column was placed in a clean microfuge tube and 30-50 µl of RNase 
free water was added to the centre of mini spin column. The tube was centrifuged at 
8,000 g for one minute to collect RNA and stored in -20oC.  
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 Densitometry Analysis 
DNA and RNA was quantified using Nanodrop, ND-1000 that can measure as low as 
2 ng/µl up to 3000 ng/µl of nucleic acid. The samples were thawed completely, 
vortexed and spun briefly. The pedestal of Nanodrop was clean with dH2O using 
Kimwipes.  Upon opening the Nanodrop program on the computer, 1 µl of dH2O was 
loaded onto the pedestal to initialise the instrument. An appropriate buffer that was 
used to elute the RNA was then pipetted onto the pedestal to blank the 
measurement. In case of RNA, it was RNAse-free water; however, it might be 
different for DNA samples. An amount of 1 to 2 µl of the samples was pipetted onto 
the pedestal to measure the nucleic acid concentration. The purity of nucleic acids 
was assessed based on the 260/280 nm ratio, where a pure RNA is generally 
between 1.8-2.0 ratio and 1.7-2.0 for DNA.  
2.5.4.1 cDNA Synthesis 
Synthesis of complementary DNA (cDNA) from RNA was carried out using RevertAid 
First Strand cDNA Synthesis Kit. The reaction includes binding of random primers to 
RNA and synthesis of hybrid DNA by reverse transcriptase in the presence of 
deoxynucleotide triphosphates.  
This protocol was carried out on ice throughout the procedures unless otherwise 
stated. A total of 500-1000 ng RNA was used as template to make cDNA and mixed 
with 1 µl random primer in a 0.2 ml PCR tube. Then, nuclease-free H2O was added 
to make the total volume of 12 µl. The reaction was incubated in thermal cycler at 
70oC for 5 minutes and cooled down to 4oC to let random primers anneal to the 
single-stranded RNA.  
A master mix of one sample reaction was prepared based on the following 
components: 
Components Volume (µl) 
5X reaction buffer 4 
dNTP 2 
RevertAid H Minus 1 
RiboLock RNase Inhibitor 1 
Total 8 
Table 2-18: Master mix components for cDNA synthesis for one sample. 
 A volume of 8 µl master mix was then added to the tube, incubated at 25oC for 10 
minutes to extend the random hexamer primers and continued with reverse 
transcriptase by incubating at 42oC for 60 minutes. The enzyme was then heat-
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inactivated at 70oC for 10 minutes. The product was diluted with H2O to a final 
concentration of 4-10 ng/µl, stored in -20oC for longer storage or continued for further 
application.  
2.5.4.2 Quantitative Real-Time Polymerase Chain Reaction  
Quantitative real-time polymerase chain reaction (RT-PCR) is a technique to amplify 
gene of interest in real-time by the use of fluorescent reporter that binds to the DNA. 
In our lab, we use Platinum® SYBR® Green qPCR SuperMix-UDG as a reporter, that 
intercalates with double-stranded DNA and emits high fluorescence upon excitation.  
Primers targeting each gene of interest were synthesised from Sigma (Table 2-21). 
Forward and reverse primers were designed using Primer Express 2.0 by covering 
two different exons and have a melting temperature between 50-60oC. The length of 
the primers was generally between 18-22 bp with consideration of 40-60% GC 
content. Forward and reverse primers were synthesised in individual tubes and 
lyophilised in H2O to make a final concentration of 100 µM. Each of forward and 
reverse primers was mixed in a tube to make the final concentration of 10 µM.  
A master mix of a single reaction was prepared based on the following components: 
Components Volume (µl) 
2X SyBr Green  5.0 
Primer mix (10 µM) 0.3 
H2O 2.7 
Total 8.0 
Table 2-19: Master mix components for RT-PCR. 
For each target gene, a triplicate was prepared and a volume of 8 μl master mix was 
pipetted into the bottom of 384-well plate and 2 μl of cDNA (2.5.4.1) was added later. 
The 384-well plate was sealed using heat-resistant adhesive film (MicroAmp® 
Optical Adhesive Film, Applied Biosystems), centrifuged for 1 minute at 1,000 g and 
loaded into the Real-time PCR Machine (Applied Biosystem).  
Table 2-20 listed the thermal profile of PCR reaction: 
 
Temperature (°C) Time Cycles 
50 2 min 
1 
95 10 min 
95 15 s 40 
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60 1 min 
95 15 s 
1 60 15 s 
95 15 s 
   Table 2-20: Temperature profile for RT-PCR reaction. 
 
Data were analysed using SDS 2.3 System Software or QuantStudio Real-Time PCR 
System. Comparative Ct method was used in most of the analysis by first normalising 
Ct values of each gene to the internal control gene i.e.: housekeeping gene to 
produce ∆Ct values. Next, the ∆Ct values were compared to the control ∆Ct value of 
particular experiment, yielding ∆∆Ct. Relative RNA expression was finally linearised 
using antilog to the base of 2 since Ct value was represented in two-fold expression 
change.  
Genes  Sequence 
GAPDH Fwd GAAGGTGAAGGTCGGAGTC 
Rv GAAGATGGTGATGGGATTTC 
CYCLO Fwd CAGGTCCTGGCATCTTGTCC 
Rv TTGCTGGTCTTGCCATTCCT 
TUBULIN Fwd AGGAGCTGGCAAGCATGTG  
Rv CGGTGCGAACTTCATCGAT 
PFKP Fwd TGAAGGAGCAATTGATACCCAAA 
Rv CCAGCTGCGTGACGACAA 
SLC2A3 Fwd GCGCGGGTGTGGTTAATACT 
Rv TCCTTCTTCCTGCCCTTTCC 
SLC2A1 
 
Fwd GCCCCCCAGAAGGTGATC 
Rv GCAGGATGCTCTCCCCATAG 
SLC2A5 
 
Fwd GGGAGGCTGACGCTTGTG 
Rv GTTGTACCCATACTGGAAGGATGAC 
TBP 
 
Fwd CCTAAAGACCATTGCACTT 
Rv GTTCGTGGCTCTCTTATCCT 
RUNX1/ETO Fwd AATCACAGTGGATGGGCCC 
 Rv TGCGTCTTCACATCCACAGG 
CCND2 Fwd CTGTGTGCCACCGACTTTAAGTT 
 Rv TGCTCCCACACTTCCAGTTG 
CCND1 Fwd GCCCTCTGTGCCACAGATGT 
 Rv GAAGCGTGTGAGGCGGTAGT 
CCND3 Fwd CAGGCCTTGGTCAAAAAGCA 
 Rv GCGGGTACATGGCAAAGGTA 
HK3  Fwd GGACAGGAGCACCCTCATTTC  
Rv  CCTCCGAATGGCATCTCTCAG 
HK2  Fwd  GAGCCACCACTCACCCTACT  
Rv  CCAGGCATTCGGCAATGTG 
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HK1  Fwd  GCTCTCCGATGAAACTCTCATAG  
Rv  GGACCTTACGAATGTTGGCAA 
GPI Fwd  CAAGGACCGCTTCAACCACTT  
Rv CCAGGATGGGTGTGTTTGACC 
ALDOC Fwd  ATGCCTCACTCGTACCCAG  
Rv  TTTCCACCCCAATTTGGCTCA 
PFKP  Fwd  GCATGGGTATCTACGTGGGG  
Rv  CTCTGCGATGTTTGAGCCTC 
TPI1 Fwd  CTCATCGGCACTCTGAACG  
Rv  GCGAAGTCGATATAGGCAGTAGG 
PGK1  Fwd  GAACAAGGTTAAAGCCGAGCC  
Rv  GTGGCAGATTGACTCCTACCA 
PKM2 Fwd  ATGTCGAAGCCCCATAGTGAA  
Rv  TGGGTGGTGAATCAATGTCCA 
ENO1 Fwd  GCCGTGAACGAGAAGTCCTG  
Rv  ACGCCTGAAGAGACTCGGT 
ALDOA Fwd  ATGCCCTACCAATATCCAGCA  
Rv  GCTCCCAGTGGACTCATCTG 
G6PD  Fwd  CGAGGCCGTCACCAAGAAC  
Rv  GTAGTGGTCGATGCGGTAGA 
PGLS Fwd  GGAGCCTCGTCTCGATGCTA  
Rv  GAGAGAAGATGCGTCCGGT 
PDG  Fwd  ATGGCCCAAGCTGACATCG  
Rv  AAAGCCGTGGTCATTCATGTT 
TKT  Fwd  TCCACACCATGCGCTACAAG  
Rv  CAAGTCGGAGCTGATCTTCCT 
TALDO1 Fwd  CTCACCCGTGAAGCGTCAG  
Rv  GTTGGTGGTAGCATCCTGGG 
PISD  Fwd  CCACCGACTGGACTGTGTC  
Rv  CCGCTCGTTATGGCAGAAGA 
ACAD9 Fwd  AGTTCTTGGGACCCGTGGAA  
Rv  GTCTTGAGTACATGGTGTTGGAG 
BAX Fwd CTGCAGAGGATGATTGCCGC 
 Rv ATCAGTTCCGGCACCTTGGT 
BCL2 Fwd GCCTTCTTTGAGTTCGGTGG 
 Rv GAAATCAAACAGAGGCCGCA 
NOXA Fwd CAGAGCTGGAAGTCGAGTGTGC 
 Rv GGAGTCCCCTCATGCAAGTTTTT 
P21 Fwd GACACCACTGGAGGGTGACT 
 Rv CAGGTCCACATGGTCTTCCT 
CDK4 Fwd TGCAGAGATGTTTCGTCGAAA 
 Rv CCCAACTGGTCGGCTTCA 
CDK6 Fwd CTTCGAGCACCCCAACGT 
 Rv GGTTTCTCTGTCTGTTCGTGACACT 
Table 2-21: Forward and reverse primer sequence for RT-PCR analysis. 
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 Protein Analysis 
Protein analysis was performed to determine protein expression level by separating 
the protein based on the molecular weight. Briefly, purified protein samples were run 
through electrophoresis system and immunoblotted with a specific antibody, hence 
the expression of the protein can be detected. 
2.5.5.1 Protein purification and quantification 
Protein quantification was done using Bradford Assay (Bio-Rad) that utilises 
Coomassie Brilliant Blue G-205 which changes colour in different physiological 
conditions. In acidic condition, Coomassie Blue is cationic, mainly doubly protonated 
and is red in colour. In the presence of protein, the first electron is donated to the 
charged groups of the protein, disrupts the structure and exposes the hydrophobic 
pocket of the protein. The dye then binds to these pockets with sulfonic acid groups 
binding to positive amines and stably bound Coomassie Blue emits blue 
fluorescence, unprotonated form and can be measured spectroscopically. 
Protein precipitate from section 2.5.3 was spun down at 13,000 g for 15 minutes at 
4oC. The supernatant was removed, a 50-70 μl of urea buffer was added to the tube 
and mixed by pipetting. The tube was left on the roller mixer for 15 minutes at room 
temperature to completely dissolve the proteins. The protein samples were diluted 
with urea buffer in a ratio of 1:10. Besides that, standard was prepared by making a 
stock of bovine serum albumin (10 mg/ml) in H2O. The standard was diluted in urea 
buffer ranging from 0 mg/ml to 2.0 mg/ml. Both protein samples and standards (5 μl) 
were pipetted into 96-well plate in triplicate. Bradford dye concentrate was diluted 1:5 
in H2O and a volume of 195 μl was pipetted into each sample and standard well. The 
plate was quickly measured in FLUOstar Omega Microplate Reader (BMG Labtech) 
at A595 nm. The protein quantity was calculated by constructing a standard curve of 
the standards against its absorbance values. The absorbance value of the triplicates 
was averaged and relatively calculated according to the standard curve. 
  
 63 
 
2.5.5.2 SDS-PAGE electrophoresis 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was used to 
separate proteins according to molecular weight. Firstly, linear protein chains were 
prepared by adding reducing agent (β-mercapthoethanol) that cleaves disulphide 
bonds and produces linear polypeptide chains. Hence, SDS that is present in both 
gel and running buffer provides uniform negative charge to the proteins during 
electrophoresis. 
The SDS-PAGE gels consisted of two layers; the top layer was stacking gel usually 
prepared at 4% acrylamide. The less concentrated gel provides bigger pores and 
allows all the proteins to stack before migrating to the bottom layer. The bottom layer 
was separating gel which the percentage of acrylamide varies based on the 
molecular weight of protein of interest (7-20%). Higher percentage of acrylamide is 
useful to detect low molecular weight as it travels slowly in dense acrylamide pores, 
while, higher molecular weight protein can be detected in lower acrylamide 
percentage. 
The SDS-PAGE separating gels were cast with the components of 30% acrylamide 
diluted with deionised water to the desired percentage, 0.1% (w/v) ammonium 
persulphate (APS) and 0.01% (w/v) Tetramethylethylenediamine (TEMED). The 
solution was quickly mixed and poured into 2.0 mm or 1.5 mm gel casting chamber 
followed by addition of 200 µl of isopropanol. In the mixture, TEMED induces APS 
decay to release free SO4- ions, which react with acrylamide molecules and start 
polymerisation. The overlay of alcohol on top of the gel prevents oxygen molecules 
from reacting with SO4- ions and inhibit the polymerisation reaction. After 15 
minutes, isopropanol was removed and the stacking gel mixture was prepared at 4% 
acrylamide and poured on top of the separating gel. Desired comb was inserted onto 
the chamber and left to solidify for approximately 15 minutes. The gel was used 
directly or stored in 4oC up to a week.  
Before running the electrophoresis, the protein samples were prepared in 1X loading 
buffer containing 20% (v/v) glycerol, 4% (w/v) SDS, 5% (v/v) β-Mercaptoethanol and 
0.1% (v/v) Bromophenol Blue. As described previously, SDS gives uniform charge of 
unfolded protein catalysed by β-Mercaptoethanol, while glycerol and bromophenol 
blue give weigh to the sample volume and track the protein movement.  
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The gels were placed in electrophoresis tank containing electrophoresis buffer. 
Samples and protein ladder were carefully loaded into the wells and the 
electrophoresis was started at 80V until the proteins (indicated by bromophenol blue) 
reached separating gel. The voltage was increased to 100-150V until all the protein 
samples reached the bottom of the gel. 
 
2.5.5.3 Immunoblotting  
Immunoblotting was used to detect the separated proteins by immobilising the 
protein onto activated membrane, probing with specific antibodies and detecting it 
with a developer.  
Gel was removed from the electrophoresis unit and placed onto a methanol activated 
PVDF membrane (0.4 µm) and blotting sandwich was assembled using wet sponges 
and filter papers. The blotting process was performed in blotting buffer at 100 V for 
one hour. The transfer was assessed by staining the membrane with Ponceau-S red 
staining for few minutes. The stain was removed by washing the membrane with 
water followed by blocking the membrane with 10% TBST-milk for one hour. The 
membrane was then incubated with the primary antibody (Table 2-22) in 4oC 
overnight or at room temperature for one hour.  
After primary antibody incubation, membrane was washed with TBST solution for 
three times, 5 minutes each to remove unbound primary antibody. It was then 
incubated in secondary antibody prepared in 10% TBST milk for one hour at room 
temperature. The washing step was repeated to remove unbound secondary 
antibody following by detection by chemiluminescence.  
Enhanced chemiluminescence (ECL) was used to detect the protein of interest. ECL 
substrates A and B was mixed freshly at 1:1 ratio and pipetted onto the membrane 
for one minute. The activated HRP conjugate was then captured using Chemi Doc 
imaging instrument.  
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Antibody-species 
raised in 
Supplier Catalogue 
number 
RUNX1 - Rabbit Cell Signalling Technology CST14334 
PFKP – Rabbit Cell Signalling Technology D2E5 
ATG7 – Rabbit Cell Signalling Technology D12B11 
Actin – Mouse Abcam AB49900 
GAPDH – Mouse HyTest Ltd 564 Mab 6C5 
Table 2-22: Antibodies for detection of proteins using western blotting 
technique.   
 
 Metabolic Assay Methods 
 Glucose Uptake Assay 
Glucose uptake was done by incubating the cells with fluorescent glucose, 2-(N-(7-
Nitrobenz-2-oxa-1,3-diazol-4-yl)Amino)-2-Deoxyglucose (2-NBDG). The glucose 
molecule was modified at C-2 position with NBDG fluorescent molecule. Upon entry 
into the cells, the molecule is phosphorylated by hexokinase, trapped within the cells 
and can be analysed by flow cytometry. Cells were incubated in glucose-free media 
for 12-16 hours. 2-NBDG was added into the culture at the final concentration of 200 
µM and incubated for another 3 hours at 37oC in CO2 incubator. Cells were washed 
twice with cold PBS to slow down metabolic activity, resuspended in 300-400 µl cold 
PBS, transferred into facs tube and quickly analysed with flow cytometer. The data 
was analysed using FlowJo software. 
 ATP Assay 
Luminescent ATP Detection Assay Kit was purchased from Abcam (Ab113849). This 
assay detects total levels of cellular ATP based on the production of light caused by 
the reaction of ATP with added firefly’s luciferase and luciferin. The emitted light is 
proportional to the ATP concentration inside the cells. The reaction can be 
summarised as follows: 
𝐴𝐴𝐴𝐴𝐴𝐴 + 𝐷𝐷 − 𝑠𝑠𝑢𝑢𝑐𝑐𝐶𝐶𝑜𝑜𝑖𝑖𝑒𝑒𝐶𝐶𝐶𝐶 + 𝑂𝑂2 → 𝑂𝑂𝑖𝑖𝑂𝑂𝑠𝑠𝑢𝑢𝑐𝑐𝐶𝐶𝑜𝑜𝑖𝑖𝑒𝑒𝐶𝐶𝐶𝐶 + 𝐴𝐴𝐴𝐴𝐴𝐴 + 𝐴𝐴𝐴𝐴𝐶𝐶 + 𝐶𝐶𝑂𝑂2 + 𝐿𝐿𝐶𝐶𝑠𝑠ℎ𝐶𝐶 
A total of 5 x 104 cells was seeded in a 500 µl in a 96-well plate. 50 µl of detergent 
was added into each well to disrupt the cell membrane. Plate was shaken for 5 
minutes in an orbital shaker at 600-700 rpm to lyse and stabilise the ATP molecule. A 
total of 50 µl of luciferin substrate solution was added to each well and shaken again 
on orbital shaker at 600-700 rpm for 5 minutes. The plate was covered with 
aluminium foil for 10 minutes at room temperature. Luminescence readings were 
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captured using Omega plate reader.  Each luminescence readings were subtracted 
from background well before taking the average. ATP level was calculated as relative 
to the experimental control. 
 Seahorse Glycolysis Stress Test 
Seahorse assay is a real-time measurement of extracellular acidification and oxygen 
consumption that reflects the changes of glycolysis flux. Cells were plated in 
Seahorse 96-well plate in non-buffered medium and followed by sequential injection 
of glycolysis inhibitors using Seahorse XFe96 Analyzer machine. In all steps of this 
experiment, the media used was Seahorse XF Base media. 
2.6.3.1 Plate preparation and hydration of sensor cartridge  
Seahorse 96-well plate was coated with Corning Cell-Tak prior to experiment. Cell-
Tak adhesive is a formulation of polyphenolic proteins extracted from marine mussel, 
Mytilus edulis. In higher pH, Cell-Tak adhesive comes out from solution and adsorbs 
to the first surface it contacts. The optimal Cell-Tak concentration for Seahorse XF96 
plate is 22.4 µg/ml. A total of 1245 µl of neutral buffer, NaOHCO3 1M was added to 
Cell-Tak solution and 25 µl was quickly applied into each well and left for 20 minutes 
at room temperature. Each well was washed twice with 200 µl of sterile water and 
stored in 4oC.   
The XFe96 sensor cartridge that came with the plate was hydrated on the day prior 
to the experiment. A total of 200 µl of PBS was added into each well of utility plate 
and sensor cartridge was lowered to submerge the sensors in the PBS solution. The 
plate was placed in 37oC supplemented without CO2.   
2.6.3.2 Seahorse media preparation 
The media was supplemented with 1 mM glutamine and 3% FBS and warmed to 
37oC. NaOH 1M and HCl 1M were used to adjust the pH value to 7.4.  
2.6.3.3 Sample preparation 
On the morning of the experiment, 2.0 x 105 cells for each well were pelleted at 300 g 
for 5 minutes, washed with phosphate buffered saline (PBS) and resuspended in 25 
µl of warm media. The 25 µl of cells was pipetted slowly along the side of each well 
to form a monolayer except for background wells. For each well, a minimum of 
triplicate was prepared. To the background wells (highlighted in black colour in Figure 
2-1) 25 µl of assay medium was added. The plate was then centrifuged at 200 g for 1 
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minute with zero braking. The plate was transferred to 37oC incubator not 
supplemented with CO2 for 30 minutes to ensure the cells have completely attached. 
After the cells were confirmed to stably attach to the culture surface by microscope, a 
125 µl of warm assay media was pipetted along the side of all wells to make a total 
volume of 175 µl and returned to the incubator for 15 minutes. The confirmation of 
the health of the cell included cell morphology, seeding uniformity and no cells in 
background wells.    
 
Figure 2-1: Seahorse Analyzer 96-well plate.  Background wells highlighted in 
black. 
 
2.6.3.4 Compound preparation 
The compounds used in the glycolysis stress assay were glucose, oligomycin and 2-
deoxyglucose (2DG) with a final concentration of 100 mM, 2.5 µM and 50 mM, 
respectively. The concentration of stock compounds loaded in each port were 
prepared based on the volume in the wells after every injection. The details of the 
concentration prepared are illustrated in Table 2-23 below.  
Port - 
Compound 
Volume in culture 
well after every 
injection; starting 
volume = 175 µl 
(µl) 
Final 
concentrati
on in each 
well 
Volume 
injected 
(µl) 
Stock 
concentration 
to prepare 
A – Glucose 200 100 mM 25 800 mM 8X 
B – Oligomycin 225 2.5 µM 25 22.5 µM 9X 
C – 2-DG 250 50 mM 25 500 mM 10X 
Table 2-23: The stock concentration prepared and port of injection for 
glycolysis stress assay.  
2.6.3.5 Seahorse glycolysis stress test normalisation  
Seahorse plate was loaded into Seahorse XFe96 Analyzer located in Flow Cytometry 
Facs Facility. After running the plate, the cells were lysed with lysis buffer and protein 
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assessment were performed according to the protein assessment method (section 
2.5.5.1). Next, extracellular acidification rate were analysed using Wave 2.0 software.  
 
 In-vivo studies 
 Mice strain  
Animal work was carried out in accordance to Home Office regulations with project 
license number PPL60/4522. Two immunodeficient mice strains were used in this 
study and the characteristic of each strain is listed below.  
Abbreviation  Strain name Source  
NSG NOD.Cg-Prkdcscid 
Il2rgtm1Wjl/SzJ 
Jackson Laboratory 
Rag2-/- ɣC-/- (RG) Rag2−/−Il2rg−/−129×Balb/c Jackson Laboratory 
Table 2-24: Mouse strain used in the study. 
Mice weighing and checking were carried out at least once per week. Checking of 
mice general health included movement, signs of anaemia, coat quality, piloerection, 
and the colour of the eyes, paws, feet and ears. The mice were humanly killed when 
they reached the endpoints listed below:   
1. Body weight loss of 20% or more, (30% if mouse under treatment).  
2. Body weight loss of 10% – 20 % and maintained low for three days.  
3. Tumour size is 1 cm in any dimension, (1.5 cm if mouse under treatment).  
4. Tumours are affecting the mice movement.   
5. Any sign of sickness that is severely affecting the health of the mouse.  
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 Xenotransplantation models of t(8;21) AML 
2.7.2.1 Intrahepatic transplantation  
Intrahepatic injection was used to transplant Kasumi-1 cells based on the method 
established by our lab before (Soria et al., 2008). Briefly, injection was performed 
using a fine flexible Hamilton needle. Newborn mouse was held firmly by the end of 
the thumb and the index finger then the needle was inserted in the top of the chest 
under the skin. When the needle reached the end of the ribs, the needle was pushed 
toward the mouse chest in 45° towards the right of the mouse where it was bent and 
reached the liver. The cells then released slowly and the needle was withdrawn 
smoothly. After the injection, the mouse was placed back to the nest and monitored 
closely for any sign of health deterioration.   
2.7.2.2 Intrafemoral transplantation  
Cells were injected with interfemoral (IF) route in NSG female mice. The injections 
were performed under a sterile environment in a category II hood. Mice were 
anaesthetised with 5% isoflurane then anaesthesia was marinated with 2-3% 
isoflurane. Before transplantation, mice were weighed and injected with 5 mg/kg 
Carprofen for analgesia. The injected leg was shaved and sterilised with skin 
disinfection spray. A hole was made in the injected femur by inserting 29G insulin 
needle in the kneecap and through the femur then the needle was removed and new 
needle with the sample was inserted and 20 µl of cell suspension was injected. Mice 
were placed back into the cage and monitored for anaesthesia recovery. 
2.7.2.3 Intravenous   
Intravenous (IV) injection route was used to inject the 2FDG. Mice were held tightly in 
a restraint tube under category II hood. If the tail vain was not clear then the tail is 
either massaged or placed in warm water to reveal the vain. The tail was stretched 
straight tightly and the needle inserted at around 180° and the drug released steadily. 
Once the injection was completed, the pressure was applied on the injection site for 
10-30 seconds to prevent any bleeding then the mouse placed back into the cage 
and monitored.  
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 In vivo imaging 
Bioluminescence was measured by in vivo imaging system (IVIS). Mice were 
intraperitoneal (IP) injected with 5 mg/kg luciferin. After 5 minutes from luciferin 
injection, mice placed in the anaesthesia induction box and anaesthetised with 5% 
isoflurane followed by maintaining the anaesthesia at 2-3% isoflurane. Mice were 
moved to the IVIS machine, the head was placed into a face mask and the body 
temperature was maintained at 37°C via heat mat. After 10 minutes of the luciferin 
injection, imaging was performed. Once imaging was completed, mice were placed 
back into the cage and monitored for recovery.   
 Mice dissection and cells isolation  
The mice where dissected for isolation of leukaemic cells depending on the 
engraftment patterns. Tumours, spleen, bone marrow were regularly harvested. The 
spleen and tumours were weighed first then homogenised and the cells passed 
through a cell strainer using PBS under sterile conditions. For a collection of the bone 
marrow, femur, tibia, desk, and spine were regularly collected and cleaned from any 
muscles and tissues.  
Harvested cells washed with PBS at least once and counted using trypan blue and 
also methylene blue to eliminate the mouse blood cells count. 
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Chapter 3 : Validation of SLC2A3 and PFKP as potential partner 
in RUNX1/ETO in maintaining leukaemic survival 
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 Introduction  
RUNX1/ETO is an oncogenic transcription factor classically known as transcription 
repressor in AML (Gelmetti et al., 1998). We showed that RUNX1/ETO can also 
activate target genes to drive leukaemic propagation and survival (Martinez-Soria et 
al., 2018). The associated shRNA screen suggested two putative RUNX1/ETO target 
genes, SLC2A3 and PFKP as crucial components of the RUNX1ETO programme. 
For each of the genes, two shRNAs were depleted significantly in vivo; however, 
there were no changes in in vitro assays. Both of the genes are the key genes 
involved in glycolysis. 
SLC2A3 is also known as GLUT3 and facilitates the transport of glucose across the 
plasma membrane. It has the highest affinity to glucose (Km approximately 1.4 mM) 
compared to the other members in the family (Arbuckle et al., 1996, Ian et al., 2008).  
SLC2A3 was the third of 14 members of SLC2 family that was cloned from mouse 
brain and was originally thought to be a neuronal transporter (Nagamatsu et al., 
1992, Ian et al., 2008). However, SLC2A3 is also expressed in both vascular and 
intravascular in human lymphocytes, monocytes/macrophages, neutrophils and 
platelets (Mantych et al., 1992). High expression of SLC2A3 is predominantly seen in 
advanced tumours such as squamous cell laryngeal cancer and is associated with 
poor survival in glioblastoma (GBM) patients (Starska et al., 2015, Cosset et al., 
2017). Some studies have suggested that SLC2A3 is associated with cancer stem 
cells properties (Flavahan et al., 2013, Cosset et al., 2017). 
The expression pattern of SLC2A3 was cross-examined on the BloodSpot website 
(Bagger et al., 2016). This database provides expression plot of genes in healthy and 
cancerous haematopoietic cells at different maturation stages. In normal cells, 
SLC2A3 shows a low expression in stem cells with further increasing expression as 
the cells differentiate (Figure 3-1-A&B). The expression of SLC2A3 is elevated in 
normal myeloid differentiated stages, to support the substantial increase in energy 
need associated with cell activation. For instance, in the case of the maturation of 
monocytes to macrophages, energy is required to undergo changes in shape and 
size to facilitate phagocytosis. In RUNX1/ETO-leukaemia, SLC2A3 expressions were 
shown to be significantly (p<0.01) upregulated when compared to stem cells 
populations (Figure 3-1-A). High expression was also observed in other AML 
subtypes and is thought to support high rate of glucose uptake to meet energy 
demand and promote leukaemic cells expansion in the immature myeloid population.  
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Another target that also scored in the in vivo shRNA screen was PFKP, a gene that 
encodes the platelet isoform of phosphofructokinase (PFK), a gatekeeper in 
glycolysis. Other isoforms of PFK are PFKL and PFKM; however, only PFKP is 
shown to be dysregulated in cancer (Thakkar et al., 2010). From BloodSpot 
database, PFKP is shown to be highly expressed in both normal haematopoietic 
stem cells and other AML subtypes including RUNX1/ETO-leukaemia and gradually 
decreases in differentiated stage. The fact that stem cells rely heavily on anaerobic 
glycolysis to maintain dormant and quiescent state (Ito and Suda, 2014) might 
explain the high expression of PFKP in these populations.  
 
 Aims  
This chapter aims to validate SLC2A3 and PFKP as direct targets of RUNX1/ETO by 
using RNAi approach in both in vitro and in vivo. The strategy that will be used to 
achieve this aim is individual knockdown to evaluate the effect of each gene as well 
as double knockdown on both genes in targeting the axis of glycolysis. 
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Figure 3-1: Snapshots of SLC2A3 and PFKP expression data from BloodSpot.    A, C) Strip charts show SLC2A3 and PFKP 
expression relative to normal counterparts in haematopoietic system and different AML subtypes. Each dot represents one sample 
and grey eclipse indicates median. Significance was evaluated using students t-test **p<0.01), ***p<0.001. (B, D) Hierarchical tree 
showing the relationship between different cell types in database. The colour represents the expression level of the genes, and 
node size indicates median gene expression. HSC, haematopoietic stem cells; MPP, multipotent progenitors; CMP, common 
myeloid progenitors; GMP, granulocyte monocyte progenitors; MEP, megakaryocyte-erythroid progenitor cell; PM, promyelocyte; 
MY, myelocyte; MM, metamyelocytes; BC, band cells; PMN, polymorph nuclear cells; Mono, monocytes.  
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 Results  
 Knockdown of RUNX1/ETO abolished its binding in close proximities 
region based on Chip-sequencing data 
Firstly, I sought to examine RUNX1/ETO binding location on SLC2A3 and PFKP 
genes by cross-inspection of Chip-sequencing and RNA-sequencing data (Ptasinska 
et al., 2012, Ptasinska et al., 2014). Ptasinska (2012) has identified RUNX1/ETO 
target sites by chromatin immunoprecipitation (ChIP) followed by high-throughput 
sequencing (ChIP-sequencing) on Kasumi-1 cell line 48 hours post-RUNX1/ETO 
knockdown by siRNA. The antibody used in the experiments targeted specific ETO 
protein, and the genome-wide cell line ChIP-sequencing data was validated by 
comparing primary, patient-derived t(8;21) AML cells. High-confidence of 
RUNX1/ETO target regions was identified based on ETO ChIP peaks that were 
shared between mock-transfected and mismatch control-transfected cells and finally, 
cross-inspected with peak disappearances upon RUNX1/ETO knockdown. RNA-
sequencing data set was derived from a four-day siRUNX1/ETO knockdown in 
Kasumi-1 cell line consisted of three independent biological replicates (Ptasinska et 
al., 2012).  
As depicted in Figure 3-2-A, RUNX1/ETO occupied an open chromatin region 
located 20 kb upstream of SLC2A3 in both mock and mismatch-transfected cells. 
Knockdown of RUNX1/ETO diminished its binding to this element and further 
reduced the RNA expression of this gene. Figure 3-2-B shows an RUNX1/ETO 
binding peak at 150 kb upstream of the transcriptional start site of the PFKP gene in 
both mock and mismatch-transfected cells, and the peak disappeared upon 
RUNX1/ETO knockdown. However, the expression of PFKP was barely reduced in 
RUNX1/ETO knockdown cells.   
I next examined whether RUNX1/ETO depletion affected the expressions of other 
family members of these two genes. Figure 3-2-A bottom panel shows other SLC2 
family members that were detected in Kasumi-1 cell line, which were SLC2A1 and 
SLC2A5. Depletion of RUNX1/ETO did not lead to reduction of SLC2A1; however, 
SLC2A5 increased upon knockdown of RUNX1/ETO.  
For PFKP, depletion of RUNX1/ETO led to a 30% reduction of PFKP expression. 
Furthermore, only PFKL was highly expressed but the expression was barely 
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reduced upon RUNX1/ETO knockdown. Another isoform, PFKM was not detected in 
the RNA-sequencing data. 
 
   A   SLC2A3    B   PFKP 
 
 
Figure 3-2: Identification of SLC2A3 and PFKP as partner genes in Kasumi-1 
cells.   A&B) Top: UCSC genome data aligned Chip-sequencing and RNA-
sequencing of RUNX1/ETO knockdown and mismatch control siRNA 48 hours after 
knockdown. A&B) Bottom: Expression level of different transporters of SLC2A3 and 
isoforms of PFK with and without RUNX1/ETO knockdown after 48 hours (n=3 
independent experiments).  
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 In vitro validation of SLC2A3 and PFKP as RUNX1/ETO partner genes  
RNA sequencing, ChIP-sequencing and shRNA screening data indicated that 
SLC2A3 exhibit potential partner genes bound by RUNX1/ETO. However, PFKP was 
determined to be affected in longer exposure of RUNX1/ETO knockdown based on 
bead array time course data (Figure 3-3). Therefore, to validate whether RUNX1/ETO 
directly regulates SLC2A3 and PFKP, I employed two well-studied cell lines in t(8;21) 
AML: Kasumi-1 and SKNO-1. Small interfering RNA (siRNA) targeting RUNX1/ETO 
(siRE), mismatch-control transfected (Pui et al.), mock-transfected as well as siRNA 
targeting SLC2A3 (siSLC2A3) and PFKP (siPFKP) were used in the experiments. 
siRE was designed to target against the fusion site of RUNX1/ETO mRNA and, thus, 
does not interfere with wild type RUNX1 or ETO mRNA  (Heidenreich et al., 2003). 
Mismatch control, siMM contained two centrally located A-to-U transversions in 
comparison to siRE. siRNAs targeting SLC2A3 and PFKP mRNA were purchased 
from Qiagen, and the sequences are listed in Table 2.1. The siRNAs were delivered 
to the cells by electroporation with an electroporator on day 0, 4 and 7. Cells were 
collected on day 2, 4, 7 or 10 for RNA analysis.  
 
Figure 3-3: Long-term knockdown of RUNX1/ETO leads to greater reduction of 
PFKP. Bead array analyses on day 2, 4, 7 and 10 were performed on the cell lines 
treated with siRNA targeting RUNX1/ETO. The relative enrichments were normalised 
to the control (siMM).  
 
As shown in Figure 3-4-A, SLC2A3 expression levels diminished by almost 60% in 
siRE-treated Kasumi-1 cell lines 48 hours post-transfection and almost completely 
disappeared on day 10 when compared to mock treated control, indicating that 
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SLC2A3 is a transcriptional target of RUNX1/ETO. In contrast, PFKP expression only 
slightly reduced by 20% in Kasumi-1 cells on day 2 post-transfection, and gradually 
reduced to ~50% with serial electroporation on day 7 and 10. In SKNO-1 cell line, 50-
80% RUNX1/ETO knockdown caused SLC2A3 mRNA to reduce to 40% after a 
prolong siRNA treatment and had an only negligible impact on PFKP mRNA levels. 
Taken together, SLC2A3 is directly affected by RUNX1/ETO in both Kasumi-1 and 
SKNO-1 cell lines. Depletion of RUNX1/ETO led to a massive reduction of SLC2A3 
especially in Kasumi-1, while a modest reduction was observed in SKNO-1. PFKP; 
however, requires a potent and longer knockdown of RUNX1/ETO before loss of 
expression could be observed in Kasumi-1 cell line. However, no substantial PFKP 
changes observed in SKNO-1 cell line. 
 
Figure 3-4: Knockdown of RUNX1/ETO in t(8;21) positive cell lines reduces 
SLC2A3 mRNA but takes longer to inhibit PFKP expression in Kasumi-1 cell 
line.    A) Kasumi-1 cells were transfected with either 200 nM corresponding siRNA 
or mock treated by electroporation on day 0, 4 and 7. Cells were harvested on day 2, 
4, 7 and 10 and checked for RNA expressions (n=3, non-independent experiments). 
B) SKNO-1 cells were transiently transfected with corresponding siRNA or mock 
treated by electroporation on day 0, 4 and 7. Cells were harvested on day 2, 4, 7 and 
10 and checked for RNA expressions (n=1). 
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3.3.2.1 Single knockdown of SLC2A3 and PFKP by siRNA did not reduce 
leukaemia burden; however double knockdown strategy led to loss of 
populations 
 
RUNX1/ETO knockdown substantially reduced SLC2A3 transcript level and modestly 
impaired PFKP transcript in Kasumi-1 cells. So, I next sought to investigate if 
depletion of individual gene or double knockdown targeting SLC2A3 and PFKP would 
affect the leukaemic propagation. I reasoned that a double knockdown strategy 
targeting these genes would completely impairs glycolytic functions, as shown in 
GSEA analysis (Figure 5-1). Cells were serially transfected with siRNA on day 0, 3 
and 6, with 200 µM of corresponding siRNA and cultured at 5 x 105 cells/ml. Since 
this experiment included double knockdown of SLC2A3 and PFKP, each individual 
siRNA was treated in combination with siMM, making up 400 µM total final 
concentration of siRNA. Cells were counted on day 3, 6, 9 and 12. RNA analyses 
were done on day 3, 6 and 9.  
Figure 3-4 shows the mRNA level of RUNX1/ETO, SLC2A3 and PFKP on day 3, 6 
and 9 in Kasumi-1 cell line. As expected, depletion of RUNX1/ETO led to 70% 
reduction of SLC2A3 mRNA on day 3 and almost depleted to 0.5% on day 9. PFKP 
transcript level gradually decrease over the period of transfection with a reduction of 
10% on day 3 and 40% on day 9. In siSLC2A3 treated cells, SLC2A3 mRNA level 
reduced by 60% on day 3, 6 and 9, and the depletion had no effect on RUNX1/ETO 
and PFKP mRNA levels. Furthermore, siPFKP treatment caused a 60-70% reduction 
of PFKP mRNA on day 3 and 9. Similarly, double knockdown of both SLC2A3 and 
PFKP reduced expression of both genes by 60-70% between day 3 and 9.  
Figure 3-5 shows the corresponding proliferation curve for each of the knockdown 
cells. Mismatch treated control had a doubling time of 72 hours on day 12. There 
were no changes observed in SLC2A3 and PFKP knockdown as both of them had 74 
and 73 hours doubling time respectively on day 12. However, double knockdown of 
SLC2A3 and PFKP caused the cells to increase the doubling time to 98 hours which 
was similar to the doubling time observed in siRUNX1/ETO treated cells. 
Collectively, Kasumi-1 cells were not affected by even a substantial knockdown of 
either SLC2A3 or PFKP. However, the double knockdown approach targeting 
SLC2A3 and PFKP led to a slower proliferation mimicking RUNX1/ETO knockdown 
cells. 
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Figure 3-5: mRNA expression level of RUNX1/ETO, SLC2A3 and PFKP after 
series of electroporation in double knockdown approach in Kasumi-1 cells.   
Kasumi-1 cell were transfected with siRNA on day 0, 3, and 6 and cells were 
harvested on day 3, 6 and 9 for RNA analyses (n=3, non-independent experiments). 
 
Figure 3-6: siRNA treated Kasumi-1 cell line reduces proliferation in double 
knockdown strategy.   Cells were transfected with 200 µM of corresponding siRNA 
in combination with 200 µM siMM at day 0, day 3 and day 6. Cells were counted on 
day 3, 6, 9 and 12; and re-cultured at 0.5 x 106 cell/ml after counting. Number of cells 
were calculated based on accumulation of cells at every timepoint divided by the 
dilution factor (n=3, non-independent experiments).  
 
 
 81 
 
3.3.2.2 Loss of SLC2A3 did not affect expression of other glucose transporters 
 
Since SLC2A3 knockdown did not affect the leukaemic proliferation in vitro, I 
wondered about the possibility of increased expression of other glucose transporters 
in order to compensate for loss of SLC2A3. Based on the RNA sequencing data 
(Figure 3-2), there were two other transporters, SLC2A1 and SLC2A5, that were 
highly expressed in Kasumi-1 cells. SLC2A1 is another glucose transporter that is 
predominantly overexpressed in cancer (Yan et al., 2015), whereas SLC2A5 
functions to transport both glucose and fructose into the cells. 
Figure 3-6 shows the transcript levels for both SLC2A1 and SLC2A5 after 3 
electroporations in Kasumi-1 cell. Neither individual nor double knockdown of 
SLC2A3 and PFKP caused changes in the expression of SLC2A1 and SLC2A5. An 
increment was only observed for SLC2A5 in RUNX1/ETO knockdown cells, which it 
increased 2-fold on day 9. This result indicates that there were no changes in other 
transporters to potentially compensate loss of SLC2A3 in Kasumi-1 cells.   
 
Figure 3-7: mRNA expression level of SLC2A1 and SLC2A5 after series of 
electroporations in Kasumi-1 cell line.   Kasumi-1 cell were transfected with siRNA 
on day 0, 3, and 6 and cells were harvested on day 3, 6 and 9 for RNA analyses. 
RNA expression was measured against shNTC-treated cells and GAPDH served as 
a housekeeping gene (n=3, non-independent experiments). 
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 In vivo validation of SLC2A3 and PFKP as potential therapeutic target for 
leukaemic expansion and survival 
 
Depletion of SLC2A3 and PFKP did not reduce leukaemic burden in Kasumi-1 cell 
line. However, this finding is expected as the genes were not scored in vitro in the 
shRNA screen. I next sought to explore the functional role of these genes in vivo by 
shRNA-mediated knockdown. A constitutive shRNA expression vector, 
pLKO.5d.miRNA30 was used in this study (Figure 3-7-C). This vector incorporates 
shRNA sequences into endogenous human micro-RNA backbones, miR-30a, that is 
processed through complete RNAi biogenesis pathway and leads to a stable shRNA 
system in both in vitro and in vivo (Martinez-Soria et al., 2018). The system utilises 
polymerase II promoters to generate micro-RNA30a-based shRNA, allowing 
constitutive and potent gene knockdown (Stegmeier et al., 2005, Dickins et al., 
2005). Dickins (2005), demonstrated a single copy of shRNA expressed from 
Polymerase II 5’ LTR drove extremely efficient knockdowns in comparison with 
conventional shRNA-expressing vector containing Polymerase III U6 promoter. 
Although several studies have shown that U6 promoter drives efficient shRNA 
expression in haematopoietic cells (An et al., 2006, Banerjea et al., 2003); however, 
it is often associated with high toxicities (An et al., 2006, McBride et al., 2008) 
through possible interference with endogenous miRNAs (An et al., 2006). In contrast 
to that, miR30-based shRNA system has been reported to overcome this issue 
(McBride et al., 2008).  
 
3.3.3.1 Production of cells stably expressing shRNA targeting SLC2A3 and 
PFKP using human miRNA30 shRNA vector 
 
Cells stably expressing shRNA targeting SLC2A3 and PFKP mRNA were produced 
using second generation lentiviral vectors as described in Materials and Method 
section 2.4. Three shRNAs for each SLC2A3 and PFKP were designed and 
oligonucleotides were cloned into this vector. Plasmid DNAs were extracted and sent 
for Sanger sequencing for sequence validation. Sequencing primer was designed 
110 bp upstream of shRNA insert which enabled the sequences to be confirmed as 
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illustrated in Figure 3-7-D. The left side of the figure shows part of vector sequence, 
and the right side proves successful insertion of shRNA sequence.  
Lentivirus containing these shRNAs was produced by co-transfecting 293T cells with 
the packaging vector pCMVdeltaR8.91, the envelope vector pMD2.G and transfer 
vectors with the pLKO.5d.miRNA30 backbone (Figure 3-7-A-C).  
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Figure 3-8: Maps of packaging, envelope and transfer vectors used to produce 
cells stably expressing shRNA.   A) Map of packaging vector, pCMVdeltaR.8.91. 
B) Map of envelope vector, pMD2.G. C) Map of transfer vector 
(pLKO5d.SFFV.miRNA30. Representative of RFP657 expressing vector. D) 
Electropherogram showing confirmation of the pLKO5d.miRNA30 vector sequence 
by Sanger sequencing. The left panel showed nucleotide sequence associated with 
the vector and right panel showed shRNA sequences confirming the insertion of 
shRNA.  
 
To produce shRNA virus particles, 293T cells were transfected by calcium phosphate 
precipitation method. The precipitates were added onto 293T cells cultured at 30-
40% confluency seeded a day before. I employed three different variants of 
pLKO.5d.miRNA30 harbouring either RFP657, dTomato or eGFP as fluorescent 
marker, thus enable the cells to be viewed under a microscope equipped with 
different filters (Figure 3-8). To view the cells, I used an inverted microscope that was 
equipped with three filters which were Dapi, GFP and Texas Red; but only two filters 
can be used to visualise the cells which were, GFP and Texas Red for the 
expression of eGFP and dTomato fluorescent proteins respectively.  
 
Figure 3-9: Transfection of 293T cells with pLKO5d.miRNA30 expressing 
colours associated with the transfer vector.   293T cells were seeded at a density 
of 2 x 105 cells/ml in a 10 cm tissue culture dish a day before lentiviral co-
transfection. A total of 15 µg DNA of packaging plasmid, pCMVdeltaR8.91, 5 µg DNA 
of envelope plasmid, pMD2G and 20 µg DNA of transfer plasmid, pLKO5d.miRNA30 
were mixed to produce precipitates using calcium phosphate method. Images were 
captured 72 hours post-transfection using an inverted microscope equipped with 
Texas Red and GFP filters. Images were captured at 100X magnification using 
phase contrast microscope.   
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Due to high virus titre produced by this transfer vector, concentrating the viruses was 
not required. This step was considered crucial as high speed centrifugation might led 
to loss of virus particles. To determine virus efficiency, a series of virus supernatant 
volume was used to transduce target cell. Briefly, in 48-well plate, cells were 
prepared in a density of 1.0 x 106 cell/ml in 500 µl media volume and supplemented 
with 8 µg/ml polybrene. Virus supernatant was added to the cells and plate was 
centrifuged at 900 g, 50 minutes at 34oC. Cells were collected on day 3-post 
transduction and gene transfer efficiency was determined by checking the level of 
endogenous fluorescent protein expression using flow cytometry. Based on the 
vector map, shRNA is placed adjacent to the fluorescent marker (Figure 3-7-C); 
therefore the fluorescent percentage indicates successful integration coupled with 
expression of shRNA. FlowJo analyses of cytometry data showed a high transduction 
efficiency with non-concentrated virus as showed in Figure 3-9 and Table 3-1.  
 
 
Figure 3-10: High transduction efficiency was achieved using 
pLKO5d.miRNA30 vector.  Cells were lentivirally transduced with a series of virus 
supernatant according to the transduction method. Transduction efficiency was 
captured on day 4 post-transduction by flow cytometry. Flow cytometry data were 
processed using FlowJo software and image is representative of an analysis from a 
virus supernatant.  
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Table 3-1: High virus transduction efficiency was achieved using 
pLKO5d.miRNA30 vector.   Cells were lentivirally transduced with a series of virus 
supernatant according to the transduction method. Transduction efficiency was 
captured on day 4 post-transduction by flow cytometry. Flow cytometry data were 
processed using FlowJo software and image is representative of an analysis from a 
virus supernatant. 
 
To determine if shRNA expression leads to silencing of target genes, mRNA level 
was analysed according to RT-PCR method as described in Materials and Method 
section. Cells were harvested on day 4-post transduction, washed and protein 
assessment was carried out as described below. 
For SLC2A3, only two from four constructs were shown to have reduced transcript 
level; shSCL2A3#1 construct reduced the expression up to 50%, while shSLC2A3#2 
led to 90% knockdown of SLC2A3 in Kasumi-1 cell line (Figure 3-10-A). For PFKP, 
while shRNA construct #1 (shPFKP#1) caused a 50% reduction at RNA level, the 
other two shRNA; shPFKP#2 and shPFKP#3 led to 65% reduction when compared 
with the control (Figure 3-10-B).  
 
Figure 3-11: mRNA analyses for shRNA constructs selected to be used in this 
study.   Cells were lentivirally transduced with vector expressing shRNA targeting 
SLC2A3 and PFKP and harvested 72-hours post transduction. RNA expression was 
Volume of virus 
(µl) 
Percentage of transduction 
(shSLC2A3-dTomato/PE) 
0 0.0 
1 17.1 
10 26.0 
100 72.6 
250 96.5 
500 98.2 
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measured against shNTC treated cells and GAPDH served as a housekeeping gene. 
A) Two shRNA constructs targeting SLC2A3 with construct number 2 had 90% 
reduction of SLC2A3 mRNA (n=3). B) Three PFKP shRNA with shPFKP#2 and 
shPFKP#3 had 65% knockdown at mRNA level and shPFKP#3 was chosen to be 
used in this study. Error bars represents SD of three non-independent experiments 
(n=3).  
 
These genes were further validated in double knockdown approach as similar as in 
siRNA-mediated knockdown. I then selected shSLC2A3#2 and shPFKP#3 constructs 
to be used in subsequent experiments. From this point onward, both constructs are 
referred as shSLC2A3 and shPFKP respectively; unless otherwise stated. Cells were 
lentivirally transduced with pLKO5d vector expressing shRNA targeting non-targeting 
control (shNTC), SLC2A3 (shSLC2A3), PKFP (shPFKP), SLC2A3+PFKP 
(shSLC2A3+shPFKP) and RUNX1/ETO (shRUNX1/ETO). Each shRNA targeting 
each gene associated with different colour as listed in Table 3-2 for useful 
manipulation in the subsequent experiments. After 72-hours post transduction, the 
transduction efficiency was analysed with flow cytometry and cells were either 
harvested for mRNA analyses and protein quantification or fixed with 2% 
paraformaldehyde for flow cytometry analysis.  
 
Target shRNA Associated colour 
shNTC RFP657 
shSLC2A3 dTOMATO 
shPFKP eGFP/dTOMATO 
shRE dTOMATO 
Table 3-2: Each shRNA associates with different colour expression.   Each 
colour has different excitation and emission spectrum, thus serves as useful tool to 
be manipulated during flow cytometry analyses.  
 
Figure 3-11 indicates level of mRNA after shRNA knockdown on SLC2A3, PKFP and 
RUNX1/ETO. An 80% depletion of RUNX1/ETO led to a statistically significant 80% 
loss of SLC2A3 transcript level (p<0.01), but caused a non-significant 20% reduction 
in PFKP mRNA. Knockdown of SLC2A3 and SLC2A3+PFKP led to significant 70-
80% loss of SLC2A3 transcript (p<0.01). Both PFKP and SLC2A3+PFKP 
knockdowns caused PFKP mRNA level to reduce significantly to 15% remaining 
mRNA levels (p<0.01). However, SLC2A3 knockdown did not have any impact on 
PFKP and vice versa showing that both genes do not regulate each other. 
Furthermore, depletion of SLC2A3 and/or PFKP seemed to have no impact in 
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RUNX1/ETO expression level. These data showed that, constitutive expression of 
shRNA using miRNA30 backbone drives a strong gene knockdown at mRNA level.  
 
Figure 3-12: mRNA level of SLC2A3 and PFKP upon knockdown with shRNA in 
double knockdown approach.   Cells were lentivirally transduced with vector 
expressing shRNA targeting SLC2A3 and PFKP and harvested 72-hours post 
transduction for RNA analyses. RNA expression was measured against shNTC 
treated cells and GAPDH served as a housekeeping gene. Error bars represents 
standard deviations of three independent experiments. Significance was evaluated 
using students t-test, ns: not significant, **p<0.01, ***p<0.001, p****<0.0001 (n=3). 
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SLC2A3 protein knockdown was assessed using flow cytometry. Cells on day 4 post-
transduction were fixed and permeabilised before incubating with FITC-conjugated 
SLC2A3 antibody. Cells were analysed using flow cytometry at FITC-channel and 
Isotype IgG2B control was used as a negative control. Protein level by western blot 
was not accomplished after three antibodies did not give any conclusive results. Flow 
cytometry data showed a significant two-fold protein reduction in RUNX1/ETO 
knockdown sample compared to experimental control, shNTC (Figure 3-12-B and 
Table 3-3) confirming the mRNA transcript data described previously. In addition to 
that, SLC2A3 knockdown cells reduced 2.5-fold of protein in comparison to shNTC. 
Whereas, double knockdown of SLC2A3 and PFKP caused more potent reduction of 
SLC2A3, which was 3.3-fold in comparison with the control.  
For PFKP protein assessment, protein lysate was co-extracted during RNA extraction 
during ethanol precipitation method as described in Materials and Method section. 
Protein containing flow-through was collected, precipitated with acetone and 
continued with western blotting. PFKP and double knockdown led to a reduction of 
PFKP protein level in Kasumi-1. However, RUNX1/ETO knockdown and shSLC2A3 
knockdown did not led to reduction of PFKP protein level. This observation is in line 
with mRNA level data as shown previously.  
Taken together, the shRNA constructs selected in this study drove a potent 
knockdown in both mRNA and protein level. RUNX1/ETO knockdown in Kasumi-1 
cell line did not show any effect on PFKP mRNA and protein level; however, this 
could be due to early timepoint when the cells were harvested.  
 
Figure 3-13: Protein level of SLC2A3 and PFKP upon knockdown with shRNA in 
double knockdown approach.   Cells were lentivirally transduced with vector 
expressing shRNA targeting SLC2A3 and PFKP and harvested 72-hours post 
transduction for protein quantification. A) Cells were fixed with 4% paraformaldehyde, 
permeabilised with 0.25% Triton-X 100 and stained with mouse anti-human Glut3 
Alexa Fluor 488-conjugated antibody. Cells were analysed with flow cytometry at 
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FITC-channel (n=3). B) Membrane was blotted against α-RHD antibody and α-
GAPDH loading control.  
Sample SLC2A3-FITC 
(Geo Mean) 
IgG Control 213 
shNTC 1328 
shRE 711* 
shSLC2A3 513** 
shSLC2A3+shPFKP 394** 
Table 3-3: Geometric mean of SLC2A3 protein measured by flow cytometry.   
Cells were fixed with 4% paraformaldehyde, permeabilised with 0.25% Triton-X 100 
and stained with mouse anti-human Glut3 Alexa Fluor 488-conjugated antibody. 
Cells were analysed with flow cytometry at FITC-channel. Error bars represent 
standard deviation of the mean (n=3). Significance was evaluated using students t-
test *p<0.05), **p<0.01. 
 
3.3.3.2 RUNX1/ETO moderately regulates PFKP expression 
 
Based on the mRNA levels of PFKP in siRNA treated cells in Kasumi-1 cells, 
RUNX1/ETO was suggested to moderately regulate PFKP expression, therefore a 
potent knockdown is required to confirm the direct regulation of RUNX1/ETO on 
PFKP. Three independent experiments using shRNA-mediated knockdown resulted 
in two RUNX1/ETO expression pattern. As indicated in Figure 3-13, in shRE-A cell 
pool, RUNX1/ETO knockdown led to 90% reduction of RUNX1/ETO mRNA and 
caused 50% reduction of PFKP mRNA. In the other two experiments, where 
RUNX1/ETO mRNA reduced to 70% (higher than shRE-A cell pool), PFKP 
expression level reduced by maximally 10%. These observations were in line with the 
prolong treatments with siRUNX1/ETO data, that potent RUNX1/ETO knockdown is 
required to impact PFKP transcript levels.   
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Figure 3-14: Potent knockdown of RUNX1/ETO led to greater loss of PFKP in 
Kasumi-1 cells.   Cells were lentivirally transduced with shRNA targeting 
RUNX1/ETO in three independent experiment. Cells were harvested on day 4 post-
transduction for RNA analyses. RUNX1/ETO and PFKP expressions levels were 
normalised to shNTC (n=1).  
 
 
3.3.3.3 Neither individual knockdown on SLC2A3 or PFKP nor double 
knockdown induce compensation of other transporters 
 
I then sought to determine if potent constitutive shRNA-mediated knockdown leads to 
differential expression of other transporters as described previously in section 
3.3.2.2. Figure 3-14 showing the expression level of SLC2A1 and SLC2A5 after 
individual and double knockdown of SLC2A3 and PFKP. SLC2A3 knockdown caused 
insignificant reductions of both SLC2A1 and SLC2A5 mRNA level. Depletion of PFKP 
led to a minimal 30% but significant reduction of SLC2A1 and insignificant 20% 
reduction of SLC2A5 mRNA level. Double knockdown of SLC2A3 and PFKP; 
however, caused no changes in SLC2A1 transcript level and insignificant 30% 
reduction of SLC2A5. Whilst, RUNX1/ETO knockdown led to 40% reduction of 
SLC2A1 but no change was observed in SLC2A5 transcript level.  
Taken together, potent and constitutive shRNA knockdown on SLC2A3 and PFKP 
did not contribute to any changes of SLC2A1 and SLC2A5 expressions. However, 
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this mRNA was measured at 72 hours timepoint post-transduction, perhaps it is still 
too early to see the downstream effect of the knockdown on these genes.  
 
 
Figure 3-15: Neither individual nor double SLC2A3 and PFKP knockdown 
induced SLC2A1 and SLC2A5 at mRNA level.   Cells were lentivirally transduced 
with vector expressing shRNA targeting SLC2A3 and PFKP and harvested 72-hours 
post transduction for RNA analyses. RNA expression was measured against shNTC 
treated cells and GAPDH served as a housekeeping gene. Error bars represents 
standard deviations of three independent experiments. Significance was evaluated 
using students t-test, *p<0.05 (n=3, independent experiments). 
 
3.3.3.4 Reduced glucose uptake in both normoxia and hypoxia 
 
Before continuing in vivo, I next asked if SLC2A3 knockdown impairs its primary 
physiological function, which is passaging glucose molecule into the cells. To answer 
that, glucose uptake assay was performed in Kasumi-1 cell line in standard culture 
condition in normoxia and hypoxia. The reasoning behind hypoxia culture condition 
was to determine if limited oxygen on SLC2A3 knockdown have greater effects on its 
physiological functions as low oxygen content showed to increase expression of 
glucose transporters, and promote higher glycolysis (Yu et al., 2012, Christensen et 
al., 2015). Figure 3-15 shows the expressions of SLC2A3 in normoxia and hypoxia 
with and without SLC2A3 knockdown. The samples were normalised to shNTC in 
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normoxia condition as I wanted to show the differential expression of SLC2A3 in 
each condition. In hypoxia condition, SLC2A3 mRNA level increased 2-fold higher in 
shNTC sample when compared to the control shRNA in normoxia. Furthermore, in 
normoxic condition, SLC2A3 knockdown caused 70% mRNA reduction in 
comparison to the shNTC. While SLC2A3 knockdown in hypoxia condition led to only 
30% mRNA reduction when compared to shNTC in normoxia; however, the actual 
reduction was 60% as it compared to its own shNTC in hypoxic condition. Therefore, 
I postulated, in hypoxia condition, leukaemic cells exhibit higher dependency on 
SLC2A3 expression and thus its knockdown will give greater impact in its primary 
function.  
 
Figure 3-16: SLC2A3 expression level in shNTC-expressing Kasumi-1 cell line.  
Cells were lentivirally transduced with shRNA expressing RFP657 or dTOMATO and 
incubated in both normoxic and hypoxic conditions for 72 hours. mRNA analyses 
were measured against shNTC treated cells and CYCLO served as a housekeeping 
gene. Error bars represent standard deviation (n=3). 
 
I next performed glucose uptake assay utilising green fluorescent labelled glucose, 2-
NBDG, which was used primarily to monitor glucose uptake in cells. Studies have 
shown that 2-NBDG competes with the naturally occurring D-glucose to enter the cell 
(Lloyd et al., 1999, O’Neil, 2005), indicates that this molecule has the same kinetics 
as glucose and provides as useful quantitative marker for glucose uptake. 2-NBDG 
has the same structure of glucose except that on C-2 position of glucose was 
replaced by fluorescence molecule, NBDG. Upon uptake into the cells, hexokinase 
phosphorylated on C-6 position and trapped the molecule within the cells. As the C-2 
was replaced by NBDG, the phosphorylated molecules incapable to undergo further 
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reaction in glycolysis pathway and accumulate in the cells. The green fluorescents 
emitted by NBDG can be detected by flow cytometry and that represents direct 
measurement of glucose uptake into cells.  
To determine this, Kasumi-1 cells were lentivirally transduced with either RFP657 or 
dTOMATO and collected after 72 hour post-transduction. Briefly, a total of 0.1 – 0.2 x 
106 cells were cultured in 200 – 400 µl of glucose-free media for 12-18 hours as per 
manufacturer’s recommendation in standard 20% oxygen content and limited 1% 
oxygen content. On the next morning, 2-NBDG was added to a final concentration of 
200 µM and incubated for 180 minutes in standard tissue culture incubation. The 
cells were washed once with PBS and cytometry analysis was performed 
immediately with proper compensation setting applied for each sample due to 
overlapped spectrum of green and dTOMATO.  
Overall, 2-NBDG glucose uptake was lower in all samples in hypoxia condition. 
Knockdown of RUNX1/ETO significantly diminished its glucose uptake capacity in 
both normoxia and hypoxia which recorded 30% and 20% reduced fluorescence 
intensity when compared to their own wild type in each condition (p-value<0.05 for 
both). Interestingly, SLC2A3 knockdown significantly decreased 20% of 2-NBDG 
uptake in normoxia (p-value<0.05), but more potent effect was observed in hypoxic 
condition which recorded significant 30% reduction in comparison to wild type in 
hypoxia (p-value<0.05). The observation was also consistent in double knockdown in 
higher oxygen condition which recorded 25% reduction of 2-NBDG uptake which is 
significant in comparison to the wild type cells (p-value<0.01). In hypoxic condition, 
although double knockdown caused the cells to reduce glucose uptake by 15% when 
compared to its wild type control; however, it was not significant. Interestingly, while 
there was no changes of 2-NBDG fluorescence intensity observed in PFKP 
knockdown cells in normoxic condition, PFKP knockdown in hypoxia significantly 
reduced glucose uptake by 20% when compared to its wild type Kasumi-1 (p-
value<0.05). 
Taken together, RUNX1/ETO illustrates addiction to glucose through SLC2A3 and 
that depletion of SLC2A3 led to a significant reduction of glucose uptake in both 
conditions, with a greater loss observed in the limited oxygen content. Although 
SLC2A3 showed to have higher expression in hypoxic condition; however, this was 
not necessarily associated with higher glucose uptake.  
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Figure 3-17: Knockdown of SLC2A3 reduced glucose uptake in Kasumi-1 cell 
line.   Cells were lentivirally transduced with shRNA expressing RFP657 or 
dTOMATO and incubated in glucose-free media for 12-18 hours. The next day, 2-
NBDG was added to the final concentration of 200 µM, incubated for 3 hours and 
analysed with cytometry on FITC channel (n=3, independent experiments). 
 
3.3.3.5 PFKP knockdown cells loss to shNTC in vivo in newborn 
Rag2−/−Il2rg−/−129 ×Balb/c mice 
 
To further validate if SLC2A3 and PFKP are important in leukaemia propagation in 
vivo competitive transplantation was performed in newborn Rag2−/−Il2rg−/−129 
×Balb/c (RG) mouse strain as depicted in Figure 3-17. Cells were lentivirally 
transduced with either shNTC- or shSLC2A3+shPFKP-expressing vector at 
approximately 30% transduction efficiency on the day of mice were born. The reason 
behind this transduction percentage was to ensure only one particle of virus 
integration per cells. Four days later, cells were sorted and mixed with approximately 
25% of each population. A total of 2.5x105 cells in 25 µl was intrahepatically injected 
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into the mice. Liver serves as the main organ for perinatal haematopoiesis and the 
development is most rapid in the first few weeks of life. Thus, transplantation of 
human haematopoietic cells into the liver of immunodeficient newborn mice is 
thought to have better engraftment and expansion, as well as reconstitute a human 
immune system. Our team has previously established intrahepatic injection of t(8;21) 
cell line shown to have better engraftment compared to other animal model and 
method (Soria et al., 2008). Moreover, a study showed that intrahepatic 
transplantation of CD34+ human cord blood cells into newborn RG mice led to 
adaptive immune system and provide a useful tool for in vivo therapeutic study 
(Traggiai et al., 2004). Mice were humanely killed when they showed the endpoints 
as detailed in the licenses. Tumours from the mice were harvested and processed for 
further downstream analyses.  
   
 
Figure 3-18: Scheme of competitive intrahepatic transplantation in 
Rag2−/−Il2rg−/−129×Balb/c.  Kasumi-1 cells were lentivirally transduced with either 
shNTC- or shSLC2A3+shPFKP-expressing vector on the day the mice were born. 
Cells were sorted with FACS Aria sorter on day 4 and 25% of each population were 
mixed in a single mixture. A total of 2.5x105 cells in 25 µl media were intrahepatically 
transplanted in newborn RG mouse. Mice were killed when it reached endpoint and 
tumours were harvested for further analyses.  
 
The proportion of cells at baseline (pre-transplantation) were shown in Figure 3-18-A 
and knockdown level of each population was determined by mRNA analysis (Figure 
3-18-B). SLC2A3 and PFKP individual knockdown caused 70% reduction in mRNA 
transcript level after 72-hour transduction. Whereas, double knockdown of the two 
genes led to 70% reduction of SLC2A3 transcript and 80% in PFKP transcript level. 
The same pool of cells was cultured in vitro in standard culture condition. The 
percentage of shRNA-expressing cells was measured every couple of days by flow 
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cytometry. Figure 3-20 summarises the proportion of cells at baseline, in vitro 
endpoint and from tumours harvested from two mice out of six mice that have been 
transplanted with Kasumi-1 cell line. Cells from tumours were sorted using FACS Aria 
Sorter for mRNA analysis.  
 
 
 
Figure 3-19: Proportion of cells before transplantation and RNA transcript level 
at baseline.   A) Lentivirally transduced Kasumi-1 were sorted and 25% of each 
population was mixed before being transplanted newborn Rag2−/−Il2rg−/−129×Balb/c 
mice. B) Graph showing mRNA level of sorted cells before transplantation (n=1). 
 
In vitro endpoint showed that shNTC outcompeted all other populations in the long-
term suspension culture as it increased from 25% to 44% at the end of experiment 
(Figure 3-19 and Figure 3-20). Double knockdown of SLC2A3 and PFKP led to the 
greatest loss among all other shRNA, which recorded 5% remaining population at the 
end of experiment while SLC2A3 knockdown caused the cells to increase to 34% on 
day 35-post mixing. Apart from that, PFKP knockdown led to 17% remaining cells at 
the endpoint of the culture.  
On the contrary, in vivo assay showed that shNTC cells competitively loss to SLC2A3 
knockdown cells in two mice harvested. FACS analyses recorded 5% and 2% of 
shNTC-expressing cells in mice 1 and 2 respectively. Surprisingly, SLC2A3 
knockdown cells outgrew all other population to make up 86% and 93% of cells in 
both mice 1 and 2 respectively. While PFKP knockdown caused the cells to reduce to 
2% in mice 1 and completely diminished leukaemic cells in mice 2; however, double 
knockdown of SLC2A3 and PFKP led to higher cell proportion when compared to 
shNTC-expressing cells. For instance, in mice 1, 7% of double knockdown cells 
remained in the tumour which was higher than the control (5%). RT-PCR analyses of 
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these cells showed that transcript levels of SLC2A3 were reduced to 50% in both 
SLC2A3 knockdown and double knockdown cells (Figure 3-20). While, there was a 
50% reduction of PFKP mRNA in PFKP knockdown cells; however, in double 
knockdown it was only 30% depletion observed. In mice 2, double knockdown led to 
remaining 5% of cells which was greater than 2% of shNTC-expressing cells. RT-
PCR analyses of these cells revealed a greater knockdown compared to mice 1. 
There was 80% knockdown of SLC2A3 mRNA level in SLC2A3 knockdown cells and 
70% knockdown in double knockdown population. Whereas, PFKP transcript showed 
to have 70% reduction in the double knockdown cells. No RT-PCR analyses could be 
done on PFKP knockdown cells as the number of cells in the pool were very low. The 
other four mice did not develop any tumour and no sign of sickness was observed 
throughout the period of study. 
 
Figure 3-20: Graph showing competitive loss of shSLC2A3-,shPFKP- and 
shSLC2A3+shPFKP-transduced Kasumi-1 cells in vitro from the same pool of 
cells transplanted in vivo.   Cells were cultured in standard culture condition and 
fluorescence changes were monitored using flow cytometry. The change in the 
fluorescence percentages of each timepoint were normalised to the baseline of each 
construct (n=1). 
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Figure 3-21:  Graph summarises competitive assay in vivo in 
Rag2−/−Il2rg−/−129×Balb/c mouse model.    Cells were mixed with a 25% proportion 
of each shRNA knockdown cells and intrahepatically transplanted in RG newborn 
mice. The same pool of cells were cultured in standard culture condition in vitro and 
monitored every couple of days by flow cytometry. Mice were killed when it reached 
endpoint and tumours were harvested for analyses.  
 
3.3.3.6 PFKP is essential in leukaemia survival in vivo, but not SLC2A3 in NSG 
mouse model 
 
As described in 3.3.3.5, PFKP depletion impaired RUNX1/ETO-leukaemic 
propagation and survival in vivo. However, that was not the case for SLC2A3 as the 
knockdown led to the expansion of cells in RG mouse model. Previously, in shRNA 
screen we relied on intrafemoral transplantation in NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ 
(NSG) mouse model. I reasoned it may be due to different animal model used 
previously and the place where the leukaemic cells transplanted could led to this 
unlikely findings. I next sought to find the answer if it’s due to animal model and place 
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of transplantation in this section. Figure 3-21 showing the scheme utilised in this 
experiment. Cells were lentivirally transduced with either shNTC- or 
shSLC2A3+shPFKP-expressing vector at MOI of 0.3, sorted on day 4 and mixed. 
The cells mixture was injected into the intrafemoral space in adult NSG mice as 
described in Materials and Method section. The engraftments were monitored for 
physical signs of leg tumours or abnormal lesion in all parts of the body, and 
humanely killed when it reached the endpoints as described in the license. 
 
 
Figure 3-22: Scheme of competitive intrafemoral transplantation in NOD.Cg-
Prkdcscid Il2rgtm1Wjl/SzJ.    Kasumi-1 cells were lentivirally transduced with either 
shNTC- and shSLC2A3+shPFKP-expressing vector and mixed on day 4 with 25% of 
each population. A total of 1.0x105 cells in 20 µl of media were intrafemorally injected 
in adult NSG mice. Mice were killed when it reached endpoint and tumours were 
harvested for further analyses.  
 
Figure 3-22 showing the proportion of cells mixture before transplantation (baseline) 
constituted of 24% of shNTC-, 23% of shSLC2A3-, 18% shPFKP-expressing cells 
and 35% double knockdown cells. mRNA analysis showed 60% reduction of SLC2A3 
transcript derived from SLC2A3 knockdown sorted cells. However, there were not 
enough cells for PFKP knockdown and double knockdown cells to perform RT-PCR 
analysis.  
The summary of this experiment is shown in Figure 3-23. To distinguish between 
human and mouse cells, the samples were stained with human CD45 (hCD45) and 
mouse CD45 (mCD45) markers. Additional surface marker, human CD33 (hCD33) 
was also added to confirm the population of myeloid lineage which is expressed in 
Kasumi-1 cell line. Mouse 1 formed tumour in left ovary and the size was 
approximately 40 times bigger than normal ovary (Figure 3-23-A&B). Cells from this 
tumour exhibited 97% positive for hCD33 from 41% hCD45 marker. In this sample, 
shNTC-expressing cells recorded 100% of cells and outcompeted all other 
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populations. Mouse 2 developed leg tumour and unexpectedly double knockdown 
cells outcompeted all other populations from 81% of hCD45 positive population 
(Figure 3-23-A&C). By meticulously observing the dot plot in flow cytometry analyses, 
the fluorescents of shNTC-positive cells in Mouse 1 were homogenously scattered in 
the detection channel and looked alike to the shNTC in the baseline. From my 
experience, this is what I would see if the cells homogenously engraft and form 
tumours. Interestingly, in Mouse 2, a tight fluorescents formed in a distinct area when 
compared to the double positive for SLC2A3+PFKP knockdown cells in the baseline. 
It is thought that these cells originated from single cell and that selectively promote 
clonal leukaemic growth. However, this need to be further validated by downstream 
experiment, such as ligation-mediated PCR. There was no tumour detected in the 
other four mice. This experiment took 138 days until I got to detect some abnormal 
lesions in two of the six mice transplanted. The period was much longer than usual 
time it took to detect the tumours in our previous study which were about 6-8 weeks.  
As a summary, transplantation of leukaemic cell line targeting SLC2A3 and PFKP in 
the bone marrow resulted in variable results. Together with previous experiments 
from section 3.3.3.5, I summarised that there was an issue with engraftment when 
working with these two genes. Nevertheless, PFKP knockdown cells competitively 
loss in these two experiments, hence validated the shRNA screen result. Whereas, in 
the case of SLC2A3, the niche of where the cells engraft and proliferate could also 
pivotal in determining the fate of the leukaemic cells.  
 
 
Figure 3-23: Proportion of cells before transplantation and RNA transcript level 
at baseline.     Lentivirally transduced Kasumi-1 were sorted and 25% of each 
population was mixed before being intrafemorally transplanted in NSG NOD.Cg-
Prkdcscid Il2rgtm1Wjl/SzJ. Graph on the left showing mRNA analysis of sorted cells 
before transplantation. GAPDH serves as housekeeping gene (n=1). 
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Figure 3-24: Graph summarises competitive assay in vivo in NSG mouse 
model.   Cells were mixed before intrafemorally transplanted into NSG mice A) 
Proportion of cells at baseline before transplantation and endpoints from two 
engrafted mice. B&C) Cells from tumours were stained with human CD45, mouse 
CD45 and human CD33 to distinguish between human and mouse cells. B) In mouse 
1, tumour formed in left ovary (big red circle) and the ovary was approximately 40 
times bigger than normal ovary (smaller red circle). C) In mouse 2, tumour was 
detected on right leg.  
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3.3.3.7 SLC2A3 potentially as tumour suppressor in vivo  
 
Collectively from previous two in vivo experiments, I summarised that there were 
hardly engraftments in both mouse models. However, decent data and study 
involving Kasumi-1 cells particularly in RG strain mice had been established in our 
lab (Soria et al., 2008, Martinez-Soria et al., 2018). I then proceed the next 
experiment focusing only on RG mouse. As detailed in section 3.3.3.5, knockdown of 
SLC2A3 drives leukaemic expansion in RG mouse model, therefore, next 
investigation focused on SLC2A3 only. I then thought the number of virus infection 
per cell was not enough to drive SLC2A3 response in vivo. In this experiment, 
highest transduction efficiency was chosen as it was successfully tested in our recent 
publication (Martinez-Soria et al., 2018). 
Single shRNA knockdown was performed following the scheme depicted in Figure 
3-17 except that only one shRNA lentivirus targeting SLC2A3 was used to transduce 
the cells. shNTC- and shSLC2A3-expressing cells were mixed with a proportion of 
50% each and intrahepatically injected in RG newborn mice. Mice were monitored if 
there was any physical sign of abdominal tumours, and humanely killed when it 
reached the endpoints as described in the license. Cells from tumours were 
harvested, analysed by flow cytometry and sorted for RNA analyses. Figure 3-24 
depicted the proportion of cells before transplantation in newborn mice analysed 
using FACS Calibur and transcript level for both shNTC- and shSLC2A3-expressing 
cells (baseline). Further RT-PCR analysis showed 90% reduced transcript level of 
SLC2A3 expression in SLC2A3 knockdown cells compared with the control.  
As depicted in Figure 3-25, in vivo single knockdown of SLC2A3 competitively gained 
its population over shNTC-expressing cells in all five transplanted mice. SLC2A3 
knockdown cells grew from 50% of cells on baseline to 77% of cells in mice 1 
represented in Figure 3-25. The greatest increase was observed in mice 4 as the 
shSLC2A3-expressing cells gained 98% of cells in the tumour (Figure 3-25). mRNA 
analyses of sorted SLC2A3 knockdown cells showed reduced transcripts in all five 
mice as shown in Figure 3-26. There were slight increase of mRNA levels in all five 
mice when compared to the baseline; however, the increments were within the 
ranges observed with this shRNA construct in vitro.  
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Figure 3-25: The proportion of cells and RNA transcript level before 
intrahepatic transplantation in Rag2−/−Il2rg−/−129×Balb/c newborn mice.    A: 
cells were transduced with shNTC- and shSLC2A3-expressing cells on the day the 
mice were born. Cells were analysed with flow cytometry on day-4 post transduction, 
mixed in single tube with 50% proportion of each population and re-analysed with 
flow cytometry before intrahepatically injected in newborn Rag2−/−Il2rg−/−129×Balb/c 
mice. Flow cytometry data was analysed by FlowJo software. B: Remaining cells 
were extracted and checked for RNA transcript (n=1).  
 
 
Figure 3-26: Kasumi-1 cell line competitive loss of shNTC to shSLC2A3-
expressing cells in vivo.    A 50% mixture of shNTC- and shSLC2A3-expressing 
cells was intrahepatically transplanted into five newborn Rag2−/−Il2rg−/−129×Balb/c 
mice. Mice that reached endpoint were killed and cells from the tumours were 
harvested. Cells were analysed with flow cytometry and its fluorescence intensities 
were calculated accordingly.  
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Figure 3-27: mRNA level of SLC2A3 from SLC2A3 knockdown cells harvested 
from baseline and in vivo tumours.    Cells expressing shSLC2A3 from both 
baseline and tumours were harvested, sorted and extracted for mRNA level. Left: 
mRNA level from baseline and shSLC2A3-expressing cells of individual mouse. 
Right: Average mRNA level of shSLC2A3-expressing cells from five mice compared 
to the baseline.  
 
3.3.3.8 SLC2A3 knockdown reduces glucose uptake and possible longer 
survival 
 
Previous in vivo experiments on RG mice (3.3.3.5 & 3.3.3.7) indicated SLC2A3 
knockdown cells outcompeted other populations, including control. Upon completing 
the studies, there was an unusual observation I noticed from the mice that developed 
tumours. The tumours felt not as solid as normal Kasumi-1 cell tumour experienced 
by Dr Helen Blair or Mr Hasan Issa, whom have performed many in vivo experiments 
using the same cell line and mouse model. Apart from that, the tumour size did not 
grow as quickly as it usually grew. So, I thought possibly SLC2A3 knockdown alone 
will independently lead to a slower progression of leukaemic cells in vivo and 
therefore increase in the survival. In this experiment lentiviral transduction was 
performed with either shNTC- or shSLC2A3-expressing vector on Kasumi-1 cell line 
associated with pSLIEW vector (K-1.pSLIEW). This cell line expresses firefly 
luciferase and enabled us to monitor cells engraftment by in vivo imaging system 
(IVIS) (Bomken et al., 2013). After 72 hours-post transduction, the cells either 
shNTC- or shSLC2A3-expressing cells were intrahepatically transplantated into two 
groups of 4-days old newborn RG mice. IVIS imaging were performed on day 30, 44 
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and 57 following luciferin injection. Mice were humanely killed when it reached the 
endpoint as listed in the study licence (Figure 3-27).  
Apart from that, in vivo glucose uptake assay was also performed in this group of 
animals by utilising 2-deoxy-2-[18F]fluoro-d-glucose (2FDG), a glucose analogue with 
a positron-emitting 18F substitution of the 2-hydroxy group which is transported into 
the cells by glucose transporters. It was developed subsequently from 2-Deoxy-D-
glucose (described in chapter 5) for brain glucose mapping in human (Fowler and 
Ido, 2002), and further characterised as glucose uptake marker in both in vitro and in 
vivo studies (Leung, 2004, Kung, 2012, Kuwert, 2003). In a 2002 study, FDG uptake 
was shown to be significantly associated with higher expression of glucose 
transporter-1 (SLC2A1) in tumour section from untreated breast cancer patients and 
correlated with disease severity (Brown et al., 2002). In line with this, I postulated that 
SLC2A3 knockdown will lead to reduce glucose uptake in vivo measured by 2FDG. 
2FDG administration was performed by Mr Saimir Luli and Ms Julian Hunter. 
 
 
Figure 3-28: Scheme of survival analysis study using shRNA- and shSLC2A3-
expressing cells in Kasumi-1.pSLIEW cell line.    Kasumi-1.pSLIEW cells were 
lentivirally transduced with either shNTC- or shSLC2A3- expressing vector and 
intrahepatically transplanted in 4-days old RG mice. Bioluminescent imaging was 
performed on day 30, 44 and 57 to monitor the engraftment. Mice were humanely 
killed when it reached the endpoint described in the license.  
 
Figure 3-28-A shows the bioluminescent images using IVIS which demonstrated 
development of localised abdominal engraftment of Kasumi-1.pSLIEW cell line. Total 
flux of the signals for both shNTC and shSLC2A3 transplanted mice is indicated in 
Figure 3-28-B. Bioluminescent signals of shNTC transplanted mice developed a rapid 
spread of signal once it was initiated as seen between day 44 and 57 (Figure 3-28-
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B). Mouse 2 had low bioluminescent signal on day 57; however, the tumour grew 
rapidly and killed by day 65. Although shSLC2A3 transplanted mice 7 and 10 showed 
a spread signal on day 44 via IVIS; and mouse 9 on day 57, I barely could feel the 
tumour, an observation noticed in line with the previous experiment and therefore 
were left for longer period. By day 52, mouse 10 showed sign of sickness and was 
humanely killed. It had enlarged gallbladder approximately 30 times bigger than 
normal size, while the tumour weighed only 0.62 gram. Mouse 7 developed 
physically viable tumour and killed on day 52.  
Overall, shNTC transplanted mice survived a median of 61 days post-transplantation 
while shSLC2A3 mouse delayed tumorigenesis for 70 days; however, the result was 
not significant as there were not enough animals (p-value=0.12) (Figure 3-29). A 
larger animal study would give a clear and affirmative result for this experiment.  
 
Figure 3-29: Bioluminescent images of shNTC and shSLC2A3 transplanted RG 
mice.    A) Bioluminescent image of shNTC and shSLC2A3 transplanted mice on day 
30, 44 and 57. Mice were injected with luciferin 10 minutes prior to imaging and 
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images were captured using IVIS system. B) Mean bioluminescent total flux of both 
shNTC and shSLC2A3 transplanted mice for day 30, 44 and 57. 
 
 
Figure 3-30: Survival analysis of shSLC2A3-expressing Kasumi-1.pSLIEW cell 
lines promotes insignificant delayed tumorigenesis in vivo (p-value=0.12).    
Kasumi-1.pSLIEW cells were lentivirally transduced with shSLC2A3-expressing 
vector and intrahepatically transplanted into newborn mice (n=4 for control and n=6 
for shSLC2A3).  
 
Figure 3-30 showing bioluminescent and 2FDG fluorescent images of control and 
SLC2A3 knockdown mice analysed on the same range of intensity. Two shNTC-
expressing mice demonstrated high signals of tumour bioluminescent and associated 
with localisation of 2FDG fluorescent. In SLC2A3 knockdown, only one mouse is 
associated with high intensity of tumour bioluminescent and no signal of 2FDG 
detected.  
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Figure 3-31: SLC2A3 knockdown reduces glucose uptake in vivo.   Kasumi-
1.pSLIEW cells were lentivirally transduced with shSLC2A3-expressing vector and 
intrahepatically transplanted into newborn mice (n=3 for control and n=2 for 
shSLC2A3). Mice were injected with 2FDG prior to imaging. Fluorescence and 
bioluminescent images were overlapped using Living Image software.  
 
 Summary 
The major focus of this chapter was to determine if SLC2A3 and PFKP are potential 
therapeutic targets for RUNX1/ETO-leukaemia survival and propagation. The 
outcomes of this study showed irresponsive roles of SLC2A3 in disease progression 
in vivo and contradicted the shRNA screen result. Although glucose uptake was 
compromised both in vitro and in vivo; however, the in vivo survival result was not 
significant to conclude if SLC2A3 is indeed required for leukaemic propagation. On 
the other hand, PFKP was shown to be a crucial partner gene required by 
RUNX1/ETO leukaemia. In vitro analysis showed that RUNX1/ETO moderately 
regulates the expression of PFKP; however, in vivo experiments demonstrated the 
leukaemic propagation relies heavily on this gene. 
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Chapter 4 : RUNX1/ETO alters leukaemic metabolism through 
SLC2A3 and PFKP in vitro 
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 Introduction  
 
The subject of cancer and metabolism has grown over the past few years. 
Accumulated evidences have shown that cancer cells rewire their metabolic 
programme to promote survival and proliferation (Noble et al., 2017, Choi and Park, 
2018, Hou et al., 2017). Alterations in cancer metabolic programming demands an 
increase in the import of nutrients from the extracellular environment such as 
glucose, glutamine and amino acids (Choi and Park, 2018, Jones et al., 2018, Hou et 
al., 2017).  
As described in the previous chapter, SLC2A3 and PFKP are highly expressed in 
cancers to promote glucose uptake and glycolysis. Higher glucose uptake selectively 
progresses the cancer cells towards the glycolytic pathway and secretion of lactate to 
the extracellular fluid, even under aerobic condition (Warburg, 1956b). This pathway, 
called aerobic glycolysis or the Warburg effect, produces acidic environment 
surrounding the tumour and is thought to be the microenvironment required for 
tumour progression (Nagarajan et al., 2016). Glutamine is also required in parallel 
with glucose to maintain pools of carbon and nitrogen sources which serve as 
building blocks for the assembly of various macromolecules. Higher uptake of these 
two molecules also gives the advantage in obtaining reducing power in the form of 
NADH and FADH2, these either function to fuel ATP generation or maintain cellular 
redox capacity (Pavlova and Thompson, 2016).  
Low oxygen content is another critical component for tumour progression and is well 
established in solid tumours such as breast cancer (Sgarbi et al., 2018, Semenza, 
2017). In blood cancer, it could also be assumed that high blast cell proliferation 
requires high oxygen consumption and this would eventually reduce the oxygen 
availability in the blood vessel. Leukaemic initiating cells (LICs) originate from 
haematopoietic stem/progenitor cells and reside in the most hypoxic areas within 
normal HSC niche. Oxygen content in the bone marrow varies from 6%, in close 
proximity to the vessels, to anoxia in the most distant regions (Deynoux et al., 2016). 
Additionally, low oxygen condition triggers upregulation of many metabolic genes 
including SLC2A3 (Mimura et al., 2012) and PFKP (Singh et al., 2017). In leukaemia, 
these two genes are not well studied; hence this chapter characterises the 
dependency of these two genes in RUNX1/ETO-leukaemia in vitro.  
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 Aims  
The aims of this chapter are: 
i- to study competitiveness of SLC2A3 and PFKP in restriction of nutrients 
and oxygen upon shRNA-mediated knockdown.  
ii- to assess the metabolic phenotype changes upon depletion of SLC2A3 
and PFKP through Seahorse metabolic assay. 
 
 Results  
 Role of SLC2A3 and PFKP in RE-leukaemia assessed by in vitro 
constitutive expression of shRNA  
 
In section 3.3.2, I have shown that transient knockdown of SLC2A3 and PFKP with 
siRNA did not affect the proliferation when compared to the experimental control. 
This result was predicted as demonstrated by the previous shRNA screen, where we 
have observed that these two genes only scored in vivo but not in vitro (chapter 3). 
To further study the role of these genes in vitro, I have used constitutively expressed 
vector pLKO.5d.miRNA30 targeting these two genes and characterised the impact on 
survival and metabolic potential which will be described in the following sections.  
 
 Constitutive expression of shSLC2A3 lead to loss of RUNX1/ETO-
leukaemic populations in competitive assay setting under nutrient and 
oxygen deprivation conditions 
 
Competitive assay comprising at least two different populations in a single pool of 
cells is designed to measure the ability of one population to outcompete one another. 
A gene that is crucial for cell survival and propagation will be lost in long-term culture 
in comparison to the experimental control.  
As illustrated in Figure 4-1, cells were set-up in a competitive assay setting by mixing 
the experimental control cells and shRNA knockdown cells into a single pool. Before 
mixing, each cells population was transduced with shRNA lentivirus expressing 
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different endogenous fluorophore at MOI 0.3 and the changes in cell pool was 
monitored by flow cytometry. The gain and loss of fluorescence fractions over time 
represent the ability of each population to populate and outcompete each other. Cells 
were transduced with shRNA lentiviral vectors targeting RUNX1/ETO (tagged with 
dTomato), SLC2A3 (tagged with dTomato), PFKP (tagged with eGFP) and 
SLC2A3+shPFKP (tagged with dTomato+eGFP). For the control, shNTC-expressing 
cells were tagged with RFP657 fluorophore. On day 4 post-transduction, knockdown 
cells were analysed by flow cytometry, washed and mixed with shNTC. In 
RUNX1/ETO competitive assay setting, there were only two populations involved, 
which were RUNX1/ETO knockdown cells (shRE) and shNTC-expressing cells 
(shNTC). Each of the populations was mixed at 50% of transduced cells. For 
competitive assay targeting SLC2A3 and PFKP, there were four populations in a 
single pool. Each SLC2A3- (shSLC2A3), PFKP- (shPFKP), SLC2A3+PFKP-
expressing cells (shSLC2A3+shPFKP) and shNTC was mixed at approximately 25% 
of cells. Flow cytometry analysis was carried out after mixing to establish a baseline 
at day 0 and changes of the fluorescence were monitored every three to four days.  
 
Figure 4-1: Scheme of competitive assay setting utilising constitutive shRNA 
expression.    RUNX1/ETO-positive cells were lentivirally transduced with shRNA 
vector expressing different colour targeting NTC, SLC2A3, PFKP or double 
knockdown (SLC2A3 and PFKP). Cells were analysed by flow cytometry on day 4 
and mixed with approximately 25% of each population. In vitro experiment conditions 
included incubation of cells under oxygen, glucose and glutamine suppressed 
condition. O2: oxygen, -Glu: low glucose, -Gln: low glutamine. 
 
Glucose limitation was included in the assay after considering two aspects; Firstly, 
glucose is the primary substrate of glycolysis; hence, overall energy production would 
be affected by limiting this substrate. Secondly, SLC2A3 exhibits the highest affinity 
towards glucose (Ian et al., 2008, Arbuckle et al., 1996) and if the gene is depleted, it 
will demonstrate the dependency of cells to glucose through SLC2A3. Standard 
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medium used in current leukaemia cell lines (Kasumi-1 and SKNO-1) culture contains 
11 mM glucose (+glu), and the concentration was reduced four-fold lower to 2.5 mM 
in low glucose condition (-glu). The 2.5 mM glucose level was in between normal 
physiological glucose level in blood (4-8 mM) and Km of SLC2A3 (1.4 mM).  
As described earlier, glutamine provides nitrogenous compounds for cellular 
biosynthesis of amino acids and lipids. Therefore, glutamine deprivation in the media 
would reduce both carbon and nitrogen sources. The glutamine content was reduced 
ten times lower to 0.2 mM in culture media (-gln). 
Another part of the assay was the limitation of oxygen content. I reasoned oxygen 
might play a role in the behaviour of the genes as they were shown to be responsive 
in vivo in the shRNA screen. I postulated, low oxygen content leads to higher 
dependency of SLC2A3 and PFKP to support increase in glycolysis. While the 
standard incubation (normoxia) was set at 20% oxygen, the hypoxia incubation was 
set to 1% of oxygen. The experiments involving hypoxia were conducted inside the 
hypoxia station at all times.  
 
 Limitation of nutrient and oxygen significantly impact the cell 
proliferation of Kasumi-1 cells 
 
Firstly, I sought to determine whether limitation of nutrient and oxygen results in 
slower growth of the cells. Kasumi-1 cells were seeded at 5.0 x 105 cell/ml in +glu, -
glu and –gln condition media and placed in normoxia and hypoxia incubator. Cells 
were counted at 24-, 48- and 72-hour timepoint using standard trypan blue counting 
method.  
Figure 4-2-A indicates growth curve of Kasumi-1 cells in different culture media in 
both normoxia and hypoxia incubation conditions. Cells cultured in normoxia +glu 
doubled at 65-hour post-seeding and significantly proliferated at higher rate than cells 
cultured in hypoxia and nutrient deprivation conditions (p-value<0.05) (Figure 4-2-B). 
Furthermore, hypoxia had no impact on nutrient deprivation cultured as indicated in 
the Figure 4-2-B.   
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Collectively, low oxygen and nutrient deprivation caused lower cells number of 
Kasumi-1 cells, but, combination of both factors did not have any impact on the 
proliferation.   
 
Figure 4-2: Proliferation curve for Kasumi-1 cells in oxygen and nutrient 
limitation condition.     Cells were seeded at 5.0 x 105 cell/ml at day 0 and counted 
at the timepoint indicated on the x-axis. A) The growth of Kasumi-1 cells at different 
timepoint. B) Comparison of cells number at 72-hour timepoint. Significance was 
evaluated using 2-way Anova using PRISM software. p*<0.05, **p<0.01, ***p<0.001, 
p****<0.0001. Error bars indicate standard deviation (n=3, independent experiments). 
N: Normoxia, H: hypoxia, +glu: high glucose, -glu: low glucose, -gln: low glutamine. 
 
 RUNX1/ETO as master regulator in t(8;21) leukaemia 
Figure 4-3 to Figure 4-7 show changes of the fluorescence of shRNA knockdown 
cells in long-term competitive assay. In general, cells transduced with shNTC 
outcompeted shRE populations in all culture conditions in both normoxia and hypoxia 
conditions, for both Kasumi-1 and SKNO-1 cell lines (Figure 4-3 and Figure 4-5). In 
Kasumi-1 cell line, shRE cells started to loss as early as on day 3 observed in 
normoxia conditions. However, in hypoxic conditions, loss of shRE cells did not occur 
as rapid as in normoxia. These results indicate that RUNX1/ETO is indeed the 
master regulator of t(8;21) leukaemia. RUNX1/ETO knockdown in Kasumi-1 cells 
showed trends of resistance in hypoxia condition (Figure 4-5); but, consequently, the 
cells were outcompeted by shNTC cells at the end of the experiments (Figure 4-3). 
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Kasumi-1 
 
 
Figure 4-3: Stacked column showing competitive loss of shRE to shNTC in all 
culture conditions in Kasumi-1 cells.    A) shNTC and shRE cells were mixed on 
day 0 in standard media (+glu), glucose or glutamine deprived media (-glu and –gln 
respectively) and cultured in normoxic or hypoxic conditions. Fluorescence 
percentages were monitored by flow cytometry at least once a week. Briefly, the 
percentage of fluorescence was calculated by excluding non-transduced cells and 
every timepoint was normalised to day 0 as well as fractionised to an amount of 25% 
to get a matrix of 100%. B) Summary of fluorescence percentages between baseline 
and endpoint in different culture conditions. Populations of shRE loss compared to 
shNTC in all culture conditions (n=1).    
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Kasumi-1 
 
Figure 4-4: Different experiments show trends of resistance of shRE cells in 
hypoxia conditions in Kasumi-1 cells.     A&B) shNTC and shRE cells were mixed 
on day 0 in standard media (+glu), glucose or glutamine deprived media (+glu and –
gln respectively), and cultured in normoxic or hypoxic conditions. Fluorescence 
percentages were monitored by flow cytometry at least once a week. Briefly, the 
percentage of fluorescence was calculated by excluding non-transduced cells and 
every timepoint was normalised to day 0 as well as fractionised to an amount of 25% 
to get a matrix of 100%. B) Summary of fluorescence percentages between baseline 
and endpoint in different culture conditions. Populations of shRE loss compared to 
shNTC in all culture conditions (n=1).  
 
  
 119 
 
SKNO-1 
 
 
Figure 4-5: Stacked column showing competitive loss of shRE to shNTC in all 
culture conditions in SKNO-1 cell line.    A) shNTC and shRE cells were mixed on 
day 0 in standard media (+glu), glucose or glutamine deprived media (-glu and –gln 
respectively), and cultured in normoxic or hypoxic conditions. Fluorescence 
percentages were monitored by flow cytometry at least once a week. Briefly, the 
percentage of fluorescence was calculated by excluding non-transduced cells and 
every timepoint was normalised to day 0 as well as fractionised to an amount of 25% 
to get a matrix of 100%. B) Summary of fluorescence percentages between baseline 
and endpoint in different culture conditions. Populations of shRE loss compared to 
shNTC in all culture conditions (n=1).    
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 Glucose addiction via SLC2A3 in RUNX1/ETO-leukaemia in Kasumi-1, 
but not in SKNO-1 
 
Overall, in Kasumi-1 cells the percentage of shNTC cells increased in all culture 
conditions (Figure 4-6). In normoxia +glu condition, there was no significant reduction 
of the shSLC2A3 population. Whereas, in normoxia –glu condition, a statistically 
significant shSLC2A3 cells were outcompeted by shNTC (p<0.01). The same 
observation was also seen in hypoxia –glu condition. SLC2A3 knockdown cells were 
significantly outcompeted by shNTC at the end of the experiment (p<0.05). Moreover, 
neither normoxia nor hypoxia conditions had substantially affected SLC2A3 
knockdown cells cultured in glutamine deprivation media.  
shNTC cells significantly outcompeted PFKP knockdown cells in all culture conditions 
(p<0.05), with the smallest fraction of cells observed in normoxia –gln condition 
(p<0.001). Double knockdown of SLC2A3 and PFKP significantly caused the cells to 
competitively loss to shNTC in all culture conditions (p<0.05) with SLC2A3 
knockdown cells significantly contributed towards the effect (p-value<0.05). PFKP 
knockdown; however, insignificantly caused the loss in double knockdown 
populations observed in hypoxia +glu and –gln conditions.  
On the contrary, knockdown of SLC2A3 and PFKP in SKNO-1 resulted in 
unexpected and inconclusive outcomes as indicated Appendix 4-1.  
Taken together, at MOI of 0.3, SLC2A3 shown to be responsive in limited glucose 
and oxygen conditions in Kasumi-1 cells, but not in SKNO-1 cells. In Kasumi-1 cells, 
PFKP knockdown showed to be an important regulator in glycolysis, whereby the 
knockdown led to loss of cell populations in all culture conditions. Furthermore, 
targeting both SLC2A3 and PFKP led to a significant depletion of leukaemic 
population in Kasumi-1 cells (p-value<0.05).  
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Kasumi-1 
 
Figure 4-6: Stacked column showing competitive loss of shSLC2A3 in the 
absence of glucose, glutamine and oxygen in Kasumi-1 cell line at MOI 0.3.    A) 
shNTC, shSLC2A3, shPFKP and shSLC2A3+shPFKP cells were mixed on day 0 in 
standard media (+glu), glucose or glutamine deprived media (+glu and –gln 
respectively), and cultured in normoxic or hypoxic conditions. Fluorescence 
percentages were monitored by flow cytometry at least once a week. Briefly, the 
percentage of fluorescence was calculated by excluding non-transduced cells and at 
every timepoint was normalised to day 0 as well as fractionised it to an amount of 
25% to get a matrix of 100% for all the populations. B) Summary of fluorescence 
percentages between baseline and endpoint in different culture conditions. 
Significance was evaluated using one-way Anova for each culture condition using 
PRISM software. p*<0.05, **p<0.01, ***p<0.001, p****<0.0001. Error bars indicate 
standard deviation (n=3, independent experiments). 
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 SLC2A3 knockdown cells exhibit more profound loss with higher virus 
particles per cell 
 
As mentioned in chapter 3 (section 3.3.6), I wondered if the amount of virus particle 
per cell have a different impact on cell survival especially on SLC2A3 knockdown 
cells. The assays were then repeated at higher transduction rate to see the 
differences in both Kasumi-1 and SKNO-1. Both Kasumi-1 and SKNO-1 cells were 
lentivirally transduced at more than 90% efficiency. However, due to limitations in 
virus production at this stage (will be described in the chapter conclusion), only 
Kasumi-1 cells were continued to culture in standard and limited glucose in both 
normoxia and hypoxia conditions with double knockdown approach following the 
scheme in Figure 4-1.  
Whereas, SKNO-1 cells were transduced with either shNTC- or shSLC2A3-
expressing lentivirus and mixed on day 4-post-transduction. SKNO-1 cells were 
cultured in either +glu media and placed in normoxia or in -glu media in hypoxia 
condition. Due to a very low number of cells during this assay, the fluorescence was 
captured only once, at day 7-post mixing.  
Figure 4-7 shows the changes of shRNA-expressing cells in each culture condition. 
In Kasumi-1 cells, the shNTC-expressing cells significantly outcompeted other 
populations in all culture conditions (p<0.05). Confirming the previous experiments, 
hypoxia –glu significantly caused the biggest loss of SLC2A3 knockdown cells (p-
value<0.001). Furthermore, PFKP knockdown caused the cells to significantly loss to 
shNTC cells in all culture conditions (p-value<0.001). Finally, double knockdown of 
SLC2A3 and PFKP significantly loss to shNTC-expressing cells.  
In contrast to the findings with MOI 0.3, SKNO-1 cell line showed a more potent 
reduction of SLC2A3 knockdown cells in both normoxia +glu and hypoxia -glu. In 
these two conditions, shNTC cells grew from 50% of cells at day 0 to 82% of cells on 
day 7 and successfully outcompeted SLC2A3 knockdown cells (Figure 4-7-C).  
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Figure 4-7: Stacked column showing competitive loss of shSLC2A3-expressing 
cells in the absence of glucose and oxygen at higher transduction efficiency in 
both Kasumi-1 and SKNO-1 cell lines.     A) Kasumi-1 cells; shNTC, shSLC2A3, 
shPFKP and shSLC2A3+shPFKP cells were mixed on day 0 in standard media 
(+glu) and glucose deprived media (-glu) and cultured in normoxic and hypoxic 
conditions. B) Summary of percentages between baseline and endpoint in different 
culture conditions (n=3). C) SKNO-1 cells; shNTC- and shSLC2A3-expressing cells 
were mixed on day 0 in either standard media (+glu) or glucose deprived media (-
glu). Cells in the standard media were incubated in normoxic conditions, whereas 
cells in limited glucose were cultured in hypoxic condition (n=1). Fluorescence 
percentages were monitored by flow cytometry at least once a week. Briefly, the 
percentage of fluorescence was calculated by excluding non-transduced cells and at 
every timepoint it was normalised to day 0 as well as fractionised to an amount of 
25% to get a matrix of 100% for all populations. Significance was evaluated using 
one-way Anova for each culture condition using PRISM software. p*<0.05, **p<0.01, 
***p<0.001, p****<0.0001. Error bars indicate standard deviation (n=3 independent 
experiments).
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Based on these observations, higher transduction efficiency drove more potent 
effect, particularly on SLC2A3 knockdown cells in both Kasumi-1 and SKNO-1 cells. 
In Kasumi-1 cells, both PFKP and double knockdown robustly diminished leukaemic 
propagation and survival. However, I wondered which condition would give the most 
substantial effect especially on SLC2A3 knockdown cells in terms of reducing the 
leukaemic burden?  
I further explored the outcomes from these two experiments in Kasumi-1 cells. 
Comparison was performed between shNTC-expressing cells and shRNA-
knockdown cells at the endpoints to find out which condition gave the most 
substantial effect (Figure 4-8). With MOI 0.3 transduction (Figure 4-8-A), hypoxic –glu 
condition contributed to the most prominent effect, where I observed a statistically 
significant 40% loss of shSLC2A3 cells (p-value <0.01) when compared to the 
normalised shNTC cells. Whereas, PFKP and double knockdowns showed to be 
significantly loss in all culture conditions (p-value <0.001). 
With higher transduction efficiency (Figure 4-8-B), SLC2A3 knockdown cells were 
significantly lost in all culture conditions. The biggest loss was recorded in hypoxia –
glu condition, in which 41% of cells remained at the end of the experiment (p-
value<0.001). In normoxia +glu content, SLC2A3 knockdown minimally reduced to 
76% (p-value<0.01).  
Additionally, both PFKP and double knockdown significantly loss in all culture 
conditions (p-value<0.001).  
In summary, culturing the Kasumi-1 cells in limited glucose and oxygen have shown 
more substantial effect particularly on SLC2A3 knockdown cells. Therefore, this 
culture condition was carried forward for further characterisations. In parallel, 
culturing cells in normoxia with +glu content was also performed to see the difference 
of glucose and oxygen would impact on SLC2A3 and PFKP. 
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Figure 4-8: Percentage of remaining cells of each shRNA knockdown at 
endpoints.    Percentage of shRNA-expressing cells was calculated by normalising 
to shNTC-cells at endpoints. Percentages were compared between lower 
transduction efficiency (A) and higher transduction efficiency (B). Significance was 
evaluated using Student’s t-test for each group. ns: not significant, p*<0.05, **p<0.01, 
***p<0.001, p****<0.0001. (n=3, independent experiments). 
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 Glucose diminished clonal capability in SLC2A3 knockdown in Kasumi-1 
cell line 
 
To further characterise SLC2A3 and PFKP in self-renewal capacity of t(8;21) 
leukaemia, colony formation assays were performed in both Kasumi-1 and SKNO-1 
cell lines. The assays were performed by including nutrient deprivation media as well 
as oxygen limited conditions. Cells were transduced with shRNA at high transduction 
efficiency of more than 90% and collected on day 4. Cells were seeded in 24-well 
tissue culture plate on semi-solid medium at the density of 0.5 x 104 cells/ml. On day 
10 post-seeding, colonies that contained more than 50 were counted and images 
were captured.  
In general, shNTC cells formed the highest number of colonies in all culture 
conditions when compared to all shRNA knockdown cells (Figure 4-9). RUNX1/ETO 
knockdown substantially abrogated the colony forming ability in all culture conditions 
indicating that it is indeed the master for self-renewal capacity in t(8;21) leukaemia. 
Furthermore, in +glu condition, SLC2A3 knockdown did not have any substantial 
effect on the colony formation. Moreover, the size of the colonies between shNTC 
and shSLC2A3 cells were almost similar as shown in Figure 4-9-B. However, in –glu 
condition, SLC2A3 knockdown cells reduced the colonies by one-half and associated 
with much smaller colonies when compared against shNTC. In hypoxia, culturing the 
SLC2A3 knockdown cells in standard methylcellulose media caused the colony 
forming to reduce by 30% when compared to shNTC. Limitation of glucose in hypoxia 
did not further impact the self-renewal capacity in the SLC2A3 knockdown cells. 
Furthermore, the size and shape of the colonies were identical in both of these two 
conditions. 
On the other hand, PFKP knockdown reduced the number of colonies by half in +glu 
condition in both normoxia and hypoxia. Limitation of glucose further reduced the 
number of colonies by almost 75% in both of the oxygen conditions. Interestingly, 
double knockdown of SLC2A3 and PFKP seemed to have no additive impact as the 
colonies recovery were almost similar to PFKP knockdown.  
 127 
 
 
 
Furthermore, plating the knockdown cells in glutamine deprivation semi-solid media 
completely abrogated clonogenicity in all shRNA treated cells as pictured in Figure 
4-9-B. Moreover, by comparing shNTC cells between standard culture and -gln, 
limitation of glutamine caused 50% reduction in the number of colonies.  
Taken together, targeting SLC2A3 alone modestly impaired self-renewal capacity of 
Kasumi-1 cells. However, reducing glucose in culture media gave a better reduction 
in self-renewal capacity in SLC2A3 knockdown. This observation was also similar in 
PFKP knockdown and in double knockdown.  
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Kasumi-1 
 
 
 
Figure 4-9: Colony forming ability of SLC2A3 knockdown was affected in 
reduced glucose condition.    Cells were lentivirally transduced with shRNA 
targeting SLC2A3, PFKP and RUNX1/ETO and plated in semi-solid methylcellulose 
media.  Colonies were counted on day 10 when the colonies in control sample 
contained at least 50 cells. A) Percentage of colonies were calculated against the 
initial number of cells seeded on day 0. B) Phase contrast pictures of colonies 
captured on day 10. Data were average of n=2 independent experiments. For each 
experiment, 2 wells of colonies were prepared for every sample. For shPFKP in 
hypoxia –gln, there were only pictures on the edge of the plate as no colonies/cells 
observed in the middle of the plate.  
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 Glucose and oxygen limitations corrupt cell cycle in SLC2A3 knockdown 
cells 
 
Knockdown of SLC2A3 and PFKP in different culture condition caused RUNX1/ETO 
leukaemic cells to behave differently. Kuang et al. (2017) has demonstrated that low 
glucose renders accumulation of cells in G1/G0 phase. I wondered if the losses of 
cell populations were associated with cell cycle mechanism, and more interestingly if 
limitation of glucose caused different cell cycle profile particularly for SLC2A3 
knockdown cells. To answer this question, analysis of cell cycle was performed by 
flow cytometry. Briefly, 1 x 106 shRNA knockdown cells were collected on day 12 
post-transfection, fixed with 4% paraformaldehyde (PFA) and stained with DAPI. 
Data were captured using FACS Canto II and analysed with FlowJo software. 
As indicated in Figure 4-10, consistence with our previous findings (Martinez-Soria et 
al., 2018, Martinez et al., 2004), RUNX1/ETO knockdown caused a significant block 
in G0/G1 phase in all culture conditions compared with the control (p-value<0.01)  
In normoxia +glu condition, the number of shNTC cells in G0/G1 phase was recorded 
to be 77% of cells. SLC2A3 knockdown cells slightly increase the number of cells in 
the G0/G1 phase which was 78%. However, a statistically significant increase of cells 
in G0/G1 were observed in PFKP knockdown (p<0.01, 82.5%) and double 
knockdown (p<0.01, 83.7%). While shNTC cells recorded 17% of cells entering S 
phase, SLC2A3 knockdown caused an insignificant reduction of 16% of cells in S 
phase. A significant decrease in the number of cells that enter S phase was observed 
in both shPFKP (p-value<0.01, 13%) and double knockdown cells (p-value<0.01, 
12.3%).  
Greater effects on the cell cycle phases were observed in hypoxic conditions. In 
general, oxygen-limited condition led to a higher G0/G1 phase as well as smaller 
G2/M phase in shNTC-expressing cells when compared with its counterpart in 
normoxia. In the G0/G1 phase, shNTC cells recorded 85% of cells, whereas SLC2A3 
knockdown cells significantly increased the cells in this phase to 90% (p-value<0.05). 
Higher G0/G1 phase was also observed in PFKP and double knockdown cells. PFKP 
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knockdown recorded 91% of cells (p-value<0.01), whereas 93.8% of cells recorded in 
double knockdown (p-value<0.001).  
More interestingly, SLC2A3 knockdown cells showed to behave differently in the 
suppression of glucose and oxygen conditions. By comparing against normoxic +glu 
condition, culturing shSLC2A3 cells in hypoxia –glu halved the percentage of cells 
entering S phase (p-value<0.01). Suppression of glucose and oxygen also caused a 
significant 90% of SLC2A3 knockdown cells in G0/G1 phase, whereas 77% of cells 
were recorded in normoxia +glu condition.  
Taken together, SLC2A3 knockdown caused significantly higher accumulation of 
G0/G1 cells only in limited oxygen and glucose condition caused, but not in standard 
condition. However, PFKP and double knockdown increased the proportion of cells in 
G0/G1 phase in all culture conditions. Nevertheless, depletion of RUNX1/ETO 
diminished the proliferative capacity of the cells indicating that it is indeed the master 
regulator of cell cycle in t(8;21) leukaemia.  
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Figure 4-10: Cell cycle profile of SLC2A3, PFKP and RUNX1/ETO knockdown 
cells in different culture conditions.     Transduced cells with shNTC, shSLC2A3, 
shPFKP and shSLC2A3+shPFKP were cultured in either standard (+glu) and glucose 
deprived media (-glu) and incubated in normoxic and hypoxic conditions. Cells were 
harvested, fixed in 4% PFA, stained with DAPI and analysed with flow cytometry. A)  
Cell cycle profiles for shNTC, shSLC2A3, shPFKP and shSLC2A3+shPFKP in 
normoxia +glu and hypoxia -glu conditions. B) Cell cycle profile comparing 
shSLC2A3 cells in normoxia +glu and hypoxia –glu condition. Significance was 
evaluated using Student’s t-test, ns: not significant, p*<0.05, **p<0.01, ***p<0.001, 
p****<0.0001 (n=3, independent experiments). 
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 Hypoxia induced cell death of SLC2A3 knockdown cells 
 
To pursue the reason for increased of G0/G1 phase in the knockdown cells, I looked 
into a potential association with cell death. To address this, I used Annexin V 
apoptosis assay. In apoptotic cell, the membrane phospholipid phosphatidylserine 
(PS) is translocated from the inner membrane to the outer layer of the plasma 
membrane, hence exposing PS to the external cellular environment. Annexin V is a 
35-36 kDa Ca2+ dependent phospholipid-binding protein that has high affinity to PS 
and binds to cells with exposed PS. Annexin V antibody can be conjugated to  
fluorophore, in this case BV421 and can be detected by flow cytometry. This assay 
did not discriminate between early and late apoptosis cells as it was not used in 
conjunction with dead cells staining. Kasumi-1 cells were lentivirally transduced and 
cultured in normoxia high glucose (+glu) and hypoxia low glucose (-glu). Apoptosis 
analysis was performed on day 4 and day 9. Briefly, cells were harvested and 
incubated in Annexin V-BV421 in Ca2+ containing buffer. The fluorescence was 
captured using FACS Canto II and analysed using FlowJo software.  
Figure 4-11-A shows the percentage of Kasumi-1 cells positive for Annexin V for 
shRNA cells in both normoxia and hypoxia with high and low glucose. Knockdown of 
RUNX1/ETO led to minimal changes of apoptotic body in standard culture condition.  
In normoxia +glu condition, shNTC-expressing cells recorded 19.4% of apoptosis 
cells on day 4 and increased 1.5-fold on day 9. Longer incubation in hypoxia –glu 
condition caused Annexin V positive cells to increase 2.6-fold.  
Percentage of Annexin V positive cells in SLC2A3 knockdown increased slightly on 
day 9 in normoxia +glu condition. Interestingly, in hypoxia –glu culture, the 
percentage of apoptotic cells was two-fold higher on day 4 when compared with its 
counterpart in normoxia +glu condition. Annexin V positive cells continued to 
increase 3-fold on day 9.  
On the other hand, knockdown of PFKP increased two-fold of cells in apoptosis cells 
from 22% on day 4 to 46% on day 9 in normoxia +glu. Culturing the PFKP 
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knockdown cells in hypoxia –glu resulted in a massive 76% increase of Annexin V 
positive cells on day 9, which was nearly two-fold higher than on day 4 (35%).  
Moreover, double knockdown caused the highest induction of apoptosis in all 
conditions. In normal culture condition, the percentage of dying cells increase 2-fold 
from day 4 to day 9. More prominent effect was observed in limited oxygen and 
glucose condition, where it recorded 52% and 84% of apoptotic cells on day 4 and 
day 9, respectively.  
In agreement with the Annexin V staining, examination of cell cycle distribution also 
revealed increase of subG1 population in SLC2A3 and PFKP knockdowns with 
hypoxia showed to have greater effects (Figure 4-11-B). Hypoxia caused a significant 
5-fold increase of subG1 of shNTC cells (p-value<0.01). The same observation was 
also observed in SLC2A3 knockdown cells, in which subG1 cells significantly 
increased 4-fold in the low oxygen condition (p-value<0.05). Moreover, PFKP and 
double knockdown in standard condition caused higher subG1 phase in comparison 
to the shNTC. Furthermore, culturing the cells in hypoxia minimally increased the 
subG1 cells to 1.7- and 1.6-fold in both PFKP and double knockdown respectively. 
Despite the high induction of Annexin V positive cells in shRE cells in hypoxia –glu 
condition; however, subG1 analyses did not revealed any increase of subG1 
population. This could be due to the cells undergo apoptosis at G2/M or late S phase 
and result in indistinguishable G1 or early S phase peaks (Wlodkowic et al., 2009). 
 134 
 
 
 
 
Figure 4-11: Fractions of Annexin V positive cells in Kasumi-1 cells treated with 
shRNA.    Cells were lentivirally transduced with shRNA targeting SLC2A3, PFKP 
and RUNX1/ETO and cultured in limited oxygen and glucose content. A) Cells were 
stained with Annexin V for detection of apoptosis body (n=1). B) Cells were fixed in 
4% PFA, stained with DAPI and analysed with flow cytometry. Significance was 
evaluated using students t-test, ns: not significant, p*<0.05, **p<0.01. Error bar 
represents standard deviation (n=3, independent experiments). 
 
 
 CCND1 and CCND2 genes were affected in SLC2A3 knockdown cells 
 
Knockdown of SLC3A3 and PFKP in limited glucose and oxygen condition resulted in 
a lower proportion of cells in G2/M phase. As shown in the previous chapter (Figure 
3-17), knockdown of SLC2A3 reduced glucose uptake in both normoxia and hypoxia 
conditions. Further, studies have shown that glucose and hypoxia are inter-related 
with expressions of some cell cycle genes. For instance, Stamateris et al. (2016) 
demonstrated that low glucose rendered the expression of CCND2. CCND2 was also 
downregulated in hypoxia in MYC-dependent manner (Keith et al., 2011). This gene 
was shown to be a crucial transmitter in RUNX1/ETO-leukaemia propagation 
(Martinez-Soria et al., 2018). Based on the abovementioned evidences, I wondered if 
downregulations of SLC2A3 and PFKP have any effects on the expressions of this 
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gene. RNA analyses were performed on shRNA-transduced cells harvested on day 
10 post-transduction.  
Figure 4-12 showed the expression level of cell cycle-related genes in Kasumi-1 cells 
in normoxia standard condition (N +glu) and hypoxia limited glucose condition (H -
glu). In line with our previous findings (Martinez-Soria et al., 2018), RUNX1/ETO-
knockdown caused 60% and 80% reductions in both CCND2 and CCND1 transcript 
levels in both normoxia +glu and hypoxia –glu conditions, with hypoxia – glu 
condition had a slightly greater effect. However, CCND3 levels increased upon 
depletion of RUNX1/ETO. RUNX1/ETO knockdown caused the CCND3 expression 
level to increase by two-fold in normoxia +glu and 3.5-fold in hypoxia –glu condition. 
In SLC2A3 knockdown cells, CCND2 mRNA levels reduced to approximately 60% in 
both normoxia +glu and hypoxia -glu respectively. While PFKP knockdown has 
greater effect on the survival of the cells (Figure 4-6 & Figure 4-7), it caused only 
30% reductions in CCND2 mRNA levels in both conditions. CCND1 mRNA 
expression level was down to 60% in normoxia +glu condition; however, it was 
slightly lower in hypoxia –glu condition. In the case of SLC2A3 and PFKP double 
knockdown, transcript levels of CCND2 and CCND1 were down to 40% and 20% 
respectively, mimicking the expression levels in RUNX1/ETO knockdown cells. 
Furthermore, neither single nor double knockdowns of SLC2A3 and PFKP reduced 
the expression levels of CCND3 mRNA.  
Taken together, knockdown of SLC2A3 and PFKP reduced the mRNA levels of 
CCND1 and CCND2. However, hypoxia and limitation of glucose did not cause any 
differential expressions on the three cyclin-D genes. Hypoxia and glucose limitation 
only showed to have an impact on CCND3 expression in RUNX1/ETO knockdown 
cells.     
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Figure 4-12: Cell cycle-related gene upon shRNA-mediated knockdown.    
Kasumi-1 cells were lentivirally transduced with shRNA targeting SLC2A3, PFKP and 
RUNX1/ETO and cultured in limited oxygen and glucose content. Cells were 
harvested on day 8 post-transduction and extracted for RNA analysis. N +glu: 
Normoxia high glucose, H -glu: Hypoxia low glucose (n=1).  
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 SLC2A3 and PFKP as the determinant factor in RUNX1/ETO glycolytic 
function in vitro 
 
As previously shown, RUNX1/ETO-leukaemia cells increased glucose uptake 
through SLC2A3 (section 3.3.3.4). I questioned if it also regulates cell glycolytic 
functions through a SLC2A3-dependent manner. I next performed Seahorse 
Glycolytic Stress Assay to measure changes in extracellular acidification as an 
indicator of glycolytic flux. The basis of this assay is the conversion of glucose to 
lactate in glycolysis pathway that is transported out from the cell and resulted in 
increased acidity in the extracellular medium. The instrument directly measures the 
acidification rate and reports this as extracellular acidification rate (ECAR). Figure 
4-13 illustrates the sequential compound injections resulting in changes in glycolytic 
profiles. In this assay, glucose-induced response is reported as rate of glycolysis. 
The second injection is oligomycin, an ATP synthase inhibitor. This compound 
inhibits mitochondrial ATP production, shifts the energy production to glycolysis and 
increases ECAR as maximum glycolytic capacity. The final injection is acute injection 
of 2-deoxyglucose (2DG), a glucose analogue that inhibits glycolysis pathway 
resulting in decrease of ECAR. Kasumi-1 cells were lentivirally transduced and 
harvested on day 4 post-transduction. A total of 2.0 x 105 cells was prepared in 
glucose-free Seahorse XF Base media and plated on pre-coated Seahorse 96-well 
plate with CellTak Adhesive. Seahorse XF Base media is free of bicarbonate to 
prevent changes of pH in the media due to cells respiration during plate preparation. 
The plate was placed in Seahorse XFe96 Analyzer located in Flow Cytometry Core 
Facility in Medical School. Results were captured and analysed with Seahorse Wave 
Software.  
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Figure 4-13: Seahorse Glycolysis Stress Test.    Sequential injections of glucose, 
oligomycin and 2DG results in changes in glycolytic profiles. Modified from Agilent 
Technologies. 
 
Figure 4-14-A revealed glycolytic functions of t(8;21) leukaemia were impaired upon 
shRNA knockdown on the target genes when compared to the control. Control cells 
(shNTC) increased glycolysis function after injection of glucose and the rate rose 
minimally upon inhibition of the oxidative phosphorylation (OXPHOS) pathway 
leaving 30% of glycolytic reserve after 2DG injection. This indicates glucose is indeed 
metabolised mainly through glycolysis pathway rather than OXPHOS confirming that 
this cell line relied more on the least efficient energy production. Besides that, 
knockdown of RUNX1/ETO completely diminished the glycolytic phenotypes showing 
that it is undoubtedly the master regulator of glycolysis in t(8;21) leukaemia. 
Next, knockdown of SLC2A3, PFKP and both genes reduced glycolytic function to 
nearly 30% lower than shNTC-expressing cells (Figure 4-14-B). Interestingly, 
oligomycin injection caused glycolytic capacity to reduce by half in both SLC2A3 and 
PFKP knockdown cells when compared to the control (Figure 4-14-C). Whereas, 
double knockdown reduced ECAR rate to 30% when compared to the control. 
Notably, inhibition of OXPHOS neither induced major surge in glycolysis nor 
glycolytic capacity in these knockdown samples indicating that SLC2A3 and PFKP 
are undeniably crucial in regulating glycolysis in these cells (Figure 4-14-B/C/D).  
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Collectively, RUNX1/ETO leukaemia controls glycolysis through SLC2A3 as well as 
PFKP. Knockdown on these genes impaired glycolytic functions mimicking 
RUNX1/ETO knockdown indicating the roles of SLC2A3 and PFKP in maintaining 
glycolysis in this subtype of leukaemia. 
 
 
Figure 4-14: Extracellular acidification of SLC2A3, PFKP and RUNX1/ETO.    
Cells were lentivirally transduced with shRNA targeting SLC2A3, PFKP and 
RUNX1/ETO and plated in Seahorse 96-well plate. Glucose, oligomycin and 2DG 
were used for acute injection and ECAR readings were normalised to protein 
concentration (n=3).  
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 Summary  
This chapter characterised the in vitro functions of SLC2A3 and PFKP as required 
partner genes of RUNX1/ETO, as well as the controller of glycolysis in this subtype of 
leukaemia. Firstly, nutrient deprivation conditions had the biggest impact on Kasumi-
1 cells proliferation. Hypoxia was observed to significantly reduce the cell number in 
standard condition media, but did not have any influence when in combination with 
nutrient deprivation conditions.  
Depletion of RUNX1/ETO completely diminished the propagation and survival of 
leukaemic cells regardless of nutrient and oxygen limitations in both of the cell lines. 
The deflated populations associated with an increase in cell cycle arrests, lower 
expression of cell cycle-related genes and reduced self-renewal capacity. However, 
an interesting finding was observed in higher proportion of apoptotic cells in restricted 
glucose and oxygen condition, whereas this was not observed in standard condition. 
Nonetheless, knockdown of RUNX1/ETO completely diminished glycolytic 
phenotypes proving that it is indeed the master regulator of glycolysis. 
SLC2A3 required glucose for proliferation and self-renewal ability and limitation of 
oxygen increased the dependency. Depletion of SLC2A3 alone is not enough to 
cause cell cycle arrest; but, glucose and oxygen restriction led to a higher G0/G1 
phase. Even though CCND2 and CCND1 expressions were reduced in the 
knockdown cells, interestingly, there were no differences in both of the settings. 
Instead, the reduced propagation of SLC2A3 knockdown cells in restricted glucose 
condition was more related to the increase in apoptosis induction and associated with 
the increased of sub G1 populations. PFKP; however, showed to be crucial in all 
culture conditions. Loss of PFKP caused cell cycle arrests and increase of apoptotic 
cells. Besides, depletion of both SLC2A3 and PFKP abrogated leukaemic cells in all 
culture conditions, which was associated with higher number of cells in G0/G1, 
increased number of apoptotic cells as well as reduced levels of mRNA expression of 
cell cycle-related genes. In Seahorse glycolytic stress assay, knockdown of SLC2A3, 
PFKP or double knockdown of both genes simultaneously abrogated glycolytic 
functions showing that these genes are indeed required to drive glycolysis in 
RUNX1/ETO-leukaemia.  
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Chapter 5 : Efficacy of small molecule inhibitor in RUNX1/ETO- 
positive leukaemia  
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 Introduction 
Chromosomal rearrangement leading to t(8;21) leukaemia fuses RUNX1 to ETO and 
generates the aberrant transcriptional regulator, RUNX1/ETO. Current treatments 
involve intensive and genotoxic chemotherapy, which can reduce patients' quality of 
life and long-term remissions (de Rooij et al., 2015). Previous work has identified 
pathways that were affected by this oncogenic transcription factor such as cell cycle, 
MTOR and MYC-signalling (Martinez-Soria et al., 2018). 
Gene signatures associated with glycolysis were identified as enriched in 
RUNX1/ETO-positive cells (Martinez-Soria et al., 2018). RUNX1/ETO knockdown led 
to the dysregulation of genes within the glycolysis pathway, as shown in GSEA 
analysis (Figure 5-1). Studies have shown that cancer cells rely heavily on glycolysis 
even in the presence of oxygen (Warburg, 1956a). Consequently, the extracellular 
lactate level increases making the environment more acidic and favourable for 
cancer growth (Sonveaux et al., 2008). For instance, higher extracellular acidification 
levels was shown in Burkitt lymphoma cell line that promotes cell growth (Noble et 
al., 2017).  
Furthermore, it has been demonstrated that RUNX1/ETO promotes disease 
progression through direct regulation of CCND2, a gene involved in the cell cycle 
progression (Martinez-Soria et al., 2018). Inhibition of the cell cycle machinery by 
palbociclib (Fidler et al.) leads to a promising therapeutic intervention in AML cells 
with the t(8;21) fusion (Martinez-Soria et al., 2018). Palbociclib inhibits CDK4/6 
binding to CCND2, thus reducing phosphorylation of Rb1. This prevents progression 
of cells from G1 to S phase, and results in the cell cycle arrest (Finn et al., 2009). 
Palbociclib has been successfully combined with the hormonal therapy letrozole in 
estrogen-receptor (ER)-positive human advanced breast cancer, and significantly 
increased progression-free survival by nearly two-fold (24.8 months in 
palbociclib+letrozole vs 14.5 months in placebo-letrozole group; both with 95% 
confidence interval) (Finn et al., 2016, Finn et al., 2009). This makes this drug a 
compelling candidate as a potential curative strategy in RUNX1/ETO- positive AML. 
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 Aims 
The aims of this chapter are: 
i- to evaluate the efficacy of small molecule inhibitors targeting the glycolysis 
pathway, and potential combination with a cell cycle inhibitor. 
ii- to investigate the potential mechanism by which palbociclib-treated cells 
shunt its metabolic pathway. 
 
 Results 
 Glycolysis pathway is severely affected in the absence of RUNX1/ETO 
Gene set enrichment analysis (GSEA, Broad Institute) was used to analyse changes 
in the glycolysis pathway, by comparing experimental gene sets against hallmark 
gene-set signatures (Subramanian et al., 2005). In this analysis, two sets of RNA 
sequencing data were used; RUNX1/ETO knockdown in Kasumi-1 cells by siRNA 
(siRE) and mismatch-control (Pui et al.) (Figure 5-1). The x-axis ranks the most up-
regulated genes (left end) to the most down-regulated genes (right end). The y-axis 
indicates enrichment score (ES), which increases when genes are encountered in 
the pathway and decreases vice-versa leading to an assessment of the distribution 
within the set of all genes in a particular pathway. The enrichment score indicates to 
what degree a gene set is over-represented at either the top or bottom of the list. 
Genes with higher expression in siMM-cells have higher ES and are ranked on the 
left side of the graph, whereas the lower expression in siRE treated cells have lower 
ES and are plotted on the right section of the graph. The bottom part of the plot 
indicates the value of the ranking metric moving down the list of ranked genes. In the 
Kasumi-1 cell line, GSEA analysis suggests that the glycolysis pathway is 
significantly affected in siRE-treated cells (FDR q=<10-3).  
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Figure 5-1: GSEA plot of hallmark glycolysis pathway in siMM versus siRE.    
Genes in hallmark glycolysis pathway showed significant impairment in siRE versus 
siMM (FDR Q value = 0.0006). Top section of the figure plots the enrichment score 
for each gene, and the bottom section indicates the value of the ranking metric 
moving down the list of ranked genes. Analysis was carried out using Broad Institute 
software by comparing the experimental gene sets against hallmark gene signature. 
FDR, false discovery rate; ES, enrichment score.  
 
 
As described in chapter 3 and 4, shRNA-mediated knockdown targeting SLC2A3 and 
PFKP showed variable effects in Kasumi-1 progression in vitro and in vivo, 
particularly in SLC2A3 knockdown cells. However, the GSEA analyses clearly 
indicate the glycolysis pathway was affected upon loss of RUNX1/ETO. In vivo 
experiments showed that depletion of SLC2A3 alone may not be sufficient for 
leukaemia propagation (chapter 3). Furthermore, targeting the axis of glycolysis via 
PFKP could be pursued as a novel approach to tackling RUNX1/ETO-leukaemia. 
Based on sections 3.4.5, although the experiment has to be repeated due to the 
issue with engraftment, PFKP knockdown completely diminished leukaemic burden 
in both mouse models (chapter 3).  
Thus, the question arises as to whether there is value to targeting the whole 
glycolysis pathway using glycolysis antagonist. Of the many glucose analogues 
which have been studied, 2-deoxyglucose (2DG) has best been demonstrated to 
 145 
 
 
 
effectively inhibit glucose metabolism and cancer propagation (Aft et al., 2002, Zhong 
et al., 2009, Goldberg et al., 2012). This molecule is a structural derivative of glucose 
(C6H12O6) which has hydrogen replaces for hydroxyl at the second carbon atom 
(C6H12O5) (Figure 5-2-A). Upon intake into the cells, 2DG can be phosphorylated by 
hexokinase at 6-carbon to become 2-deoxyglucose-phosphate (2DG-P). 2DG-P is 
unable to undergo further reactions as the hydrogen at 2-carbon blocks isomerase 
from converting 2DG-P to fructose-6-phosphate (Figure 5-2) (Nelson et al., 1996, Aft 
et al., 2002). This cause a halt in the glycolysis pathway just before the PFKP 
enzyme (Aft et al., 2002); thereby reducing the intracellular ATP levels (Cheng et al., 
2012). Consequently, cancer cells cease growth (Jeon et al., 2015) and 2DG 
mediates the cells to undergo apoptosis (Aft et al., 2002, Saleem et al., 2012, Luo et 
al., 2018).  
  
Figure 5-2: 2DG structure and mechanism of action.    A) Structural comparison 
between naturally occurring glucose and 2DG. 2DG replaces hydroxyl with hydrogen 
at the second carbon. Empty lines indicate hydrogen molecule. B) 2DG mechanism 
of action. 2DG enters the cell through the glucose transporter and is phosphorylated 
by hexokinase. Due to low levels of intracellular phosphatase, 2-DG-PO4 is trapped 
in the cell. 2-DG-PO4 is unable to undergo further metabolism. High intracellular 
levels of 2-DG-6-PO4 cause allosteric and competitive inhibition of hexokinase. This 
results in the inhibition of glucose metabolism. Adapted and modified from Zhang et 
al. (2016). 
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 RUNX1/ETO-positive cells exhibit increased dependency on glycolysis 
compared with other AML cell lines 
 
To assess 2DG efficacy on the proliferation of RUNX1/ETO cells, a panel of AML cell 
lines including RUNX1/ETO-positive cells were treated with a concentration ranging 
from 1 µM to 10 mM. Although, these concentrations were considered pretty high for 
a small molecule inhibitor, 2DG has been classically used at even higher 
concentrations (Jeon et al., 2015, Yamaguchi et al., 2011, Zagorodna et al., 2011). 
Another reason for this was to mimic the physiological concentration of glucose in the 
culture media which was 11 mM.  
Briefly, the cells were seeded at 5x105/ml and treated with 2DG in triplicate in 96-well 
plates. The viability of the cells was assessed using WST-1 assay and the 
absorbance reading was captured at 450 nm in FLUOstar Omega plate reader. WST-
1 assay involves cleavage of stable tetrazolium salt WST-1 to a soluble coloured 
formazan which is released into the media. The absorbance readings were analysed 
using GraphPad PRISM to produce a dose-response curve and determine the GI50 
of 2DG for each cell line. The curve was presented as log [inhibitor] vs response that 
fit a non-linear regression model, assuming a Hill slope of -1.0. 
Figure 5-3 indicates 2DG inhibited the growth of all AML cell lines in a dose-
dependent manner. Notably, both RUNX1/ETO positive cell lines (SKNO-1 and 
Kasumi-1) displayed greater sensitivity to the inhibitor when compared to other AML 
cell lines. The dose that caused 50% inhibition of proliferation (GI50)was 60 µM and 
200 µM for SKNO-1 and Kasumi-1 respectively. Further, the maximum inhibitory 
concentrations for both RUNX1/ETO positive cells were three-fold lower than other 
AML cell lines (Table 5-1).  
The dose for Kasumi-1 is relatively high; however, it is still below the maximum 
concentration (Cmax)  of 700 µM of the highest dose level used in clinical trials 
focusing on advanced and drug-resistant adult tumours (Stein et al., 2010, Raez et 
al., 2013). The finding of Kasumi-1 as being more sensitive to 2DG compared with 
other AML cell lines was also described previously (Miwa et al., 2008). Although the 
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concentration reported in their study was 5-fold higher than our finding, it was due to 
the earlier timepoint they captured in their assay. Notably,  Miwa et al. (2008) also 
showed that Kasumi-1 cell line is resistant to oxidative phosphorylation inhibition by 
oligomycin, a potent inhibitor for mitochondria activity.  
 
Figure 5-3: Dose-response curve of 2-deoxyglucose across a panel of AML cell 
lines.    GI50 of 2DG across AML cell lines was determined using the WST-1 assay at 
72-hours post-treatment. Absorbance readings were captured using FLUOstar 
Omega plate reader at 450 nm and analysed using PRISM to generate log 
(concentration) vs response curve (n=4).  
 
 
Cell line Maximum effect (mM) 
SKNO-1 3 
Kasumi-1 3 
THP-1 10 
MV4-11 Not determined 
HL-60 Not determined 
Table 5-1: 2DG maximum effect on AML cell lines. Maximum inhibitory effect was 
determined at the highest concentration that caused the maximum inhibition.  
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To further investigate the effect of 2DG on cell proliferation, three drug 
concentrations of 0.5, 1 and 2 times of GI50 were administered to both RUNX1/ETO 
positive cell lines. Kasumi-1 cell line was treated with 100 µM (0.5XGI50), 200 µM 
(1XGI50) and 400 µM (2XGI50), while SKNO-1 was treated with 30 µM (0.5XGI50), 60 
µM (1XGI50) and 120 µM (2XGI50). The cells were counted 72 hours after treatment 
using the standard trypan blue exclusion method. As indicated in Figure 5-4, 2DG 
treatment reduced Kasumi-1 cell count as compared to the vehicle control. At 1XGI50 
and 2XGI50 dose, the proliferation of Kasumi-1 cells was severely impaired by almost 
half. A sub-lethal dose (0.5XGI50) of 2DG however, caused only a slight reduction of 
the cell numbers compared to the vehicle control at the 72 hour timepoint. For 
SKNO-1, 1XGI50 dose halved the number of cells when compared to the control, 
while 2XGI50 caused a massive 10-fold reduction of viable cells as shown in Figure 
5-4.   
Taken together, RUNX1/ETO-positive cell lines showed to be more sensitive to 2DG 
as compared to other AML cell lines and that resulted in reduced cell number in both 
of the cell lines.  
 
Figure 5-4:2DG treatment inhibited cell proliferation in Kasumi-1 and SKNO-1 
cell lines.    Cells were treated with 0.5, 1 and 2 times of 2DG GI50 for 72 hours and 
counted according to trypan blue cell count method. Bar graph showing decreased 
cell number of viable cells in 2DG treated cells compared to the vehicle control. 
(Kasumi-1, n=2; SKNO-1, n=1).  
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5.3.2.1 Combination of 2DG with novel cell cycle inhibitor additively impairs 
leukaemia propagation 
 
Although reports have shown that 2DG is an effective agent to hamper cancer cell 
proliferation in vitro, in vivo studies using 2DG as a single agent have been 
disappointing. For instance, 2DG treatment alone did not reduce tumour burden in a 
xenograft of a pancreatic tumour model (Goldberg et al., 2012). However, when it is 
combined with another inhibitor (Ras inhibitor S-trans-trans farnesylthiosalicylic acid), 
2DG synergistically inhibited in vivo tumour growth with no toxic side effects 
observed in the animals (Goldberg et al., 2012). Furthermore, the combination 
treatment exhibited strong and significant apoptotic cell death when compared with 
single agents used in the study. 
A recent in vitro study has shown that 2DG and palbociclib combination 
synergistically inhibits acute lymphoblastic leukaemia cell line after 48-hour treatment 
and a more pronounced effect was observed after 72-hour treatment (Zhelev et al., 
2015). This has led to the question whether the combination of 2DG and palbociclib 
would lead to the same observation in RUNX1/ETO-leukaemia. I then sought to 
answer this question by testing it on RUNX1/ETO cell line in vitro. The GI50 dose of 
palbociclib for both Kasumi-1 and SKNO-1 was established between 20-100 nM 
respectively (Figure 5-5) (Martinez-Soria et al., 2018).   
 
Figure 5-5: Dose-response curve of palbociclib in RUNX1/ETO-positive cell 
lines.    1XGI50 of palbociclib in RUNX1/ETO-positive cell lines was determined using 
luciferase assay at 72-hour time point. Luminescence was captured using FLUOstar 
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Omega plate reader and analysed using PRISM to generate log (concentration) vs 
response curve (n=3).  
 
 
I then selected a range between GI50 concentrations for Kasumi-1 cells for drug 
combination study which were 100 µM and 60 nM for 2DG and palbociclib 
respectively. Kasumi-1 cells expressing the luciferin gene were treated with a fixed 
1:2 molar ratio of the GI50 value of each drug and combination (Chou, 2010, Chou 
and Talalay, 1984). 
Figure 5-6 depicts the curve shift for each drug combinations analysed in PRISM 
Software. Due to different molarity of 2DG and palbociclib concentrations, graphs 
were transformed to two dose-response curves. Reading values for untreated and 
lowest effect were normalised to 100% and 0% respectively, and non-linear 
regression was applied to fit the curve. Chou-Talalay addresses the concentration 
that cause inhibition as effective concentration (EC), instead of GI.  
2DG combination with palbociclib resulted in lower EC50 values when compared with 
single drug treatment. Single 2DG and combination with palbociclib treatment in 
Kasumi-1 recorded as 187 µM and 100 µM EC50 value. While combination of 
palbociclib with 2DG halved the palbociclib EC50 value from 68 nM to 35 nM. 
Combination of 2DG and palbociclib at ED50 resulted in a 1.04 CI value, indicating an 
additive value of these two drugs.  
 
Figure 5-6: Dose-response curve for 2DG and palbociclib combinations in 
Kasumi-1 cell line.    Kasumi-1 cells were treated with a fixed range of 
concentrations of 2DG and palbociclib for 72-hours. Viability was assessed by 
luciferase assay using FLUOstar Omega plate reader. Reading values were 
analysed using PRISM to generate log (concentration) vs response curve. Error bar 
represents SD (n=3). 
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5.3.2.2 Apoptosis predominantly caused by hindrance in glycolysis pathway 
but minimally related with cell cycle inhibition in Kasumi-1 cells 
 
Treatment of Kasumi-1 cell line with 2DG impaired cell proliferation as depicted by 
low cell counts after 72 hours 2DG treatment (Figure 5-4). However, the counts did 
not discriminate dead cells as the indication for cytotoxicity. Next, I pursued to check 
the effect of 2DG treatment on the induction of apoptosis process with the application 
of FITC-Annexin V-propidium iodide (PI) apoptosis assay. As described earlier, 
Annexin V binds to the cells with exposed PS, whereas PI is the nuclear and 
chromosomal staining agent, thus, enables the identification of different phase of the 
cell death. Cells were harvested 72 hours after treatment with 2DG and incubated 
with FITC Annexin V and PI solution in Ca2+-containing buffer. The fluorescents 
were captured using FACS Canto and analysed using FlowJo software.  
Figure 5-7 shows quadrants plots that represents phases of cell death. Quadrant Q4 
represents viable cells (-FITC Annexin V/-PI), while quadrant Q3 represents early 
apoptosis (+FITC Annexin V/-PI). Quadrant Q2 and Q1 indicate late apoptosis 
(+FITC Annexin V/+PI) and already dead/necrotic cells (-FITC Annexin V/+PI) 
respectively. The percentage of cells present in both, early and late phase of 
apoptosis, in response to the vehicle control was set to 100%, and percentage 
obtained for treated cells were normalised to these control values.  
A sub-lethal dose of 2DG (100 µM) did not cause any significant increase of early or 
late apoptosis in the Kasumi-1 cell line (Figure 5-8). However, a 1XGI50 dose of 2DG 
caused a statistically significant two-fold increase of both early apoptosis and late 
apoptosis stages of cell death when compared to the vehicle control. A slightly more 
potent effect was observed in 2XGI50 of 2DG, where number of cells in both early and 
late apoptosis increased 2.3-fold. On the contrary, palbociclib single treatment hardly 
affected cell death with Annexin V staining indicating 10-30% reductions at different 
GI50 ratios.  Cells treated with a sub-lethal dose of 2DG and palbociclib recorded 1.3-
fold higher apoptosis in the Kasumi-1 cells. Finally, combination of palbociclib with 
2DG showed similar rates of apoptosis as 2DG alone.  
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Taken together, 2DG treatment induced a significant increase in the apoptotic bodies 
in Kasumi-1 cells. On the contrary, palbociclib as cell cycle inhibitor, did not induce 
apoptosis. Its combination with 2DG slightly increase the percentage of cells in late 
phase apoptosis; however, this was mainly induced by 2DG.   
 
Figure 5-7: Representative of apoptosis assay for Kasumi-1.    Upper panel 
refers to 2DG treated cells, middle panel refers to palbociclib treated cells and bottom 
panel represents combination treatment. Annexin V and Annexin V+PI percentages 
of each sample was set normalised to vehicle control that was set to 100%.  
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Figure 5-8: 2DG inhibition of glycolysis on the induction of apoptosis in 
Kasumi-1 after 72 hours treatment.    Cells treated with 2DG and vehicle control 
were incubated with FITC Annexin V and PI to determine the proportion of apoptotic 
cells. Significance was evaluated using students t-test, ns: not significant, p*<0.05, 
**p<0.01. Error bar represents standard deviation (n=3). 
 
 
5.3.2.3 2DG induces subG1 cells, while palbociclib halts cycling cells; 
however, both do not contribute to quiescent cells 
 
To investigate whether the increase in apoptosis in Kasumi-1 cells is associated with 
a cell cycle mechanism, I performed cell-cycle analysis with cells treated with these 
compounds. Cells were treated with 2DG, Palbociclib or combination at their 
respective GI50 dose for 72 hours and fixed with 2% PFA for DAPI staining. 
Fluorescence was captured using FACS Canto II and analysed with FlowJo software.    
Figure 5-9 (left) shows the cell cycle profile of Kasumi-1 cells treated with 2DG and 
Palbociclib. 2DG treatment significantly halved the cells entering G2/M phase when 
compared with 6.2% of untreated control and slightly reduced the percentage of cells 
in S phase. Both Palbociclib alone and in combination with 2DG significantly reduced 
the fraction of cells in the S and the G2M phase by three-fold. The concurrent pattern 
was also observed in G0/G1 phase. While 2DG treatment slightly, but significantly 
increased the number of cells present in G0/G1 phase, Palbociclib alone and in 
combination with DG significantly increased the fraction of G0/G1 cells from 80% to 
90%.  
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In agreement with the Annexin V staining, examination of cell cycle distribution also 
revealed a 2.4-fold increase of subG1 in response to 2DG treatment, while 
Palbociclib did not cause a substantial change in this cell fraction. However, 
combination treatment caused a significant 4-fold increase of cells in this phase. 
Both 2DG and Palbociclib caused accumulation of cells in G0/G1 phase and I 
wondered if the cells in this phase have a higher proportion of quiescent cells, which 
might affect chemosensitivity. To answer this question, I performed live Hoechst 
33342/Pyronin Y staining on the treated cells. Hoechst 33342 stains only DNA and 
Pyronin Y stains both DNA and RNA, thus this method enables the discrimination of 
RNA content. Briefly, after 72 hours incubation with 2DG and Palbociclib, Kasumi-1 
cells were stained with 10 µg/ml Hoechst 33342 for 45 minutes and followed by 100 
µg/ml of Pyronin Y for 15 minutes. Cells were immediately analysed with FACS 
Canto and further analyses were done using FlowJo software. 
Figure 5-10 showing Hoechst 33342 and Pyronin Y staining profile for the treated 
Kasumi-1 cells. The untreated control recorded 14% of cells in the G0 phase, the 
highest among all other samples. Both 2DG and Palbociclib single treatments 
significantly reduced the accumulation of cells in this phase by 40%, whereas 
combination treatment caused a significant reduction of G0 cells by more than 50%.  
Taken together, the increase of apoptotic cells after 2DG treatment is associated with 
a slight increase in G0/G1 cell cycle arrest, as well as a rise of subG1 phase. 
Furthermore, Palbociclib treatment predominantly halts cells in G0/G1 phase, with 
minimal increase of subG1 cells. Remarkably, combination treatment of 2DG and 
Palbociclib increased the subG1 phase and blocked the cell cycle progression at 
G0/G1 phase, which led to a decreased proportion of cells in the G2/M phase. 
Moreover, neither single nor combination treatments caused the cells to be in a 
quiescent state (Figure 5-10). 
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Figure 5-9: Cell cycle profile of Kasumi-1 cells in response to 2DG and 
Palbociclib treatment. Cells were treated with GI50 of 2DG, Palbociclib and 
combination for 72 hours, fixed with 2% PFA and stained with DAPI. Cells were 
captured with flow cytometry and analysed with FlowJo software. Significance was 
evaluated using students t-test, p*<0.05, **p<0.01. Error bar represents standard 
deviation (n=3, independent experiments)..  
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Figure 5-10: Cell cycle distribution indicated by Pyronin Y and Hoechst33342 
staining of Kasumi-1 cells. Cells were treated with GI50 of 2DG, Palbociclib and 
combination for 72 hours. Cells were stained with 10 µg/ml Hoechst 33342 and 100 
µg/ml Pyronin Y. Cells were captured with flow cytometry and analysed with FlowJo 
software. Significance was evaluated using students t-test, p*<0.05, **p<0.01. Error 
bar represents standard deviation (n=3 independent experiments). 
 
 
5.3.2.4 Palbociclib treatment impairs glycolysis, but shunts expression of 
some genes in the pentose phosphate and oxidative phosphorylation 
pathways 
 
Previous experiments which focusing on combination of 2DG and palbociclib were 
performed before RNAseq data of palbociclib treated cell was available. RNAseq 
data showed that there is a substantial overlap of pathways between cells treated 
with palbociclib and RUNX1/ETO knockdown cells. Interestingly, glycolysis pathway 
was showed to be enriched, as were other pathways such as MTOR and MYC 
signalling (Figure 5-11) (Martinez-Soria et al., 2018). Further GSEA analysis showed 
that palbociclib treatment impaired the hallmark set of genes involved in the 
glycolysis pathway as indicated in Figure 5-12.  
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Figure 5-11: Hallmarks of cancer pathways shared between palbociclib 
treatment, CCND2, and RUNX1/ETO knockdown.    Set of pathways that 
overlapped in RUNX1/ETO knockdown, CCND2 knockdown and palbociclib 
treatment (Martinez-Soria et al., 2018). 
 
 
I next sought to check if the glycolysis pathway is affected by palbociclib treatment by 
performing analysis of mRNA expression levels on set of genes involve in this 
pathway. This analysis also included Kasumi-1 treated with 2DG and a combination 
of the two drugs, since these two drugs led to an additive effect as described 
previously (Figure 5-6); therefore, this combination would lead to a severe impact on 
the pathway. Kasumi-1 cells were treated with either vehicle control, 200 µM 2DG, 30 
nM palbociclib or a combination (combo) of the two drugs for 3 days and harvested 
for mRNA analysis. Besides genes involved in the glycolysis pathway, this mRNA 
analysis also included genes in the pentose phosphate pathway (PPP) and oxidative 
phosphorylation pathway (OXPHOS). Figure 5-13 shows the fold-change of mRNAs 
involved in these pathways. In general, genes involved in glycolysis were 
downregulated in 2DG and palbociclib treatments. Combination of 2DG and 
palbociclib additively reduced the expression of genes in this pathway. There were 
no apparent changes observed in the PPP pathway except an incremental increase 
of PGLS (1.3-fold) and PGD (1.2-fold) levels in palbociclib and combo treated cells 
respectively. Interestingly, in the OXPHOS pathway, the PISD gene was shown to be 
increased by 1.6-fold in 2DG treated cells, 1.3-fold in palbociclib treated cells and 
1.4-fold in the combination treatment.  
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Figure 5-12: Gene set enrichment analysis of palbociclib-treated cells in the 
Kasumi-1 cell line.    Genes in the hallmark glycolysis pathway showed significant 
impairment in palbociclib treated cells (FDR Q value = 0.0002). The top section of the 
figure plots the enrichment score for each gene, and the bottom section indicates the 
value of the ranking metric moving down the list of ranked genes. Analysis was 
carried out using Broad Institute software by comparing the experimental gene sets 
against hallmark gene signature. FDR, false discovery rate; ES, enrichment score. 
 
 
Figure 5-13: mRNA analysis on genes in glycolysis, pentose phosphate 
pathway and oxidative phosphorylation pathways.    Kasumi-1 cells were treated 
with 200 µM, 30 nM palbociclib and combinations. Cells were harvested after 3 days 
and analysed for gene expressions. Each gene was normalised to untreated and 
CYCLO serves as housekeeping gene (n=1).  
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 Palbociclib treatment increase ATP production in the Kasumi-1 cell line 
 
RT-PCR data showed palbociclib treatment caused upregulation of gene related to 
OXPHOS. I wondered if that is a result of increased ATP level, as increased ATP 
production is a predicted consequence of OXPHOS activity. For the next sections, I 
focused on palbociclib treatment as this drug is currently used in clinical trials (Finn et 
al., 2016) and there is a potential for repurposing the drug in RUNX1/ETO-leukaemia 
(Martinez-Soria et al., 2018). Kasumi-1 cells were treated with 30 nM of palbociclib 
for 72 hours for ATP levels measurement. Fluorescent readings were measured 
using the Omega Plate Reader at 570 nm. Interestingly, cells treated with palbociclib 
induced a significant 1.6-fold higher ATP production than untreated control cells, 
indicating that palbociclib treatment caused the cells to be more dependent on 
OXPHOS (Figure 5-14).  
 
 
Figure 5-14: Palbociclib treated cells increased ATP production.    Kasumi-1 
cells were treated with 50 nM palbociclib for 72 hours. ATP was assessed by ATP 
assay using FLUOstar Omega plate reader at 570 nm. Significance was evaluated 
using students t-test, ****p<0.0001. Error bar represents standard deviation (n=3, 
independent experiments).  
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 Low glutamine induced palbociclib resistance  
 
Following an increase of PISD expression in 2DG and palbociclib treated cells 
(Figure 5-13), I sought to cross-check the function of this gene. The PISD gene 
codes for phosphatidylserine decarboxylase (PISD) and this protein catalyses the 
conversion of phosphatidylserine (PS) to phosphatidylethanolamine (PE) in the inner 
mitochondrial membrane. In the synthesis of PS, serine is the precursor required to 
form PS and becomes part of membrane phospholipids (Vance and Tasseva, 2013, 
Hoffmann et al., 2005). Serine is derived from glucose backbone to produce 
nonessential amino acid and during the synthesis, glutamine is required as nitrogen 
backbone donor. Therefore I hypothesised, limiting glutamine in palbociclib treated 
cells would reduce the precursor for phospholipids synthesis and lead to less viable 
cells.   
I then focused on palbociclib treatment in glutamine-suppressed media. Kasumi-1 
and SKNO-1 cells were treated with 50 nM, 100 nM palbociclib and 200 nM 
palbociclib in high/standard glutamine (2 mM) or low glutamine (0.1 mM) media. Cells 
were incubated for 3 days and viability was assessed by a trypan blue count. The cell 
counts were normalised to the untreated vehicle control count of each condition. 
Interestingly, the low glutamine condition resulted in a higher cell number in 
palbociclib treatment. In Kasumi-1 cells, palbociclib treatment in high glutamine 
media caused a significant 40% reduction of cell number in 50 nM concentration and 
a 60% reduction in both 100 and 200 nM concentrations (p-value<0.001) (Figure 
5-15-A). Interestingly, in the low glutamine condition, there was no change in 50 nM 
palbociclib treatment and only a 25% reduction in both 100 and 200 nM 
concentrations. However, in SKNO-1 cells, a prominent effect was observed with a 
higher concentration of palbociclib (200 nM), which recorded a 70% loss of cells in 
high glutamine media (Figure 5-15-B). Remarkably, low glutamine has less effect on 
cell viability; there was 60% of remaining cells at the end of the experiment. On the 
other hand, lower concentrations of palbociclib (50 nM and 100 nM) did not have any 
remarkable changes between high and low glutamine conditions in SKNO-1 cells. 
Treatment with 50 nM palbociclib reduced 30% of the cells in both high and low 
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glutamine media. While 100 nM palbociclib treatment reduced the cells to 60% 
remaining cells in high glutamine media; however, the cell count in 100 nM treatment 
was slightly higher (80%) in low glutamine media.  
The effect of low glutamine on cell viability varies in these two cell lines. In Kasumi-1 
cells, there was a clear indication of resistance in low glutamine condition even at low 
palbociclib concentration. In SKNO-1, although there were no substantial differences 
observed at lower palbociclib concentrations, the trend of resistance increased as the 
dose increased. These unexpected findings were also described by Pan et al. (2016). 
Their study showed low glutamine induced resistance through specific histone 
hypermethylation, which will be discussed further in chapter 7.  
 
 
 
Figure 5-15: Glutamine induced resistance in RUNX1/ETO cells.    Cells were 
treated with 100 nM and 200 nM in high (standard media) and low glutamine (0.1 
mM) media for 3 days. Cell viability was assessed by standard trypan blue counting. 
Data were normalised to the untreated vehicle control for each condition (Kasumi-1, 
n=3 independent experiments; SKNO-1, n=2). VC: vehicle control. Significance was 
evaluated using students t-test, **p<0.01, ***p<0.001, ****p<0.0001. Error bar 
represents standard deviation (n=3, independent experiments). 
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5.3.4.1 Palbociclib reduces the level of reactive oxygen species to maintain 
survival 
 
Given that palbociclib treatment increased ATP production in Kasumi-1 cells, I 
wondered if this leads to oxidative stress in these cells. ATP production is the 
hallmark of oxidative phosphorylation and several studies have shown that increased 
ATP production associated with low oxidative stress is suggested as pro-protective 
mechanism (Lagadinou et al., 2013, Jones et al., 2018); and ultimately leading to  
slow-cycling and drug resistant cells (Roesch et al., 2013). 
To address this question, I performed a flow cytometry ROS detection assay on 
Kasumi-1 cells treated with palbociclib. I also included a low glutamine parameter in 
this assay, as low glutamine increased cell viability as described in the previous 
section. This assay utilised fluorogenic probes that exhibit bright green stable 
fluorescence upon oxidation by ROS. Kasumi-1 cells were treated with 50 nM 
palbociclib and 100 nM palbociclib in high/standard glutamine (2 mM) or low 
glutamine (0.1 mM) media. After 72 hours incubation, 5.0 x 105 cells were harvested 
in 1.0 ml media and stained with CellROX green reagent to a final concentration of 1 
µM. A positive control was prepared an hour before the addition of CellROX green 
reagent by incubating the untreated cells with tert-butyl hydroperoxide (TBHP) at the 
final concentration of 200 µM. In cells, TBHP inhibits membrane-bound enzymes and 
causes membrane protein aggregations. In red blood cells, TBHP reacts with 
haemoglobin and forms free-radicals (L. K. Patterson, 1981, Roy and Sil, 2012). The 
positive control was incubated at 37oC for 45 minutes before CellROX green reagent 
was added at the final concentration of 500 nM. Following that, cells were incubated 
at 37oC for 45 minutes and protected from light. Data was captured at FITC-channel 
using flow cytometry and analysed using FlowJo software.  
Figure 5-16 shows the percentage of ROS-positive cells in both high and low 
glutamine media. In high glutamine media, while 50 nM palbociclib reduced the 
number of ROS-positive cells by a third, higher palbociclib treatment halved the 
percentage of ROS-positive cells when compared to 37% of ROS-positive cells in the 
untreated. Interestingly, in low glutamine media, the level of ROS-positive cells 
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reduced by more than a half in comparison to the untreated vehicle control in high 
glutamine media. Palbociclib treatment at 50 nM and 100 nM in low glutamine 
condition increased ROS-positive cells by almost half when compared to its control. 
Taken together, palbociclib treatment caused low cellular ROS level in Kasumi-1 
cells. Interestingly, low glutamine significantly (p-value<0.01) decreased ROS level 
which is in contrast to the previous findings (Reid et al., 2013, Burgess, 2013). 
Furthermore, combination of palbociclib and low glutamine did not cause substantial 
changes on the cellular ROS level.   
 
 
Figure 5-16: Reactive oxygen species (ROS) in palbociclib treated Kasumi-1 
cells cultured in high and low glutamine media.    Cells were treated with 
palbociclib with high or low glutamine-containing media. Cells were incubated for 72 
hours and stained with CellROX green reagent for 45 minutes at 37oC protected from 
light. Stained cells were captured using flow cytometry at FITC-channel. Left panel: 
Bar chart showing the percentage of ROS-positive cells between vehicle control and 
palbociclib treated cells in both high and low glutamine media. Right panel: Scatter 
plot of flow cytometry analyses using FlowJo software. Significance was evaluated 
using Student’s t-test, ns: not significant, *p<0.05, **p<0.01, ns: not significant (n=3 
in-dependent experiments). 
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 Summary 
RUNX1/ETO-leukaemia cells are more sensitive to 2DG inhibition than other AML 
cells. Besides that, palbociclib is particularly effective in targeting actively cycling 
cells. Combination of 2DG and palbociclib led to a slightly additive effect associated 
with increased apoptotic cells, mainly induced by 2DG. Both single and combination 
treatments increased G1 cell cycle arrest and severely impaired expression of genes 
involved in glycolysis. This combination should be further characterised in terms of its 
mechanism of action, as well as a potential RUNX1/ETO-leukaemic therapeutic 
intervention in vivo.  
Further experiments focused on palbociclib treatment as this drug is currently being 
used in clinical trial (Finn et al., 2009, Finn et al., 2016). Palbociclib treatment caused 
G0/G1 cell cycle arrest; however, it is neither associated with apoptosis nor 
dormancy. mRNA analysis revealed palbociclib treatment caused downregulation of 
genes involved in glycolysis, and a higher expression of PISD  which is implicated in 
glutamine-derived serine biosynthesis in OXPHOS. As a consequence, palbociclib 
treated cells showed a higher ATP production, suggesting that palbociclib treatment 
might induce OXPHOS activity. Increased expression of PISD indicates a 
requirement of glutamine; however, limitation of glutamine increased resistance in 
palbociclib treated cells. GSEA analysis revealed the glutamine synthesis pathway is 
deprived in palbociclib treatment (Appendix 5-1). Furthermore, palbociclib treatment 
reduced the level of ROS. Taking this together, palbociclib treatment caused the cells 
to stop cycling, shift to OXPHOS activity and induce resistance through deprivation of 
glutamine synthesis.  
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APPENDIX 
 
Appendix 5.1: Palbociclib treatment impairs a set of genes involved in glutamine 
deprivation identified by Peng et al. (2002). 
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Chapter 6 : In vitro Functional Analysis of SLC2A3 and PFKP in 
t(8;21) Patient-derived Xenograft 
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 Introduction   
AML is characterised by clonal and molecular heterogeneity which in turn affects 
response to treatment (Wang et al., 2017b, Grimwade et al., 2016). Despite the 
relatively good prognosis observed in the t(8;21) AML disease subtype (Byrd et al., 
2002, Grimwade et al., 2010) a substantial number of patients relapse further 
highlighting the need to address intra-tumour heterogeneity when designing 
treatment strategies.   
Preclinical prioritisation and patient-relevant models are essential in childhood 
leukaemia. Furthermore, unlike in acute lymphoid leukaemia (ALL) where all blasts 
are marked by equipotent stem cell properties irrespective of their immunophenotypic 
stage (Elder et al., 2017), the stemness of AML presents in only a subset of cells 
(Yassin et al., 2019). Despite recent progress in acute ALL preclinical models (Pal et 
al., 2016, Bomken et al., 2013) there are no RUNX1/ETO PDX. Currently, most 
studies and preclinical testing for novel targets and drugs in RUNX1/ETO-leukaemia 
are performed on two established cell lines, Kasumi-1 and SKNO-1(Soria et al., 
2008, Martinez et al., 2004, Martinez-Soria et al., 2018). These models have been 
derived from relapsed disease and thus do not retain the molecular complexity at 
disease presentation.  
Furthermore, cell lines proliferate in niche-independent suspension cultures and thus 
fail to capture the plethora of networks regulating leukaemia biology in patients. Over 
the years, primary t(8;21) blasts culture has been challenging as the cells do not 
propagate both in vitro and in vivo. However, primary and PDX preclinical  platforms 
are essential to define the function of RUNX1/ETO partner genes and develop novel 
“chemo-free” targeted therapies for leukaemogenesis. 
Recently, our laboratory has successfully developed and validated PDX material from 
relapsed t(8;21)-leukaemia in immunocompromised mice. A xenograft mouse model 
for t(8;21) leukaemia has not been described previously, thereby establishing in vivo 
patient model for this leukaemia subtype. One PDX, namely RL048 harbours a KIT 
D816V activating mutation and has a p53 wild-type status; the primary 
immunophenotype details for this sample are listed in Appendix 6-1 (Assi et al., 
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2019). This t(8;21) PDX model  has been instrumental to define the roles of the 
oncogenic transcription factor, RUNX1/ETO and its partner genes in a clinically 
relevant setting. 
In order to specify niche-mediated regulatory roles of RUNX1/ETO models I have 
used a human ex vivo cancer-niche platform developed by Dr Deepali Pal (Pal et al., 
2016). Epigenetic reprogramming of human bone marrow (BM) stroma cells into 
pluripotent stem cells (BM-iPSC) has enabled a standardised source for BM 
mesenchymal stem cells (BM-iPSC-MSC).  BM-iPSC-MSC support viability and 
proliferation of both CD45+ haematopoietic and CD19+ patient ALL blasts 
(unpublished data). Additionally, recent studies showed that mesenchymal stromal 
cells (MSCs) directly re-programmed from skin fibroblasts through chemical induction 
reconstitute bone marrow stroma and have similar molecular signatures to bone 
marrow mesenchymal stem cells (Lai et al., 2017). Based on the previous success of 
a preclinical model on bone marrow derived mesenchymal stem cells (MSC) ALL co-
culture system (Pal et al., 2016), this chapter focusses on the in vitro characterisation 
of the RUNX1/ETO PDX co-culture with BM-iPSC-MSC and its application in the 
functional study of SLC2A3 and PFKP.  
 
 Aims 
The aims of this chapter are; 
i. to establish an in vitro platform for RUNX1/ETO PDX cells co-culture with BM-
iPSC-MSC and to study the characteristics of cells in short-term culture. 
ii. to validate the functionality of SLC2A3 and PFKP gene in this PDX material as 
well as in other primary material. 
 
 Results 
 BM-iPSC-MSC supports short-term in vitro proliferation of RUNX1/ETO 
PDX cells 
 170 
 
 
 
To establish in vitro culture conditions for RUNX1/ETO PDX cells, BM-iPSC-MSC 
were utilised as niche-feeder cells. A 30-40% confluent cell culture was BM-iPSC-
MSC cells were pre-prepared in a 12-well Matrigel-coated tissue culture dish 4 days 
prior to the seeding of PDX cells. A total of 5.0 x 105 PDX cells were seeded in 1 ml 
SFEM II myeloid expansion medium. Characterisation of the PDX cells was carried 
out on day 0 (at thawing) and day 7-post seeding. 
As indicated in Figure 6-1-A, trypan blue cell count showed that the number of viable 
PDX cells increased four-fold from 5.0 x 105 cells on day 0 to 1.9 x 106 cells on day 7 
with BM-iPSC-MSC co-culture. In contrast, the cells cultured without BM-iPSC-MSC 
minimally increased to 9.5 x 105 cell/ml. Figure 6-1-B shows phase-contrast 
photographs of PDX cells in co-culture with and without BM-iPSC-MSC on day 0 and 
day 7-post seeding. The density of the cells visibly increased from day 0 to day 7 
when co-cultured with BM-iPSC-MSC.  
Cell cycle analysis on day 7 revealed that co-culture of PDX cells with BM-iPSC-MSC 
did not caused substantial changes in the cycling profiles as well as the subG1 
fraction (Figure 6-2). 
Collectively, BM-iPSC-MSC supported RL048 PDX propagation in vitro. 
 
Figure 6-1: BM-iPSC-MSC increases the propagation of RL048 PDX cells in 
vitro.    PDX cells were seeded on 30-40% confluent BM-iPSC-MSC at the 
concentration of 5.0 x 106 cells/ml. Readouts were captured on day 0 and day 7-post 
seeding. A) Cells counts using standard trypan blue method (n=2). B) Phase-contrast 
photographs of PDX cells co-cultured with BM-iPSC-MSC. Red arrows indicate BM-
iPSC-MSC cells (n=1). 
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Figure 6-2: Cell cycle profile of RL048 on day 0 and after 7 days cultured on 
BM-iPSC-MSC.    PDX cells were seeded on 30-40% confluent BM-iPSC-MSC at the 
concentration of 5.0 x 105 cells/ml. Cells were incubated with 10 µg/ml Hoechst 
33342 staining for 45 minutes and measured by flow cytometry. Analysis was 
performed using FlowJo software. A) Cell cycle profile of PDX cells on day 0 and day 
7. B) SubG1 analysis on PDX cells on day 0 and day 7-post seeding (n=1). 
 
 RL048 differentiate after short-term culture in vitro 
To further characterise the cells differentiation potential in short-term co-culture with 
BM-iPSC-MSC, immunophenotype profiling was performed by staining the cells with 
haematopoietic surface markers. The surface markers used in the assay included 
CD45, CD34, CD33, CD15 and CD14. Human CD45 was used to exclude mouse 
cells; while CD34 was used to determine stemness property of the cells as well as to 
differentiate between blasts cells and BM-iPSC-MSC which do not expresses CD34 
(Lin et al., 2012). Surface markers CD33, CD15 and CD14 were used to identify 
potential myeloid specific lineage differentiations. Briefly, cells were washed once 
and stained with the abovementioned antibodies in flow cytometry staining buffer. 
Data were captured by flow cytometry and analysed using FlowJo software.  
Changes in the immunophenotype of RL048 PDX cells after 7 days in culture were 
observed with and without BM-iPSC-MSC. (Figure 6-3). A total of 78% of cells were 
positive for CD34 on day 0; however, after 7 days in culture, the cells lost CD34 
expression with 17% CD34+ in culture without BM-iPSC-MSC and 14% CD34+in co-
culture with BM-iPSC-MSC. Notably, the cells maintained CD33 expression 
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throughout the experiments. Gain of CD15 was seen after the short-term culture 
indicating rise of mature myeloid lineage. The number of CD15-positive cells 
increased from 14% to 79% in culture without BM-iPSC-MSC and slightly higher in 
co-culture with BM-iPSC-MSC (87% of cells). Furthermore, CD14 was not expressed 
at the start of the culture. However, after 7 days in co-culture with BM-iPSC-MSC, 4% 
of cells were positive for CD14, whereas there was a minimal increase of 1.3% CD14 
positive cells in culture without BM-iPSC-MSC.  
Taken together, t(8;21) AML cells underwent limited myeloid differentiation in short 
culture possibly associated with a loss of stemness as indicated by the loss of CD34.  
 
Figure 6-3: Immunophenotype of RL048 cells co-cultured with and without BM-
iPSC-MSC.    Cells were checked for immunophenotyping on CD34, CD33, CD14 
and CD15 on day 0 and day 7 after co-cultured with and without BM-iPSC-MSC. Left: 
A representative of immunephenotype analysis. Right: Average of immunophenotype 
analyses (n=2). 
 
 In vitro assessment of SLC2A3 and PFKP in t(8;21) primary and patient-
derived xenograft (PDX) materials 
 
As described in chapter 4, depletion of SLC2A3 and PFKP in Kasumi-1 cells 
impaired propagation and self-renewal in vitro in glucose and oxygen deprivation 
conditions. The next aim was to validate if SLC2A3 and PFKP are relevant for 
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propagation of the relapsed t(8;21) leukaemia. To this end, I validated the 
competitiveness of the cells upon shRNA-mediated knockdown. Cells were 
transfected with shRNA lentivirus expressing different colours and analysed by flow 
cytometry after 96 hours. The media used in this experiment was SFEM II media  
which contained approximately 23 mM of glucose.  
The two populations were then mixed, analysed with flow cytometry (day 0) and 
seeded onto BM-iPSC-MSC plate. Fluorescence of the mixed populations was 
analysed on day 7-post mixing (Figure 6.4). 
The shRNA transduction on the PDX cells resulted in a high efficiency using the 
same vector used in chapter 3 and 4 (Appendix 6-2). Figure 6-5 shows a line chart of 
the representation of the four different shRNA populations before and after co-
culture. Each population was normalised to 25% on the start of experiment and 
changes on day 7-post mixing were calculated against the initial percentage. Notably, 
shNTC recorded 17% increase to reach 42% on day 7 and outcompeted all other 
populations. SLC2A3 and PFKP knockdown caused the cells to reduce to 19% at the 
end of experiment. The greatest depletion was observed in double knockdown as it 
recorded 15% remaining cells on day 7. 
I next examined whether this data is reproducible particularly on SLC2A3 
knockdown. Single shRNA knockdown on SLC2A3 was performed following the 
same scheme as depicted in Figure 6-4 except that only one shRNA lentivirus 
targeting SLC2A3 was used to transduce the cells. Each population was normalised 
to 50% on day 0 as starting percentage and changes on day 7 was calculated 
accordingly. Remarkably, shNTC-expressing cells outcompeted SLC2A3 knockdown 
cells after 7 days of co-cultured on BM-iPSC-MSC. shNTC expressing cells 
increased from 50% on day 0 to 61% and 62% on day 7 in both two independent 
experiments indicated in Figure 6-6. This led to their being 39% and 38% of 
shSLC2A3-expressing cells at the end of the experiment.  
Collectively, these findings highlight the potential roles of SLC2A3 and PFKP in 
niche-mediate RUNX1/ETO-leukaemia survival and propagation.  
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Figure 6-4: Scheme of competitive assay of t(8;21) PDX cells transduced with 
shRNA and cultured on BM-iPSC-MSC.    Cells were transduced with shRNA 
lentivirus expressing different fluorescent markers. On day 4, transduction 
efficiencies of the cells were checked by flow cytometry, mixed in single tube and 
transferred onto BM-iPSC-MSC plate. On day 7-post mixing, cells were collected and 
checked using flow cytometry. 
 
Figure 6-5: Stacked column showing shNTC competitively outcompeted 
shSLC2A3 and shPFKP populations in t(8;21) PDX cells cultured on BM-iPSC-
MSC.    shNTC and shSLC2A3/shSLC2A3+shPFKP cells were mixed on day 0 in 
SFEM media, checked by flow cytometry and cultured on BM-iPSC-MSC cells at 
standard incubation condition. On day 7, cells were collected and cells fluorescence 
percentages were monitored by flow cytometry. The percentage were normalised 
and calculated against day 0 (n=1).  
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Figure 6-6: shRNA mediated knockdown of SLC2A3 affects competitive fitness 
of RL048 PDX cells.    shNTC and shSLC2A3 cells were mixed on day 0 in SFEM 
media, checked by flow cytometry and cultured in standard incubator at 37OC. On 
day 7, cells were collected and fluorescence percentages were monitored by flow 
cytometry. The percentage were normalised and calculated against day 0. Graphs 
are two different independent experiments (n=2).  
6.3.3.1 RE regulates SLC2A3 and PFKP at transcript level in primary t(8;21)-
leukaemia 
 
To address of whether SLC2A3 and PFKP are direct transcriptional target genes of 
RUNX1/ETO in PDX and primary blasts, siRNA knockdown experiments were 
performed on two primary t(8;21) samples, LK19 and RL048.  
For LK19, a modified siRUNX1/ETO (siRE-fmds) was delivered as a lipid 
nanoparticle. This experiment was performed by Mr. Hasan Issa who demonstrated 
the efficacy of modified siRNA in targeting the RUNX1/ETO fusion gene both in vitro 
and in vivo (H. Issa PhD thesis 2019). RL048 primary cells were electroporated with 
siSLC2A3+siPFKP and were harvested for RNA extraction 24-hour post-transfection.  
In LK19 cells, knockdown of RUNX1/ETO led to a 70% reduction of oncogenic 
mRNA level itself, and reduced both SLC2A3 and PFKP transcript level to 60% and 
70% correspondingly (Figure 6-7-A). Furthermore, double knockdown of SLC2A3 
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and PFKP in RL048 blasts cells, led to a reduced 40% of SLC2A3 and 60% of PFKP 
mRNAs (Figure 6-7-B). Although, the knockdown of both genes were not as potent 
as in the cell line; however, the knockdown resulted in two distinct morphologies 
between siMM and siSLC2A3+siPFKP as shown in phase contrast microscopy in 
Figure 6-7-C. In siMM treatment, many of the cells seen to maintain plasma 
membrane integrity and smooth granules (red arrows). In contrast, 
siSLC2A3+siPFKP treatment resulted in irregularities of the cells membrane and 
coarse intracellular granules as indicated with blue arrow. Furthermore, some of the 
cells shrunk to smaller sizes after 24-hour treatment with siSLC2A3+siPFKP (green 
arrow). These cumulative observations suggestive of potential cell death through 
apoptosis pathway as previously described by Zhang et al. (2017), Bortner and 
Cidlowski (2002), Sesso et al. (1999).  
However, mRNA analyses indicates no induction of apoptotic related genes detected 
upon depletion of SLC2A3 and PFKP (Figure 6-8-A). Instead, only CCND1 mRNA 
level substantially decreased to 40% when compared to the siMM treated control 
(Figure 6-8-B). This observation was similar to the findings seen in Kasumi-1 cells, 
where only CCND1 was substantially reduced (section 4.3.9).  
Due to limited availability of PDX cells, no additional experiments were performed on 
the primary blasts. 
In summary, RUNX1/ETO regulates SLC2A3 and PFKP expression at mRNA level in 
primary leukaemic blasts. Knockdown of SLC2A3 and PFKP led to mRNA 
downregulation and changes in morphology of leukaemic blasts. The double 
knockdown did not cause inductions of apoptosis genes at mRNA level, but reduced 
the CCND1 expression level. 
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Figure 6-7: Knockdown of SLC2A3 and PFKP changed the cells morphology in 
primary t(8;21) blasts.    A) LK19 blasts cells were treated with a modified siRNA 
targeting RUNX1/ETO in encapsulated liposome and cells were harvested 24-hour 
post treatment (n=1). B) RL048 blasts cells were transfected with siSLC2A3+siPFKP 
by electroporation and cells were collected after 24-hours (n=1). C) The 
morphologies of RL048 cells changed after being transfected with siSLC2A3+PFKP 
for 24-hour. siSLC2A3+siPFKP caused changes of cell membrane integrity and 
cytoplasmic granules (blue arrows) and smaller size of cells (green arrows) in 
comparison to siMM (red arrow), potentially suggestive of apoptosis cell death. 
Images were captured using phase contrast microscope. Scale bar, 10 µm (n=1). 
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Figure 6-8: Knockdown of SLC2A3 and PFKP led to reduction of CCND1 mRNA 
levels in primary t(8;21) blasts.    RL048 blasts cells were transfected with 
siSLC2A3+siPFKP by electroporation and cells were collected after 24-hours. mRNA 
levels of genes related to apoptosis (A) and cell cycle (B) (n=1).  
 
6.3.3.2 RUNX1/ETO does not regulate TIGAR expressions in wild-type p53 
 
Furthermore, previous study has shown that RUNX1/ETO activates p53 and led to 
non-ROS associated cell death (Krejci et al., 2008). The p53 protein positively 
regulates TIGAR which increases the flux to pentose phosphate pathway, thereby 
producing antioxidant including NADPH and GSH (Lee et al., 2015). Interestingly, 
TIGAR (C12orf) located in a close proximity with CCND2 (Appendix 6-3). CCND2 has 
been shown to play a critical role in modulating RUNX1/ETO-leukaemia (Martinez-
Soria et al., 2018).   
Since the PDX and primary cells used in this study exhibit wild-type p53 (Assi et al., 
2019), I wondered if RUNX1/ETO controls the expression of TIGAR. To answer this 
question I electroporated siRNA targeting RUNX1/ETO in RL048 PDX cells and 
harvested for mRNA analyses 24-hour post-transfection. mRNA analyses were also 
performed on the sample from section 6.3.1.1.  
 179 
 
 
 
The mRNA analyses on siRUNX1/ETO-treated cells revealed that there were no 
changes detected in TIGAR expression levels in both PDX and primary samples 
(Figure 6-9-A-B). Furthermore, double knockdown on SLC2A3 and PFKP also did not 
change the TIGAR mRNA level (Figure 6-9-C). This data indicates that RUNX1/ETO 
did not regulate the expressions of TIGAR gene.   
 
Figure 6-9: RUNX1/ETO and SLC2A3+PFKP knockdowns did not change the 
expression of TIGAR in wild-type p53 cells.    Cells were transfected with siRNA 
by electroporation and were collected after 24-hours for RNA extraction. mRNA 
analyses were performed in PDX (A) and primary (B, C) samples (n=1). DK: double 
knockdown.  
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 Summary 
Collectively, I have characterised the in vitro RUNX1/ETO PDX co-culture system 
with BM-iPSC-MSC and this could be brought forward as pre-clinical platform for 
other primary or PDX materials of this subtype of leukaemia. BM-iPSC-MSC support 
improved viability and propagation of RUNX1/ETO PDX cells ex vivo as indicated 
through the cell counts. Following short-term culture, BM-iPSC-MSC directed blast 
differentiation into specific myeloid specific lineage as indicated by CD33 and CD15 
surface markers. However, the culture led the reduction of CD34 surface expression 
implying a loss of stemness.  
Furthermore, knockdown of SLC2A3 and PFKP in PDX cells reduced leukaemic cell 
proliferation in high glucose media in competitive assay experiments. mRNA levels 
for both SLC2A3 and PFKP were downregulated upon depletion of RUNX1/ETO 
suggesting that RUNX1/ETO regulates these two genes in primary blasts. 
Furthermore, transient double knockdown of SLC2A3 and PFKP caused reduction in 
mRNA levels and resulted in altered cell morphologies; however, no inductions of 
apoptotic related genes observed in mRNA analyses. CCND1 expressions were 
shown to be substantially reduced in the double knockdown strategy. Moreover, 
neither RUNX1/ETO nor double knockdown showed inter-connection on the TIGAR 
expression as shown by the mRNA analyses. This somehow could give an 
advantage of targeting SLC2A3 and PFKP in p53 intact leukaemia as TIGAR 
additively can suppress glycolytic activity at PFKP level.       
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APPENDIX 
 
Appendix 6-1: Immunophenotype profiles of primary blasts RL048. 
University’s email communication with Dr D. Coleman, Institute for Cancer Studies, 
University of Birmingham. 
RL048 profiles 
Relapse with t(8;21) translocation 
CD14- 
CD15- 
CD11b- 
89% FLT3+ 
82% CD34+ 
86%CD117+ 
61%CD19+ 
80%CD33+ 
5%CD3+ 
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Appendix 6-2: Transduction efficiency of RL048 PDX cells on day 4 after 
transduction.  
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Appendix 6-3: Screenshot of UCSC genome browser indicating close proximity of 
TIGAR (C12orf5) to CCND2 (shown in red box).  
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Chapter 7 : Discussion and Conclusion 
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 RUNX1/ETO is the master regulator in t(8;21) leukaemia 
 
The t(8;21) translocation is the most common genetic alteration in AML and involves 
rearrangement of the RUNX1 gene on chromosome 21q22 and the ETO gene on 
8q22. This rearrangement generates the RUNX1/ETO fusion protein and regarded as 
the aberrant regulator of the disease.  
Loss of RUNX1/ETO knockdown cells in competitive assay experiments confirmed its 
role in maintaining the leukaemic survival in line with previous findings (Martinez et 
al., 2004; Soria et al., 2008). The competitive inhibition of wild-type RUNX1 by 
RUNX1/ETO is considered as the mechanism for leukaemogenesis. RUNX1/ETO 
competitively shares 60% of the binding peaks with RUNX1 that are enriched with 
the E-box-binding proteins (Ptasinska et al., 2012). E-box-binding protein forms a 
stable complex with ETO protein (Zhang et al., 2004b) and interestingly E-box 
proteins interacts at the RUNX1/ETO locus in both SLC2A3 and PFKP gene 
(Appendix 7-1). A study demonstrated that deletion of the E-box-like motif within 
intron 2 of SLC2A3 substantially abrogated proliferation in 293T cells (Masin et al., 
2014). 
Furthermore, RUNX1/ETO co-operates with transcription factor AP-1 to maintain 
expressions of CCND2 (Martinez-Soria et al., 2018). Loss of RUNX1/ETO leads to 
reduce expressions of CCND2 and cell cycles disruption (Martinez-Soria et al., 
2018). Additionally, RUNX1/ETO promotes leukaemic clonogenicity by direct binding 
at the TERT promoter and controls CD34 stem cell marker expression (Martinez et 
al., 2004). These studies corroborate the role of RUNX1/ETO as a master regulator 
in maintaining leukaemia. 
Moreover, the glycolysis stress test showed depletion of RUNX1/ETO severely 
impairs glycolysis in t(8;21) leukaemia. However, there is a gap of knowledge 
regarding RUNX1/ETO regulates glycolysis. Recent publications showed putative 
binding of RUNX1/ETO at the PKM2 gene, a gene that encodes rate-limiting enzyme 
in the final step of glycolysis (Ptasinska et al., 2012, Yan et al., 2017). One study 
claimed that RUNX1/ETO directly repressed PKM2 in Kasumi-1 cells and shifted the 
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cells towards glycolytic phenotype, which is a contrast to its normal biological 
function (Yan et al., 2017). However, the finding is in contrast with our established 
data. Firstly, our data shows PKM is highly expressed in Kasumi-1 cells and 
secondly, the depletion of RUNX1/ETO do not increased the expression of PKM 
(Appendix 7-2) (Ptasinska et al., 2012). Furthermore, RUNX1/ETO indeed 
preferentially utilises glycolysis for metabolism, as shown in the glycolysis stress test. 
In addition, depletion of SLC2A3 and PFKP simulated the glycolytic phenotype 
caused by RUNX1/ETO knockdown indicating that these two genes are potentially 
the partner genes of RUNX1/ETO in regulating glycolysis. 
 
 Hypoxia causes decreased proliferation and induces resistance in 
RUNX1/ETO knockdown cells in Kasumi-1 
 
Hypoxia induced slower Kasumi-1 cell growth when compared with the cells in 
normoxia conditions (section 4.3.3). Studies have shown that hypoxia induces the 
cell cycle inhibitor, p27 and blocks the transition of cells from G0 to G1 in the cell 
cycle phase (Drolle et al., 2015). Hypoxia also decreases the proportion of cells in S 
phase (Griessinger et al., 2014, Liang et al., 2012, Gardner et al., 2001). In human 
ovarian cancer cell lines, hypoxia reduces growth rate and acute exposure to hypoxia 
causes aggressive invasion of cell in an in vitro invasion assay (Liang et al., 2012).  
Furthermore, RUNX1/ETO knockdown in Kasumi-1 cells showed a trend of 
resistance in hypoxia. This observation could be explained by the accumulation of 
cells in the G1 phase (section 4.3.8) (Soria et al., 2008, Martinez et al., 2004, 
Martinez-Soria et al., 2018) seen in both RUNX1/ETO knockdown and hypoxia, thus 
resulted in a delayed effect in the RUNX1/ETO knockdown samples.  
Several studies have previously shown that low oxygen tension promotes 
chemoresistance in leukaemia (Griessinger et al., 2014, Hsu et al., 2009, Drolle et 
al., 2015) and solid tumours (Sullivan et al., 2008, Frederiksen Lisa et al., 2003, 
Deynoux et al., 2016). For instance, treatment with DNA damaging agent, 
doxorubicin in AML cell lines in normoxia resulted in apoptosis; however, the amount 
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of apoptosis was reduced in the hypoxic condition (Hsu et al., 2009). The same 
findings were also observed in primary AML samples where hypoxia improved the 
recoverable leukaemia cells after cytarabine treatment when compared to the treated 
cells in 20% oxygen culture (Griessinger et al., 2014). Notably, both of the 
chemotherapy agents, especially cytarabine, require cells in the S phase of cell cycle 
for an effective anti-leukaemic activity (Mills et al., 2018, Farge et al., 2017, Kufe et 
al., 1980). In line with that, hypoxia induced smaller S phase and G0G1 accumulation 
hence decreases the sensitivity of this drug (Drolle et al., 2015). The antiapoptosis 
signalling has been shown to be the protective mechanism in hypoxia-induced 
chemoresistance (Drolle et al., 2015, Petit et al., 2016). Increased expression of the 
antiapoptotic proteins was shown to inhibit apoptosis in AML and ALL cells treated 
with chemotherapy standard treatment agents (Drolle et al., 2015, Petit et al., 2016). 
Furthermore, in the low oxygen condition, leukaemic cells activate the PI3K pathway 
and promote cell survival and growth (Drolle et al., 2015).  
 
 Targeting SLC2A3 and PFKP in RUNX1/ETO-leukaemia 
 SLC2A3 is not essential for RUNX1/ETO-leukaemia progression in vivo in 
Kasumi-1 cells but is required in vitro in glucose and oxygen limitation 
conditions 
 
Knockdown of SLC2A3 led to the expansion of the leukaemic population as 
described in chapter 3. Although SLC2A3 was shown to be correlated with cancer 
progression (Cosset et al., 2017, Fei et al., 2012), this was not the case in this study. 
One possible reason for this is the doxycycline effect. The previous shRNA screen 
utilised a doxycycline-inducible pTRIPZ vector to induce shRNA expression and gene 
knockdown. Doxycycline is reported to have an impact on the metabolic gene 
expression (Ahler et al., 2013). Glycolysis and OXPHOS pathways are enriched in 
breast cancer cell line, MCF12A, when treated with 1 µg/ml of doxycycline. Ahler et 
al. (2013) also showed that expression of the PFK gene was significantly enriched; 
however, there was no indication of any glucose transporters being upregulated upon 
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treatment with the doxycycline. Notably, this finding was conducted in vitro, where in 
our case, there was no indication of PFKP and SLC2A3 as potential candidate genes 
in vitro. Furthermore, both GSEA analysis and RNA sequencing data clearly showed 
that the glycolysis pathway (Figure 5-1) and SLC2A3 expression are severely 
impacted in siRUNX1/ETO treatment (section 3.3.1). Additionally, doxycycline was 
also reported to impair mitochondrial function in glioma cells, induce glucose 
consumption in an increasing dose-dependent manner and is associated with 
decreased cell death (Luger et al., 2018). To confirm a doxycycline effect, a study is 
being carried out using the inducible vector system which expresses the shRNA 
targeting SLC2A3. 
In this study, glucose uptake was compromised in the SLC2A3 knockdown cells; 
however, it did not diminish the leukaemic population both in vivo (chapter 3) and in 
vitro in standard culture conditions (section 4.3.5). These findings are in agreement 
with a recent study that demonstrated that low glucose levels did not affect the 
leukaemic stem cell (LSC) population. Instead, these cells rely more on amino acid 
metabolism to support proliferation (Jones et al., 2018). A characteristic of LSCs is 
the presence of low reactive oxygen species (ROS) and their ability to re-established 
AML in vivo re-transplantation (Lagadinou et al., 2013, Jones et al., 2018). 
Interestingly, only AML blasts with high ROS were affected by glucose starvation 
(Jones et al., 2018). Furthermore, glucose uptake is not affected in the ROS low 
LSCs in the absence of amino acids showing that glucose is not essential in this 
population. This notion was supported by increased production of glycolysis 
products, pyruvate and lactate in AML high ROS blasts but not in ROS low LSCs 
(Jones et al., 2018). Jones’s study highlighted the metabolic inflexibility of LSCs with 
regard to glucose metabolism which is in stark contrast to the classic knowledge of 
high dependence of HSCs on glycolysis (Suda et al., 2011).  
Furthermore, the in vivo outcomes were also in line with a recent publication that 
warrants caution when targeting genes related to metabolism. Despite well-
established evidence of HIF as the main driver for cellular quiescence and 
chemoresistance (Ishikawa et al., 2007), one study showed that deletion of HIF-1a 
caused unexpected aggressive in vivo development of AML after chemotherapy 
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(Velasco-Hernandez et al., 2018). The transcriptomic analysis of the cells revealed 
enrichment of mRNA processing, DNA replication and protein folding which support 
the progression of the disease (Velasco-Hernandez et al., 2018).  
Moreover, the in vitro competitive assay showed the SLC2A3 knockdown cells were 
dependent on glucose and oxygen limitation conditions (section 4.3.5). Limitation of 
nutrients increases the expressions of the transporters, thereby increasing the 
dependency of the cells to the transporter. For instance, glutamine starvation 
increased glutamate transporter (SLC1A3) expression (Tajan et al., 2018). Deletion 
of SLC1A3 selectively abrogated cell proliferation in glutamine deprivation condition, 
but no effect was observed in well-fed glutamine cultures (Tajan et al., 2018). 
Furthermore, expressions of SLC2A3 was also shown to be higher in hypoxia 
environment (section 3.3.3.4), thus, showing that SLC2A3 is indeed dependent on 
glucose and oxygen to support the proliferation. 
CCND1 and CCND2 expression was downregulated in the SLC2A3, PFKP and 
double knockdown cells (section 4.3.10). Studies have shown that cell cycle-related 
protein CCND2 is required for glucose-induced proliferation (Stamateris et al., 2016, 
Moreno-Asso et al., 2013). Interestingly, glucose controlled the expression of CCND2 
in quiescent β-cells through glucokinase-mediated glycolysis (Salpeter et al., 2011). 
Glucokinase is the enzyme to mediate phosphorylation of glucose in liver and 
pancreas. Both low glucose and loss of glucokinase abrogated the CCND2 level in 
mouse and human β-cells (Salpeter et al., 2011). In addition, in low glucose supply, 
the cell metabolic sensor, AMPK is activated and stabilises the cell cycle inhibitor, 
p27 and further increasing cell cycle arrest (El Mjiyad et al., 2010, Jones and 
Thompson, 2009, Liang et al., 2007).  
Moreover, a higher Annexin V positive cells associated with a higher sub G1 fractions 
were observed in low glucose and oxygen condition in the SLC2A3 and PFKP 
knockdown cells (section 4.3.9). Hypoxia is shown to mediate glucose-dependent cell 
death through ATP depletion as shown in a study (Steinbach et al., 2003). Low ATP 
is a potent activator for AMPK. AMPK could be either tumour-suppressor roles or 
tumour-supportive roles. Activation of AMPK by metformin attenuates esophageal 
squamous cell carcinoma and promotes cell death as indicated by increased of 
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apoptotic cells (Feng et al., 2014). However, in AML, an in vivo study demonstrated 
that activation of AMPK is required for leukaemia initiating cells (LICs) maintenance 
(Saito et al., 2015). This study also showed that deletion of AMPK diminishes LICs 
located in the bone marrow (Saito et al., 2015).  
Furthermore, hypoxia increases intracellular ROS levels in breasts cancer cells 
(Azimi et al., 2017) and ROS can mediate cell death (Reczek and Chandel, 2017). 
The notion that hypoxia induced the ROS level is a contrast to the well understanding 
that the generation of ROS occurs in high oxygen level. The mechanism of which 
hypoxia induces generation of ROS is not well understood (Murphy, 2012). Recent 
evidences showed that the mitochondrial ROS (mtROS) is produced at complex III of 
the electron transport chain in the mitochondria in hypoxia condition and stabilises 
HIF1-α (Mansfield et al., 2005, Guzy et al., 2005). Consequently, ROS mediates the 
activation of hypoxia-induced epidermal growth factor receptor and contributes 
towards breast cancer cells migration (Azimi et al., 2017). ROS is also reported to 
associate with the increased risk of relapse and poor survival in AML (Johnson et al., 
2011). However, current data are lacking on the cause of cell death and further study 
is required to rule out the mechanistic of the cell death as well as glucose regulation 
on the cell cycle.  
In conclusion, the gain of the SLC2A3 knockdown cells in the in vivo competitive 
assay setting in this study could be assumed by a scenario. The cells reprogrammed 
towards more of stem cells-like property to drive leukaemogenesis; thus, they did not 
rely on glucose for proliferation. Moreover, a study also showed that targeting a gene 
related to metabolism is not a straightforward approach in eliminating LSCs which 
was also supported by others (Vukovic et al., 2015, Velasco-Hernandez et al., 2014). 
However, this was not the case in the PDX sample where the SLC2A3 knockdown 
led to a reduced population in high glucose and oxygen conditions. These cells 
exhibit a KIT activating mutation which confers poor prognosis in the t(8;21) AML 
(Beghini et al., 2000). The presence of both RUNX1/ETO and KIT mutations resulted 
in the aggressive leukaemic phenotypes and murine fatality (Nick et al., 2012b). 
Furthermore, the PDX cells contain wild-type p53 which is in contrast to the Kasumi-1 
and SKNO-1 cells used in this study (Banker et al., 1998, Martinez-Soria et al., 2018, 
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Asou et al., 1991, Matozaki et al., 1995). The roles of p53 in regulating glycolysis will 
be discussed in section 7.3.3.  
 
 PFKP as a potential therapeutic target in treating RUNX1/ETO-leukaemia  
 
In vivo and in vitro experiments in both cell lines and PDX cells showed that PFKP 
plays an important roles in the RUNX1/ETO leukaemia propagation. PFKP is shown 
to be primarily over-expressed in cancers in comparison to its other isoforms; PFKL 
and PFKM (Lee et al., 2017). However, its role and mechanism in tumorigenesis are 
not well understood. The most comprehensive study to date described the stability of 
PFKP by AKT to prevent degradation of the protein and promote tumour growth in 
glioblastoma cell lines (Lee et al., 2017). Notably, activating phosphorylation of AKT 
exclusively at PFKP Ser386 is shown to be higher in a group of PTEN loss patient 
samples (Lee et al., 2017). AKT is shown to be activated in many cancer cells (Fang, 
2015).  
Additionally, although PFKP is considered as the axis in the glycolysis pathway, loss 
of PKFP is not always on the advantage side. Several studies have shown that 
inhibition of the glycolysis axis redirects glucose flux towards shunt pentose 
phosphate pathway (PPP) (Yi et al., 2012, Yamamoto et al., 2014, Kim et al., 2017b) 
and thereby increasing NADPH levels as a protective mechanism from ROS (Kim et 
al., 2017b). Kim et al. (2017b) also demonstrated knockdown of PFKP rescued 
cancer cells from chemotherapy treatment in breast cancer cells and led to the 
metastatic potential in vivo.  
Therefore, PFKP could be one of the partner genes required by RUNX1/ETO for the 
leukaemic program. Future studies should be emphasised on the mechanism and in 
vivo setting in RUNX1/ETO cell lines, primary and PDX leukaemia cells to further 
validate its therapeutic values. Knockdown of PFKP in normal and leukaemic cells is 
required to validate the specificity of this gene in leukaemic propagations and 
survivals.  
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 RUNX1/ETO and p53 in regulating glycolysis 
 
As described earlier (section 1.5.1), p53 suppression on glycolysis is mediated by the 
TP53-inducible glycolysis and apoptosis regulator (TIGAR). TIGAR inhibits glycolysis 
and consequently increases flux through PPP (Bensaad et al., 2006). Previous study 
has shown that RUNX1/ETO ectopic expression of CD34+ cells causes DNA 
damage and activates p53 that leads to non-ROS cell death (Krejci et al., 2008). 
However, in this study, depletion of RUNX1/ETO did not change the expression level 
of TIGAR. This could be explained by the presence of functional RUNX1 that acts as 
the co-activator for p53 transcriptional activities (Wu et al., 2013). Notably, p53 target 
genes are activated after 5 weeks upon ectopic expression of RUNX1/ETO (Krejci et 
al., 2008), but the mRNA samples in this study were collected after 24 hour post-
siRNA treatment. This notion was also supported that TIGAR is induced in a time-
dependent manner after ischemic exposure (Zhou et al., 2016).  
Furthermore, p53 modulates expression of glucose transporters (Zhang et al., 2013), 
such as SLC2A3 (Kawauchi et al., 2008). p53 deficient in Ras-transformed MEF cells 
upregulated SLC2A3 through activation of IKK/NF-KB pathway in p65 dependent 
manner and consequently accelerated glycolysis without compromising mitochondrial 
oxygen consumption (Kawauchi et al., 2008). Notably, SLC2A3 was not the only 
glycolysis-regulating factor in p53 deficient cells, as p65 knockdown led to a more 
suppressed Ras-transformation capability. The roles of p53 in suppressing glycolysis 
was also reported in vivo (Zhang et al., 2013). Interestingly, Zhang et al. (2013) 
showed mutant p53 did not increase expression of any glucose transporters; instead, 
it promoted translocation of SLC2A1 to the plasma membrane mediated by 
RhoA/ROCK positive signalling both in mice and breast cancer cell lines. Notably, 
RhoA pathway is reported to be enriched in RUNX1/ETO (Rodriguez-Perales et al., 
2015).   
As described in chapter 2, RUNX1/ETO strongly regulates SLC2A3 where the 
expression was almost depleted in the absence of RUNX1/ETO mRNA. Given that 
TIGAR expression level did not change in the double knockdown approach in the 
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PDX cells, TIGAR gives an advantage in suppressing glycolysis at the axis of PFKP. 
TIGAR has the function similar to the fructose-2-6-biphosphate, a potent inhibitor for 
PFKP activity. Therefore, targeting SLC2A3 and PFKP in RUNX1/ETO-leukaemia 
with wild-type p53 could provide a promising therapeutic strategy (Figure 7-1).  
However, given the intra-tumour heterogeneity that presents in either primary or PDX 
cells, one could target both of the TP53 wild-type and mutated subclones. In order to 
assess the impact of targeting SLC2A3 and PFKP in TP53 mutated subclones, future 
experiments should include knockdown of SLC2A3 and PFKP with and without p53 
knockdown in both in vitro and in vivo settings. This strategy will provide a clear 
appreciation of how these two genes interact with p53 and further unravel the roles of 
SLC2A3 and PFKP in this subtype of leukaemia.   
 
 
Figure 7-1: Proposed model on RUNX1/ETO cooperation with p53 to mediate 
glycolysis through SLC2A3 and PFKP.    RUNX1/ETO directly targets SLC2A3 
and PFKP to promote glycolysis. RUNX1/ETO and RUNX1 competitively regulate 
p53. P53 controls TIGAR expressions and inhibits glycolysis.  
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 BM-iPSC-MSC supports RUNX1/ETO PDX cells in vitro  
 
Currently, there is a need to establish a pre-clinical model of RUNX1/ETO-leukaemia 
in order to improve the clinical translation of new targets intervention and drugs 
strategy. Here I showed, RUNX1/ETO PDX cells can be successfully expanded ex 
vivo with the support of BM-iPSC-MSC niche culture. 
Previous studies have shown that mesenchymal stem cells (MSC) culture system 
supported long-term maintenance of primary AML (Brenner et al., 2017) and 
primograft ALL blasts in vitro (Pal et al., 2016). MSC is easily obtainable; however, its 
limited lifespan in vitro has become a disadvantage for long term application (Baxter 
et al., 2004) thus a new system is required for the continuous long-term preclinical 
study. Previous study has shown that induced-MSCs were characterised to exhibit 
MSC phenotypes and molecular characteristics (Soontararak et al., 2018) making it a 
suitable platform for a preclinical research.  
In this study, leukaemic blasts proliferated at a higher rate with BM-iPSC-MSC 
support and slightly reduced sub-G1 fractions after 7 days in co-culture. In vitro 
primary AML cell without co-culture support showed stress-induced apoptosis effect 
associated with low viability (Ryningen et al., 2006). Conversely, co-culture with 
MSCs shown to have an antiapoptotic effect and support leukaemic growth 
proliferation through cytokine secretion such as CXCL12 (Brenner et al., 2017). 
Given that KIT mutation prevalence is high in RUNX1/ETO relapse cases and shorter 
leukaemia-free survival (Kim et al., 2007), this preclinical model can be a proper 
model for this subtype of leukaemia. However, more detailed study on the cytokine 
release by BM-iPSC-MSC and the effect on this PDX should be performed. 
Additionally, BM-iPSC-MSC culture reduced the expression of CD34 positive blasts 
cells and directed the cells toward specific lineage, CD33 and CD15. CD34 is 
described as the criterium for RUNX1/ETO-leukaemic stemness potential (Mulloy et 
al., 2003). However, this may not be necessary as the cells are positive for KIT+ 
mutation. Quek et al. (2016) showed that lack of CD34 but the enrichment of KIT+ 
populations have the functional leukaemic stem cells activity. Another study showed 
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in vivo engraftment success was not linked with the homing capability of CD34+ cells, 
but mainly correlated with disease behaviour (Pearce et al., 2006). Thus, further 
experiments are required to determine if the cells are still able to self-renew by either 
re-transplantation into immunocompromised mice or performing in vitro colony 
formation assay.  
Furthermore, expansion of CD15 marks the rise of terminally differentiated myeloid 
cells which is expressed mainly on mature granulocytes (neutrophils and 
eosinophils), some monocytes but not on lymphocytes and basophil (Tao et al., 
2004). One possible cause of the enrichment is due to IL-3 and G-CSF cytokines that 
were present in the myeloid expansion media that promote granulocytic 
differentiation (Mehta et al., 2015, Lachmann et al., 2015).  
Consequently, BM-iPSC-MSC supports RUNX1/ETO cells ex vivo; however, further 
optimisation of the myeloid expansion cocktail should be carried out to maintain the 
leukaemic immunophenotype profiles. 
 
 Palbociclib treated cells reprogrammed metabolic requirement 
 
We have previously shown that palbociclib could provide a novel therapeutic value in 
treating RUNX1/ETO-leukaemia (Martinez-Soria et al., 2018). Palbociclib treated 
cells stopped the cells from proliferating by decreasing the cell cycle-related proteins 
(CDK4/6) and led to senescent (Martinez-Soria et al., 2018). Interestingly, inhibition 
of the cell cycle machinery by palbociclib at a ten-fold higher concentration than this 
study caused reactive oxygen species (ROS)-mediated cell death (Wang et al., 
2017a, Vijayaraghavan et al., 2017). Wang et al. (2017a) also demonstrated that 
palbociclib treated cells drive autophagy as a cell-protective mechanism and 
combination with autophagy inhibitor synergistically induced senescence. 
Senescence is thought to be an anticancer activity. However, a recent study shows 
that senescent cells acquired senescence-associated secretory phenotype (SASP) 
that directly causes transformation of adjacent cells and destruction of the 
extracellular matrix, a hallmark of cancer growth (Schosserer et al., 2017). SASP 
 197 
 
 
 
factors include interleukin-1 and -6 that is known to promote tumorigenesis (Kumari 
et al., 2016), and p-53 loss caused more chemokines than wild-type p53 such as 
TECK and CXCL5 (Singh et al., 2011, Coppé et al., 2010).  
We have also shown that palbociclib treated cells shared a significant signature 
correlated with the RUNX1/ETO knockdown, making it more attractive for further 
exploration (Martinez-Soria et al., 2018). In this study, the limitation of glutamine 
induced resistance in Kasumi-1 cells (section 5.3.2.6) which is in contrast to the well-
documented evidence that glutamine deficiency abrogated cell proliferation (Kim et 
al., 2017a, Tran et al., 2017). Interestingly, a study showed that low glutamine 
induced BRAF-resistant melanoma cells through histone hypermethylation of H3K27 
(Pan et al., 2016). Furthermore, glutamine deficiency caused the depletion of αKG 
which is the critical factor for histone demethylases. Cross-checked with GSEA 
analysis showed that genes in glutaminolysis pathway were also impaired in 
palbociclib treated cells. A question, therefore, arises here. Is the resistance 
mechanism in G0G1 populations in palbociclib-treated cells are related to the 
glutamine deficiency? 
Furthermore, palbociclib treatment increased ATP production, a consequence of 
OXPHOS. However, this is in contrast to the low ATP level detected in the G0G1 
phase (Du et al., 2017). Furthermore, the ROS levels decreased in palbociclib cells in 
both standard and glutamine deficiency media. Jones et al., (2018) demonstrated 
that LSCs are associated with low ROS and not affected by glutamine deprivation. In 
particular, Farge et al. (2017), have shown high OXPHOS AML cells were exclusively 
chemo-resistant in vivo. The LSCs have been shown to associate with dormancy in 
G0 population (Al-Asadi et al., 2016), but there was no enrichment of this population 
in palbociclib treated cells. Nevertheless, Jones et al. study has opened a new 
perspective in targeting LSCs through metabolic rewiring of the resistance cells. This 
leads to an open question with current experimental strategy using palbociclib, in 
which the treatment caused changes in metabolic characteristics and requires further 
attention. Future study to determine the characteristics of these populations is 
particularly pertinent for selective combination to eliminate these cells. 
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 Glycolysis and cell cycle inhibitors as a possible therapeutic combination 
Current leukaemia treatments involve intensive and genotoxic chemotherapy, which 
can severely affect patients' quality of life; hence low-risk treatment regiments are 
required to address this issue. 
The RUNX1/ETO cells showed to be more sensitive to 2DG inhibition in comparison 
to other AML cells (chapter 5). This observation is in agreement with the previous 
study that RUNX1/ETO cells are more sensitive to 2DG inhibition but show resistant 
towards OXPHOS inhibition (Miwa et al., 2008). Furthermore, lower glucose uptake 
was observed in the hypoxia than in normoxia condition in wild-type cells (section 
3.3.3.4). This finding further corroborates that 2DG is more effective in hypoxic 
condition as the low oxygen induces more glycolytic phenotype. For instance, in 
Burkitt lymphoma cells, the sensitivity of 2DG is four times lower in hypoxia than in 
normoxia condition (Pang et al., 2015). Nevertheless, 2DG is also shown to modulate 
cancer cells in normoxia successfully. A low dose of 2DG is not only effective to 
eradicate ALL cells in normoxia (Gu et al., 2017) but also sensitise glucocorticoid-
resistant cells to chemotherapy drugs (Gu et al., 2017, Hulleman et al., 2009).  
Furthermore, as hypoxia is described as common feature of the tumour 
microenvironment (Hohenberger et al., 1998, Rundqvist and Johnson, 2013), 2DG is 
suggested to have even more powerful therapeutic efficiency in vivo than in vitro. 
However, some studies have shown that 2DG alone is not sufficient to eliminate 
cancer cells in vivo (Goldberg et al., 2012, Maschek et al., 2004), Sobhakumari et al. 
(2016). Instead, combinations of 2DG with other anti-tumour agents result in greater 
effect in comparison with every single treatment (Goldberg et al., 2012, Maschek et 
al., 2004). 
Moreover, 2DG induced cell death as indicated by Annexin V staining (section 
5.3.2.2). 2DG mediates cell death mechanism through the induction of pro-apoptotic 
protein, Bax (Zagorodna et al., 2011). Besides, 2DG also caused the reduction of 
intracellular ATP levels seen in chronic lymphocytic leukaemia (Tidmarsh et al., 
2004). Reduced ATP level is thought to be the mechanism of 2DG sensitisation in 
drug combination study. Lack of ATP caused p-glycoprotein to cease its function to 
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pump out small molecule inhibitor, thus sensitise the cells towards the treatment 
(Sauna et al., 2001, Tagg et al., 2008). On the contrary, 2DG antileukaemic activity 
on T-ALL cells was not due to glycolytic inhibition (Gu et al., 2017). Instead, 2DG cell 
death was induced through N-linked glycosylation and endoplasmic reticulum stress-
mediated apoptosis. 
The in vitro study has shown a possible combination of 2DG and palbociclib, further 
study on the mechanism should be carried out which include both in vitro and in vivo 
platforms. Moreover, palbociclib has the potential therapeutic values and has been 
used in a combination of clinically available drugs in breast cancer treatment (Finn et 
al., 2016). Therefore, an ongoing study is being carried out to focus on the resistance 
side of palbociclib as well as repurposing with other clinically available anti-leukaemic 
agents. 
 
 Limitation and future work 
SLC2A3 and PFKP were identified in vivo but not in vitro in the shRNA screen. This 
has become quite a challenge in validating these partner genes as there is no proper 
in vivo model for RUNX1/ETO-leukaemia. Furthermore, although we have improved 
the transplantation capability of Kasumi-1 cells through the intrahepatic injection 
method in RG mice; however, there were issues with the engraftments involving 
SLC2A3 and PFKP knockdown cells as clearly indicated in the two experiments 
described in chapter 3. Furthermore, 2DG inhibition might be of benefit in eradicating 
leukaemia cells and could provide improved sensitisation for palbociclib treatment.  
Additionally, during the labwork phase, I encountered with a lentiviral production 
problem which lasted approximately eight months until it was improved. This had 
caused me a delay mainly in the in vitro work.  
Nevertheless, from this study, several key questions have arisen and provide 
potential future works.  
i. The resistance showed in RUNX1/ETO knockdown in Kasumi-1 cells in hypoxia 
indicates roles of hypoxia in modulating resistancy. This observation was also 
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shown previously where the knockdown of RUNX1/ETO did not lead to survival 
advantage in vivo (Mr Hasan’s thesis, 2019).This could be a model of relapse in 
RUNX1/ETO leukaemia which worth an investigation. Future study will 
emphasise on the roles of HIF-1a in regulating the resistance populations as 
well as gene expressions profiling to check the enriched pathways. The enrich 
pathways will be cross-examined with current expressions profile of 
RUNX1/ETO knockdown in normoxia.   
ii. Glutamine deficiency leads to resistance in the palbociclib treated cells which is 
further evident by low ROS levels. Further investigations on how and why this 
metabolite caused resistance could provide an insight into how we can 
manipulate this substance for therapeutic strategy. Moreover, recent 
publications showed that cancer cells are not only dependent on the glutamine 
and glucose. Instead, amino acids also play the roles in maintaining LSCs to 
fuel shunt metabolic pathway as shown in Jones et al. study. Future study will 
include assays of the leukaemic cells in different nutrient conditions to measure 
the dependency of the cells toward each nutrient. This will be followed by 
changes in metabolic activity possibly through Seahorse, ATP and lactic acid 
assays. 
 
 Concluding remarks and outlook 
This study has provided an insight into metabolic rewiring in RUNX1/ETO-leukaemia 
cells. The in vivo study has yet to prove the potential therapeutic value for SLC2A3, 
but in vitro analyses showed the variable response towards different nutrient and 
oxygen conditions. Contrasting findings in this study to the well-documented 
evidences indicate that targeting metabolic reprogram in cancers is not a straight 
forward approach, as the cells could shunt to another complex pathway in order to 
survive. Furthermore, the complexity of rewired metabolism is even further extended 
by tumour heterogeneity which is present in AML. This requires a better 
understanding of the underlying genetic and biochemical processes that support 
tumour development, progression and therapy resistance.  
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APPENDIX 
Appendix 7-1: The E-box protein at the locus of RUNX1/ETO binding site 
downstream of SLC2A3 (highlighted in red box). 
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Appendix 7-2: The expressions of PKM isoforms upon depletion of RUNX1/ETO in 
Kasumi-1 cells. 
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